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ABSTRACT 
Novel secreted peptides represent an important field of research because delineation of their 
function affords new insights into the pathophysiological processes causing disease, and 
provides opportunities for the development of pharmacological therapies. Augurin is a recently 
identified secreted peptide of unknown function expressed in the central nervous system (CNS), 
pituitary, and several endocrine tissues. Because of its expression pattern I hypothesised that 
augurin may be involved in the neuroendocrine system. I therefore investigated the effects of 
central injection of augurin on the hypothalamo-pituitary axes and food intake in male Wistar 
rats.  
Intracerebroventricular (ICV) or intraparaventricular nucleus (iPVN) injection of augurin 
increased plasma adrenocorticotrophic hormone (ACTH) and corticosterone levels compared 
with vehicle-injected controls. Augurin also increased the release of corticotrophin releasing 
hormone (CRH) from hypothalamic explants, and pre-treatment with a CRH receptor antagonist 
in vivo prevented the rise in ACTH and corticosterone caused by ICV augurin, suggesting 
activation the hypothalamo-pituitary-adrenal (HPA) axis via by the release of CRH from 
neurons in the PVN. In addition to stimulating the HPA axis, iPVN injection of augurin at the 
start of either the light or dark phase caused a robust increase in food intake.  
To assess whether augurin might have a physiological role in the regulation of the HPA axis or 
food intake, I investigated its endogenous distribution in the rat CNS using 
immunohistochemistry and in situ hybridisation histochemistry. Augurin positive neurons were 
present in several regions of the CNS including the hypothalamus and the dorsal vagal complex 
of the brainstem, a distribution consistent with a possible role in neuroendocrine function. 
Augurin is therefore anatomically positioned to play a role in the hypothalamic regulation of the 
HPA axis and food intake.  
While the data presented suggest a novel role for augurin, these are preliminary studies. 
Currently, little is known about the physiology of the augurin system. Further characterisation 
of the neuroanatomy, identification of receptors, and the development of receptor agonists and 
antagonists would provide further data on the physiological role of augurin, and on the potential 
therapeutic benefits of manipulating the augurin system. 
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1 GENERAL INTRODUCTION 
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1.1 NEUROENDOCRINE PEPTIDES 
This thesis aims to examine the biological and physiological role of augurin, a novel 
neuroendocrine peptide (NEP), in the hypothalamic regulation of feeding and endocrine 
function. The characterisation of novel human proteins furthers our understanding of normal 
physiology, and provides new opportunities for the treatment of diseases. Uncharacterised NEPs 
are particularly good targets for therapeutic intervention as both peptide and cellular target are 
readily accessible via the circulation. In cases where deficiency causes disease, such as the lack 
of insulin in type 1 diabetes mellitus, purified peptide can be administered directly to an 
individual (Banting et al., 1922). Alternatively, specific antibodies or receptor antagonists can 
readily suppress biological activity (Elliott et al., 1994, Hokfelt et al., 2003). In some cases a 
NEP system may have therapeutic potential even if it does not play a direct role in the 
pathophysiology of a disease (Izzo and Zion, 2011).  
The term NEP encompasses both neuropeptides and peptide hormones; a critically important 
and diverse set of regulatory molecules whose functions are to convey specific information 
amongst cells and organs. Many arose early in the evolution of life and are highly conserved 
throughout lower vertebrates, insects, yeasts, and bacteria (Roth et al., 1982). NEPs are a subset 
of secreted proteins loosely defined by their shared characteristics. They are typically short 
polypeptides produced by the proteolytic cleavage of preprohormone precursors (Hook et al., 
2008).  
Mature peptides then localise to the secretory pathway where particular stimuli regulate their 
secretion (Burbach, 2010). Once released into the extracellular space they can bind to specific 
cell surface receptors through which they modulate cellular functions. The majority of NEPs are 
ligands for G-protein-coupled receptors (GPCRs), all of which share common structural features 
(Lagerström and Schiöth, 2008). The high degree of homology between GPCRs makes them 
particularly amenable to bioinformatic analysis which has suggested there may be some 25-30 
orphan GPCRs which have as yet undiscovered peptide ligands (Vassilatis et al., 2003). 
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NEPs function both as hormones whose actions on distant organs are mediated by way of their 
transport through the bloodstream, and as local cell-to-cell communicators. Many are 
pleiotropic and in addition to both endocrine and paracrine activity, function as 
neurotransmitters in the central, autonomic, and peripheral nervous systems (Hokfelt, 1991). 
Irrespective of the mechanism, the primary action of NEPs is to coordinate the behaviour of 
receptive cells to ultimately advantage the organism as a whole. They modulate processes as 
diverse as neurogenesis, blood pressure regulation, glucose homeostasis, arousal, feeding 
behaviour, fear, anxiety and stress, addiction, and pleasure (Hokfelt et al., 2000, Stanic et al., 
2008, Ogren et al., 2010). Given their diverse functions and their potential as therapeutic 
targets, considerable efforts have been made to identify and characterise the complement of 
human NEPs and their receptors (Clark et al., 2003).  
1.1.1 METHODS OF IDENTIFYING NEPS 
The discovery of thyrotrophin-releasing hormone (TRH) by Guillemin and Schally exemplifies 
the classical peptide discovery method; bioactivity assays guiding repeated fractionation of 
peptides extracted from specific tissues (Guillemin et al., 1965, Schally et al., 1966). Since 
1986, homology screening and bioinformatics analyses have identified hundreds of GPCRs, and 
those whose ligand was unknown were termed ‘orphan’ GPCRs (Dixon et al., 1986). 
Concomitant improvements in molecular cloning technology enabled the ‘reverse 
pharmacology’ strategy for deorphanising receptors, whereby ligands were identified based on 
their activity at GPCRs coupled to an in vitro reporter assay (Civelli et al., 1998). Reverse 
pharmacology has led to the discovery of several notable NEPs within the last two decades, 
including the orexins, ghrelin, and kisspeptin (Sakurai et al., 1998, Kojima et al., 1999, Ohtaki 
et al., 2001). Nevertheless, although the identification of putative GPCRs can be accomplished 
relatively easily, the discovery of the endogenous ligands that activate these receptors is far 
more difficult. This has fuelled the increasing use of bioinformatics approaches to try to identify 
potential NEPs (Gustincich et al., 2003, Sonmez et al., 2009). 
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1.1.2 BIOINFORMATICS APPROACHES TO IDENTIFYING NEPS 
The successful sequencing of entire genomes of many different organisms has yielded a large 
number of deoxyribonucleic acid (DNA) sequences that potentially encode novel candidate 
NEPs, as well as hundreds of orphan GPCRs with no known cognate ligands (Chung et al., 
2008). In 2007, Mirabeau and colleagues developed an algorithm based on the hidden Markov 
model (HMM) to quantify the likelihood that a given protein contained a NEP (Mirabeau et al., 
2007). Taking advantage of the fact that the primary sequences of NEPs contain several 
common features, they identified esophageal cancer related gene 4 protein (ECRG4) as likely to 
contain a NEP which the authors named augurin (Mirabeau et al., 2007).  
Although a formal definition of an HMM is beyond the scope of this thesis, I will outline the 
principles of HMMs, and their strengths and weaknesses when applied to protein prediction. 
HMMs are a mathematical foundation for making probabilistic models of linear sequence 
‘labelling’ problems (Eddy, 1998). HMMs are ‘learning’ algorithms; they adjust their free 
parameters gradually by repeated presentation of a training data set, and thereby learn to 
generalise from the examples on which they have been trained. As a result, an HMM can learn 
the probability that an amino acid sequence corresponds to a particular state defined by a 
training set. A state might be a signal peptide or a transmembrane domain, while the training set 
would be a list of amino acid sequences known to correspond to that state. An HMM can 
incorporate multiple features as separate states, and calculate the probabilities that a sequence 
corresponds to a particular state, and that one state will transition into the next (Winters-Hilt, 
2006). For example, NEPs have an identifiable secretory signal peptide (SP) cleavage site 
following the SP. An HMM should therefore ‘learn’ that, for NEPs, the probability of a 
transition from SP to SP cleavage site is equal to 1. It follows that if a sequence does not 
transition from SP to SP cleavage site, it is unlikely to belong to the NEP family. 
The HMM’s strength lies in the simplicity with which individual HMMs can be combined to 
model complex sequences. In the case of protein profiling, individual HMM states, for example 
the existence of an SP or peptidase cleavage site, can be incorporated into a single HMM by 
modelling the transition from the former state to the latter (Eddy, 1996). The major drawback of 
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HMMs is their short ‘memory’ span. The HMM assumes that the probability of transitioning to 
the subsequent state is entirely dependant on the current state (Eddy, 2004). In practise, this 
makes it difficult for an HMM to model correlations between distant states because it assumes 
the probability of each state depends only on the previous one. 
As a group, NEPs share several common amino acid motifs and features that are highly 
conserved relative to other regions of the primary sequence, illustrated in Figure 1.1A. These 
include a relatively short length, an N-terminal SP, basic residue prohormone cleavage sites, 
and an absence of transmembrane domains (Sonmez et al., 2009).  
1.1.2.1 N-terminal secretory signal peptide 
Much of the information about the subcellular localisation of a protein is localised at the 
N-terminus of a protein (Devillers-Thiery et al., 1975, Wiedmann et al., 1987). As it starts to be 
translated in the cytoplasm, a number of RNA/protein complexes binds to the nascent protein 
and target it into specific organelles (Wiedmann et al., 1987). The prototypical N-terminal 
signal is the SP, which targets a protein for translocation across the endoplasmic reticulum (ER) 
membrane in eukaryotes (Von Heijne, 1990). It is typically 15–30 amino acids long and is 
cleaved during translocation of the protein across the membrane (Nagai et al., 2003). There is 
no simple consensus sequence for SPs, but they typically show three distinct compositional 
zones: an N-terminal region which often contains positively charged residues, a hydrophobic 
region of at least six residues, and a C-terminal region of polar uncharged residues (Perlman and 
Halvorson, 1983).  
It should be noted that not all proteins with SPs are actually secreted to the outside of the cell. In 
eukaryotes, proteins translocated across the ER membrane are by default transported through 
the Golgi apparatus and exported by secretory vesicles, but many have specific retention signals 
that hold them back in the ER or the Golgi, or divert them to the lysosomes (Van Vliet et al., 
2003). In addition, several proteins such as the fibroblast growth factors are secreted without an 
SP through the non-classical pathway, which does not follow the classical route through the ER 
and Golgi (Nickel and Rabouille, 2009). 
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Figure 1.1: Alignment of preproaugurin orthologues and potential peptidase cleavage sites. Orthologues were identified using a Markov Clustering algorithm (Kim 
et al., 2008). The multiple sequence alignment was generated using the T-Coffee algorithm and annotated using Jalview alignment editor (Notredame, 2007, 
Waterhouse et al., 2009). Amino acid residues are coloured with the Clustal X colour scheme (Procter et al., 2010). The SignalP 3.0 algorithm predicted amino acid 
residues 1-31 comprised the signal peptide sequence (Dyrlrv Bendtsen et al., 2004, Emanuelsson et al., 2007). Cleavage sites, marked with red arrows, were 
compiled from the following studies (Mirabeau et al., 2007, Gotze et al., 2009, Kujuro et al., 2010, Gonzalez et al., 2011, Ozawa et al., 2011). The consensus 
sequence is shown below the multiple species alignment, amino acid conservation is represented by relative bar height on the histogram.  
Ailuropoda melanoleuca (giant panda), Bos taurus (cow), Callithrix jacchus (marmoset), Canis lupus familiaris (dog), Danio rerio (zebrafish), Equus caballus 
(horse), Gallus gallus (chicken), Homo sapiens (human), Loxodonta africana (elephant), Mus musculus (mouse), Oryctolagus cuniculus (rabbit), Osmerus mordax 
(rainbow smelt)  Pan troglodytes (chimpanzee), Pongo abelii (sumatran orangutan), Rattus norvegicus (rat), Salmo salar (atlantic salmon), Sus scrofa (wild boar), 
Taeniopygia guttata (zebra finch), Xenopus laevis (african clawed frog), Xenopus silurana tropicalis (western clawed frog), Macaca mulatta (macaque) 
 ECRG4!(1!148) 
 Signal'P'(1!31)$  ECRG4&(32!148) 
 ECRG4&(32!70)  Augurin'(71!148) 
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1.1.2.2 Absence of transmembrane domains 
By default, SP-containing proteins are trafficked into the secretory pathway, however, if in 
addition to an SP a protein contains stretches of 15-25 hydrophobic residues, it is incorporated 
into the plasma membrane of the cell (Krogh et al., 2001). GPCRs are an example of 
transmembrane proteins that have SPs. 
1.1.2.3 Preprohormone cleavage sites 
NEPs are initially synthesised as relatively large preprohormone precursors that gradually 
mature into specific bioactive forms via the sequential action of post-translational processing 
enzymes (Hook et al., 2008). The SP is removed by signal peptidases, forming the prohormone, 
which is commonly further cleaved by prohormone convertase (PC) enzymes. The PCs are a 
family of at least seven enzymes that typically cleave C-terminally to basic residue (Arg/Lys) 
motifs (Fricker, 2005, Hook et al., 2008). PC1/3 and PC2 are primarily responsible for 
prohormone maturation; they are specifically expressed in neuroendocrine tissues where they 
localise to secretory vesicles (Azaryan et al., 1995, Zhou et al., 1999). Other enzymes including 
carboxypeptidase E/H, cathepsin L, and Arg/Lys aminopeptidase may be necessary for cleavage 
and maturation of a prohormone (Fricker, 1988, Hook et al., 2004, Biswas et al., 2009). In 
many cases processed peptides undergo further post-translational modifications which are 
necessary for biological activity such as C-terminal amidation (Eipper et al., 1992).  
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1.2 AUGURIN IS A CANDIDATE NEP 
Mirabeau et al. constructed an HMM based on the aforementioned features to predict the 
probability a peptide belonged to the NEP family. When applied to the mammalian proteome it 
identified ECRG4, now named preproaugurin (RefSeq NP_115787.1), as likely to contain a 
NEP (Mirabeau et al., 2007). Since then, several studies using similar methodology have 
identified homologues of preproaugurin in cattle, zebrafish, and chicken, as likely to contain a 
NEP (Southey et al., 2009, Delfino et al., 2010, Xie et al., 2010). 
1.2.1 THE CHROMOSOME 2 OPEN READING FRAME 40 GENE 
Preproaugurin is encoded by the Chromosome 2 open reading frame 40 (C2orf40) gene. 
C2orf40 was first identified in 1998 as a potential tumour suppressor gene in human 
oesophageal epithelium (Su et al., 1998). It is located on human chromosome 2q14.1-14.3, 
spans approximately 13kb, and is highly conserved amongst vertebrate animals (Figure 1.1). 
C2orf40 has 4 exons, all of which are coding (Su et al., 1998). No alternative splicing has been 
reported yet in mammals, however there are two paralogous genes in the zebrafish and 
chimpanzee (Figure 1.1). C2orf40 does not appear to be a member of any known gene family. 
1.2.2 PREPROAUGURIN  
Preproaugurin is a 17kDa peptide that has several, highly conserved, characteristic features of a 
preprohormone; it is short at 148 residues (in most species), contains a canonical SP, and 
several potential PC cleavage sites (Figure 1.1). Based on its distribution, subcellular 
localisation, post-translational processing, and secretion from cells, there is now considerable 
evidence to support the hypothesis that preproaugurin contains one or more secreted peptides.  
1.2.2.1 Post-translational processing 
Post-translational processing of preproaugurin is poorly understood. In particular, the sites of 
prohormone cleavage, and the identity and nature of the resultant peptides are not known. Six 
potential cleavage sites have been suggested based predominantly on data from in vitro studies 
(Figure 1.1). Prior to beginning work for this thesis, only the canonical dibasic PC cleavage site 
corresponding to residues Lys69 and Arg70 was supported by direct experimental evidence. 
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Cleavage at this site has been demonstrated in vitro following transfection of two different rat 
pancreatic β-cell lines with preproaugurin cDNA, in which the FLAG-tag was inserted adjacent 
to Arg70 (Mirabeau et al., 2007). Western blotting of culture medium from 
FLAG-preproaugurin transfected cells demonstrated a 10kDa immunoreactive band consistent 
with secretion of an Arg70 cleaved peptide (Mirabeau et al., 2007). Furthermore, the 10kDa 
peptide is immunoreactive when probed with an antibody specific for FLAG at the N-terminus, 
suggesting the C-terminal sequence from residues 71-148 is secreted. 
Since then, several studies have investigated the post-translational processing of preproaugurin 
in vitro and various other cleavage sites have been inferred based on the presence of multiple 
bands on western blots. Of the six studies that have investigated the post-translational 
processing of preproaugurin, identification of a 14kDa, a 10kDa, and an 8kDa immunoreactive 
band is almost universal (Mirabeau et al., 2007, Gotze et al., 2009, Kujuro et al., 2010, 
Gonzalez et al., 2011, Ozawa et al., 2011). In one study, no 8kDa band was observed 
transfection into chondrocytes (Huh et al., 2009). These bands most likely correspond to 
preproaugurin (31-148) following removal of the signal peptide sequence, preproaugurin 
(71-148) following cleavage at Arg70, and preproaugurin (71-132) following further cleavage at 
Arg132. The 14kDa, 10kDa, and 8kDa bands are consistently identified in the culture medium 
of preproaugurin transfected cells, suggesting predominant secretion of these forms (Mirabeau 
et al., 2007, Gotze et al., 2009, Gonzalez et al., 2011). 
Despite the reasonable consistency between studies, extrapolation of these results to 
endogenous processing of preproaugurin is potentially misleading. Because the preproaugurin 
cDNA used in each of the aforementioned studies lacks intron-exon boundaries, alternative 
mRNA splicing cannot occur (Johnson et al., 2003, Adamson et al., 2011). Furthermore, 
post-translational processing depends on the coexistence of both prohormone and protease 
enzyme in the same cell, and varies depending on which proteases are expressed (Ozawa et al., 
2010). For example, co-expression of preproglucagon and PC2 predominantly generates 
glucagon in pancreatic α-cells, whereas in enteroendocrine L-cells glucagon like peptide-1 
(GLP-1) and glucagon like peptide-2 (GLP-2) are the predominant products due to 
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co-expression with PC1/3 (Rothenberg et al., 1995, Furuta et al., 1997, Rouille et al., 1997). 
Therefore, although several preproaugurin products have been identified in vitro, their existence 
in vivo will depend on the co-expression of both preproaugurin and the appropriate cleavage 
enzymes. To date, only one study has investigated preproaugurin processing in vivo. Gonzalez 
et al. demonstrated that in the choroid plexus, a tissue expressing high levels of preproaugurin 
mRNA, the vast majority of preproaugurin-like immunoreactivity (LI) is a 14kDa band, while 
an 8kDa band is also present at much lower levels (Gonzalez et al., 2011).  
The data above support the hypothesis that post-translational processing of preproaugurin 
generates one or more secreted peptides, however their identity is very much unclear. I began 
the work presented in this thesis soon after the identification of augurin by Mirabeau et al., at 
which time the primary sequence of endogenous augurin was unknown (Mirabeau et al., 2007). 
I hypothesised preproaugurin (71-148) was a likely endogenous form because it appeared to be 
the predominant peptide secreted from preproaugurin transfected β-cells, and its primary 
sequence is highly conserved between species (Figure 1.1) (Mirabeau et al., 2007). I therefore 
chose to investigate the biological effects of residues 71-148 of preproaugurin, a likely 
endogenous form, which I refer to as augurin throughout this thesis. Although further cleavage 
at Arg132 into an 8kDa product had been suggested, the identity of the C-terminal cleavage site 
had not been confirmed (Mirabeau et al., 2007). PC cleavage at a single Arg residue is atypical, 
and compared to the canonical dibasic cleave site residues Lys69/Arg70, Arg132 is less well 
conserved (Figure 1.1) (Fricker, 2005).  
1.2.2.2 Subcellular localisation 
Several studies have investigated the subcellular localisation of preproaugurin, and the majority 
demonstrate trafficking into the secretory pathway. FLAG-preproaugurin and insulin co-localise 
to punctate intracellular bodies in transfected β-cells, while in the HCT116 colorectal carcinoma 
cell line, eGFP-tagged preproaugurin predominantly localises to the Golgi apparatus (Mirabeau 
et al., 2007, Gotze et al., 2009). Although these studies suggest preproaugurin is trafficked into 
the secretory pathway, they should be interpreted with caution as these cells may not express 
augurin endogenously, and the presence of a tag can alter the post-translational processing of 
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peptides (Hanson and Ziegler, 2004). To date, no studies have examined the subcellular 
localisation of endogenous preproaugurin in situ. 
1.2.3 FUNCTION  
Despite being identified in 1998 very little is known about the physiological functions of 
preproaugurin, although it is recognised as down-regulated in many, if not most cancers (Su et 
al., 1998, Yue et al., 2003, Mori et al., 2007, Gotze et al., 2009, Li et al., 2009, Vanaja et al., 
2009, Li et al., 2010a, Li et al., 2010b, Gonzalez et al., 2011). Very recently, a role for 
preproaugurin in the central nervous system (CNS) has been proposed as a secreted inducer of 
neural precursor cell (NPC) senescence (Kujuro et al., 2010). RNA interference-mediated 
knockdown prevented the onset of senescence in NPCs, suggesting preproaugurin is a necessary 
for NPC senescence (Kujuro et al., 2010). 
1.2.4 DISTRIBUTION 
Preproaugurin is broadly expressed in rodents and in humans. Using reverse transcription 
polymerase chain reaction, in situ hybridisation histochemistry (ISH), or northern blotting, 
preproaugurin mRNA has been demonstrated in the heart, placenta, lung, liver, lung, skeletal 
muscle, kidney, and skin (Steck et al., 2002, Mirabeau et al., 2007, Huh et al., 2009, Gonzalez 
et al., 2011). High levels of preproaugurin mRNA are consistently found in the choroid plexus, 
cartilage, adrenal gland, pancreas, and in areas of the CNS (Mirabeau et al., 2007, Huh et al., 
2009, Gonzalez et al., 2011). Preproaugurin-LI in neurons has been reported in an abstract 
submitted for a recent scientific meeting (Roberton et al., 2009). In addition to the choroid 
plexus, preproaugurin-LI was detected in the paraventricular nucleus (PVN) and supraoptic 
nucleus (SON) of the hypothalamus, where it co-localised with arginine vasopressin (AVP) and 
oxytocin (OXT). This pattern of immunoreactivity is characteristic of a NEP and suggests that 
preproaugurin or a product thereof may be a novel hypothalamic neuropeptide. Prominent 
preproaugurin expression in the CNS and endocrine organs is consistent with a physiological 
role in the neuroendocrine system. 
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1.3 THE NEUROENDOCRINE SYSTEM 
The primary biological imperatives are to first ensure an organism’s survival and second to 
propagate its species. To satisfy these necessities, multicellular organisms must coordinate 
complex physiological processes with diverse environmental conditions, and elaborate 
appropriate adaptive responses to specific sensory cues. Thus, the maintenance of homeostasis 
represents a key component of biological adaptation, and depends upon the successful 
integration of behavioural, somatomotor, and visceral function by the autonomic nervous and 
endocrine systems.  
There are considerable similarities between autonomic nervous system (ANS) and endocrine 
system. Endocrine cells and neurons are prototypical secretory cells; both have electrically 
excitable plasma membranes and specific ion conductances that regulate exocytosis of their 
signalling molecules from storage vesicles (De Camilli and Jahn, 1990). NEPs often have a role 
in both systems, acting as hormones in the periphery and as neurotransmitters in the nervous 
system (Hokfelt et al., 2000). The ANS and the endocrine system can therefore be considered as 
a single neuroendocrine regulatory system. 
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1.4 THE HYPOTHALAMUS 
Normal cellular function is exquisitely sensitive to the local environment. In order to maintain 
the cellular environment within the narrow optimum range, mammals have evolved an array of 
regulatory mechanisms. Commonly these regulatory mechanisms operate on the principle of 
negative feedback, whereby, deviations from a given set point are detected by a sensor, and 
signals from the sensor trigger appropriate antagonistic responses that continue until the set 
point is re-established (Fleming, 1984). Many of the complex mechanisms that maintain the 
internal environment are mediated via the hypothalamus (Swanson and Mogenson, 1981). 
The hypothalamus is considered the critical integratory relay between afferent and efferent 
homeostatic signals (Figure 1.2). In mammals for example, the hypothalamus has been shown to 
regulate multiple hormonal axis, circadian rhythms, body temperature, as well as appetitive, 
sexual, and affective behaviours (Paxinos, 2004). It is also a site at which the majority of NEPs 
have some biological activity (Williams and Bloom, 1989, Hokfelt et al., 2000, Burbach, 2010). 
Sensory information from both the internal and external environment is relayed directly to the 
hypothalamus, which also monitors and responds to changes in numerous plasma hormone and 
metabolite levels (Kastin and Pan, 2008, Stefater and Seeley, 2010). The hypothalamus 
processes sensory and hormonal inputs and triggers appropriate responses through outputs to 
key regulatory sites. These include the pituitary gland, cerebral cortex, premotor and motor 
neurons in the brain stem and spinal cord, and parasympathetic and sympathetic preganglionic 
neurons (Swanson and Mogenson, 1981, Thompson and Swanson, 2003). The orchestrated 
hypothalamic output to these effectors ultimately results in a coordinated endocrine, 
behavioural, and autonomic response designed to maintain homeostasis (Figure 1.2). 
 
 28  
Figure 1.2: The pivotal position of the hypothalamus in maintaining homeostasis. Central 
nervous system signals including physiological and processive stress, afferent neuronal 
activation, neuropeptide, and hormone signals are processed in the hypothalamus, affecting the 
synthesis and secretion of hypothalamic hormones and neuropeptides, and regulating patterned 
neuronal outputs. Both afferent and efferent signals converge at the hypothalamus. Multiple 
levels of negative feedback are also shown.  
Abbreviations: CNS, central nervous system; ANS, autonomic nervous system. 
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1.4.1 ANATOMY  
The hypothalamus is located in the ventral diencephalon, bound anteriorly by the optic chiasm, 
laterally by the sulci formed with the temporal lobes, and posteriorly by the mammillary bodies. 
Dorsally, the hypothalamus is delineated from the thalamus by the hypothalamic sulcus. The 
smooth, rounded base of the hypothalamus encircled by the circle of Willis is the tuber 
cinereum. The pituitary stalk descends from the median eminence (ME), found in the central 
part of the tuber cinereum (Figure 1.3). The hypothalamus can be functionally and anatomically 
subdivided into three longitudinally orientated zones: the periventricular, medial, and lateral 
zones (Figure 1.4) (Crosby and Woodburne, 1940). Each zone can be further subdivided into 
discrete regions or nuclei (Figure 1.4). An overview of the structure and function of the 
hypothalamus is presented below, and the roles of the hypothalamus in the regulation of 
endocrine function and feeding are discussed in detail in chapters 2 and 3 respectively.  
1.4.2 DEVELOPMENT AND BIOLOGICAL FUNCTION 
The development of the hypothalamus reflects its longitudinal subdivisions. The neurons of the 
lateral zone are generated first during gestation (Altman and Bayer, 1986). The lateral zone 
structures are generally associated with arousal and autonomic responses in feeding, defensive 
behaviour, and reproduction, whereas their connections are dominated by the medial forebrain 
bundle and the fornix (Hahn and Swanson, 2010). The second wave of neurogenesis provides 
neurons of the nuclei of the medial zone, characterised by limbic afferents from the amygdala 
and septum, and major intrahypothalamic connections (Altman and Bayer, 1986). Functionally, 
these cell groups are thought to generate motivated behaviours such as feeding and social 
interaction (Swanson, 2005). The last to be generated are the neurons of the periventricular zone 
(Altman and Bayer, 1986). The periventricular zone contains the classical magnocellular and 
parvocellular neurosecretory systems, and is critical for the regulation of biological rhythms and 
neuroendocrine output (Swanson, 2005). 
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Figure 1.3: Diagrammatic representation of the hypothalamus showing individual nuclei and 
adjacent structures. Taken from (Berthoud, 2002). 
Abbreviations: AHA, anterior hypothalamic area; ARC, arcuate nucleus; AV3V, anteroventral 
area of third ventricle; CI, capsula interna; DP, dorsal parvocellular subnucleus of 
paraventricular nucleus; DMH, dorsomedial nucleus; F, fornix; LHA, lateral hypothalamic area; 
LM, lateral magnocellular subnucleus of paraventricular nucleus; LPOA, lateral preoptic area; 
ME, median eminence; MP, medial parvocellular subnucleus of paraventricular nucleus; MPO, 
medial preoptic area; OT, optic tract; SCh, suprachiasmatic nucleus; SON, supraoptic nucleus; 
SI, substantia inomminata; ST, subthalamic nucleus; VMH, ventromedial nucleus; VP, ventral 
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Figure 1.4: Organisation of the hypothalamus. A highly schematic representation of 
mediolateral and rostrocaudal subdivisions of the hypothalamus and their functions. Adapted 






























































$4<":%&! '()*! (+! )*,-(+./0()!



























4$E)23! '#$&'()*! -0*3$0B! 94":;?!

































































































































JIKC+L!MNO!:#,2-)B2()&-! &D! (>$! >6'&(>23250BN!K!2)*.;43()! /.5/.2.+343(,+!,7! 3*.!
;,/5*,-,0()4-!,/04+(243(,+!,7!3*.!*85,3*4-4;12?!2*,D(+0!3*.!L+,D+!71+)3(,+2!,7!(32!
H,+.2?!4/.42!4+<!+1)-.(=!K<453.<!7/,;!$E49(+,2!4+<!>432,+?!MNNO%=!
 33  
1.4.4.1 The periventricular hypothalamic zone 
The periventricular zone is considered the ‘neuroendocrine motor zone’. It contains two 
histochemically well-defined neuronal systems, the magnocellular and the parvocellular, which 
convey the neuroendocrine output from the hypothalamus to the pituitary (Markakis and 
Swanson, 1997). The pituitary gland is intimately linked to the hypothalamus; the two form a 
unit that exerts control over the function of several endocrine glands, and therefore a wide range 
of physiological functions. The pituitary has two distinct subdivisions, the adenohypophysis and 
the neurohypophysis. The neurohypophysis is embryologically and anatomically continuous 
with the hypothalamus; it contains axon terminals arising from magnocellular secretory neurons 
located in the paraventricular and supraoptic nucleus of the hypothalamus. 
Parvocellular neurons project to the median eminence, and other CNS regions. Secretion from 
the pituitary adenohypophysis is predominantly regulated by subpopulations of parvocellular 
hypothalamic neurons whose axons terminate in the median eminence (ME). The majority are 
located in the periventricular zone, including those expressing growth hormone releasing 
hormone (GHRH), somatostatin (SS), gonadotrophin releasing hormone (GnRH), corticotrophin 
releasing hormone (CRH), thyrotrophin releasing hormone (TRH), and other factors known to 
regulate pituitary functions such as dopamine (DA), vasoactive intestinal peptide (VIP), and 
γ-amino butyric acid (GABA) (Witkin et al., 1982, Bloch et al., 1983, Makara et al., 1983, 
Meister et al., 1988, Ceccatelli et al., 1989, Fliers et al., 1994, Simmons and Swanson, 2009). 
The periventricular zone also contains the suprachiasmatic nucleus that regulates the circadian 
cycle, and a large group of autonomic premotor neurons that project to preganglionic autonomic 
neurons in the brainstem and the spinal cord (Saper et al., 1976, Thompson and Swanson, 2003, 
Geerling et al., 2010). The hypothalamo-pituitary axes are discussed in more detail in chapter 2. 
1.4.4.2 The medial hypothalamic zone 
The medial zone of the hypothalamus contains a series of large nuclei that collectively play key 
roles in the initiation of motivated behaviours (Swanson et al., 1987b, Swanson, 2000). 
Recently it has been suggested that the medial hypothalamic zone and ventral midbrain nuclei 
constitute a ‘motivational’ control column (Risold et al., 1997, Swanson, 2005). The motivation 
 34  
control column can be divided on structural and functional grounds into rostral and caudal 
segments (Thompson and Swanson, 2003, Swanson, 2005). The caudal segment includes the 
dorsal and ventral regions of the paraventricular, median preoptic, and dorsomedial nuclei, and 
is primarily implicated in consummatory behaviours such as hyperphagia and polydipsia (Weiss 
and Leibowitz, 1985). The rostral segment is further subdivided; the anterior hypothalamic, 
dorsomedial parts of the ventromedial, and dorsal premammillary nuclei, and primarily 
mediates the expression of defensive or antagonistic behaviours (Risold et al., 1997, Cezario et 
al., 2008, Lin et al., 2011). In contrast, the medial preoptic, ventrolateral parts of the 
ventromedial, and ventral premammillary nuclei are implicated in the expression of 
reproductive behaviours (Thompson et al., 1996, Thompson and Swanson, 1998, Swanson, 
2000, Lin et al., 2011).  
1.4.4.3 Lateral hypothalamic zone 
The lateral hypothalamic area (LHA) extends caudally from the lateral preoptic area to the 
rostral aspect of the mammillary body (Geeraedts et al., 1990). It consists of a group of 
medium- and large-sized neurons which are distributed along the course of the medial forebrain 
bundle (MFB; Figure 1.3) (Nieuwenhuys et al., 1982). Despite being the largest region of the 
hypothalamus, and in stark contrast to the periventricular and medial zone, the cytoarchitectural 
differentiations and functions of the LHA are poorly understood. 
The functional importance of the LHA has been appreciated for several decades. Classic studies 
carried out in the 1940s and 1950s described syndromes of ravenous overeating and obesity as a 
consequence of lesioning the ventromedial nucleus of the hypothalamus (VMN) (Hetherington 
and Ranson, 1940), and of a failure to eat and drink following damage to the LHA (Anand and 
Brobeck, 1951). These observations fostered the ‘dual centre’ hypothesis, whereby food intake 
was regulated by the LHA feeding and VMN satiety centres (Stellar, 1954). However, it was 
soon recognised that lesions of the LHA encompassed the nigrostriatal dopaminergic pathway, 
which travels in the MFB, and resulted in not only in hypophagia but a near complete inability 
to respond to acute stimuli of any kind (Ungerstedt, 1970, Marshall et al., 1974). Evidence from 
recent studies suggests the LHA is critical for behavioural arousal and motivation, and thereby 
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modulates diverse functions including feeding and drinking, foraging, sleeping, and social 
behaviours (Watts et al., 1999, Taheri et al., 2002, Goto et al., 2005, Adamantidis et al., 2007). 
Much of the progress identifying the physiological functions of the LHA has been facilitated by 
the recent discovery the melanin-concentrating hormone (MCH) and the hypocretin (HCRT) 
neuropeptide systems. 
Neurons within the LHA do not form well-defined nuclei; rather, there is subtle heterogeneity in 
which regional borders are not easily discernable in common Nissl preparations (Sawchenko, 
1998). The discovery of MCH and HCRT has considerably advanced our understanding of its 
cytoarchitecture. HCRT A and HCRT B are 33 and 28 amino acid neuropeptides generated from 
the same precursor, and are predominately expressed by neurons whose soma lie within the 
LHA (De Lecea et al., 1998, Sakurai et al., 1998, Swanson et al., 2005, Hahn, 2010). HCRT-LI 
fibres project widely throughout the brain to areas including the cerebral cortex, thalamus, 
hypothalamus, ventral tegmental area, and brainstem (Elias et al., 1998, Peyron et al., 1998). 
MCH is a 19 amino acid neuropeptide isolated first from teleost pituitary (Kawauchi et al., 
1983). It is produced by neurons of the LHA and the adjacent zona incerta that project 
extensively throughout the CNS (Bittencourt and Elias, 1998, Swanson et al., 2005, Hahn, 
2010). Both neuropeptide systems are heavily implicated in the regulation of arousal and 
motivation (Chemelli et al., 1999, Lin et al., 1999, Adamantidis et al., 2007, Hassani et al., 
2009).  
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1.5 HYPOTHESIS 
Augurin is a recently identified secreted peptide of unknown function expressed in several 
endocrine tissues and in the central nervous system (CNS). Because of its prominent expression 
in the hypothalamus, pituitary, and endocrine organs, I hypothesised augurin may have a 
physiological role in the neuroendocrine system. My aims were therefore to investigate the 
potential roles of augurin in the neuroendocrine system. 
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2 THE EFFECTS OF AUGURIN ON 
THE HYPOTHALAMO-PITUITARY 
AXES 
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2.1 INTRODUCTION 
One of the major efferent pathways through which the hypothalamus maintains homeostasis is 
via the pituitary gland. The two form a unit that controls the function of numerous endocrine 
glands, and therefore a wide range of physiological functions. The pituitary is situated directly 
below the hypothalamus and lies in the hypophyseal fossa of the sphenoid bone. It is a 
composite organ comprised of two distinct subdivisions, the adenohypophysis and the 
neurohypophysis (Figure 2.1). Hormone secretion from both the adenohypophysis and 
neurohypophysis is regulated primarily by output from the hypothalamic neuroendocrine motor 
zone. In the case of the neurohypophysis, axons from hypothalamic neurons project to and 
release hormones directly into the circulation (Figure 2.2A). In contrast, hormone secretion 
from the adenohypophysis is controlled by populations of hypothalamic neurons that secrete 
hypophysiotrophic hormones into the hypophyseal portal circulation (Figure 2.2B). 
With the exception of the supraoptic nucleus (SON) and gonadotrophin-releasing hormone 
expressing cells, the vast majority of neurons that regulate pituitary function lie in the 
periventricular region of the hypothalamus, referred to as the neuroendocrine motor zone 
(Swanson et al., 1987a). Within the neuroendocrine motor zone are two histochemically 
well-defined neuronal systems, the magnocellular and the parvocellular, which convey the 
neuroendocrine output from the hypothalamus to the pituitary (Swanson and Sawchenko, 1983, 
Markakis and Swanson, 1997). 
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Figure 2.1: Schematic representation of the human pituitary and the hypophyseal portal 
vasculature. Taken from (Larsen, 2003). 
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Figure 2.2: Diagrammatic representation of the regulation of hormone secretion from the 
adenohypophysis (A) and the neurohypophysis (B) of the pituitary. 
Abbreviations: ACTH, adrenocorticotrophic hormone; AVP, arginine vasopressin; CRH, 
corticotrophin-releasing hormone; FSH, follicle-stimulating hormone; GH, growth hormone; 
GHRH, growth hormone–releasing hormone; GnRH, gonadotrophin-releasing hormone; LH, 
luteinising hormone; OXY, oxytocin; TRH, thyrotrophin-releasing hormone; TSH, thyroid-
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2.1.1 MAGNOCELLULAR NEUROSECRETORY SYSTEM 
Magnocellular neurons are located in the SON, ventrolateral paraventricular nucleus (PVN), and 
accessory supraoptic cell groups (Swanson and Kuypers, 1980, Cunningham and Sawchenko, 
1991). They are large relative to neighbouring hypothalamic neurons and synthesise the 
neuropeptides arginine vasopressin (AVP) or oxytocin (OXT) at high levels (Mezey and Kiss, 
1991). Magnocellular neurons typically have a single axon that project along the infundibular 
stalk (Sofroniew and Glasmann, 1981). Magnocellular neuronal axons collectively form the 
posterior lobe of the neurohypophysis where these hormones are released into the circulation 
(Sofroniew and Glasmann, 1981). 
2.1.1.1 The neurohypophysis  
The neurohypophysis is embryologically and anatomically continuous with the hypothalamus. It 
is composed of the posterior lobe, the infundibular stalk, and the median eminance (ME). The 
infundibular stalk is surrounded by the pars tuberalis, and together they constitute the 
hypophyseal stalk (Figure 2.1). Axon terminals from magnocellular neurons are the major 
constituent of the neurohypophysis (Swanson and Sawchenko, 1983). Neurohypophyseal 
morphology is characterised by the terminal arborisations of these axons, a rich, fenestrated 
vasculature, and glial cells (Hatton, 1990). These axon terminals are in close association with a 
capillary plexus, and they secrete substances including AVP and OXT into the general 
circulation via the hypophyseal veins. OXT release during parturition induces uterine 
contractions that facilitate birth, and release in response to suckling causes milk let-down from 
the mammary glands (Renaud and Bourque, 1991). AVP is released in response to a rise in 
plasma osmotic pressure or a fall in blood volume; it acts at the kidneys to promote water 
reabsorption, and causes vasoconstriction in some vascular beds (Renaud and Bourque, 1991). 
2.1.2 PARVOCELLULAR NEUROSECRETORY SYSTEM 
Secretion from the adenohypophysis is predominantly regulated by subpopulations of 
hypothalamic neurons known collectively as parvocellular neurosecretory neurons (PCNs). 
Hypophysiotrophic hormones are released into the ME, and then travel via the 
hypophyseal-portal circulation to the anterior pituitary, where they regulate adenohypophyseal 
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hormone synthesis and release. The six classical hypophysiotrophic hormones are growth 
hormone releasing hormone (GHRH), somatostatin (SS), gonadotrophin releasing hormone 
(GnRH), corticotrophin releasing hormone (CRH), thyrotrophin releasing hormone (TRH), and 
dopamine (DA). 
2.1.2.1 The distribution of PCNs in the rat hypothalamus 
All of the hypophysiotrophic hormones are synthesised by non-neuroendocrine neurons within 
and outside the hypothalamus (Hokfelt et al., 2000). Projection to the ME distinguishes true 
PCNs from the larger number of neurons that use hypophysiotrophic hormones as a 
neurotransmitter. CRH, TRH, GHRH, SS, and DA PCNs are distributed along a region of the 
periventricular hypothalamus bound rostrally by the vascular organ of the lamina terminalis 
(OVLT), and caudally by the posterior periventricular nucleus (PeP), with the majority clustered 
in the PVN and ARC (Markakis and Swanson, 1997). SS PCNs are commonest in the anterior 
periventricular nucleus (aPV), and the anterior and medial parvocellular portions of the PVN 
(Simmons and Swanson, 2009). Almost all TRH and CRH PCNs are located in the dorsal 
medial parvocellular (PaDM) part of the PVN (Simmons and Swanson, 2009). From medial to 
lateral, these PCNs are distributed SS, TRH, and then CRH. Scattered DA PCNs, identified by 
their expression of tyrosine hydroxylase, and GHRH PCNs are also seen in the PVN, but they 
are predominantly located in the ARC (Simmons and Swanson, 2009). The majority of GHRH 
and DA PCNs are located in the ventrolateral and dorsomedial ARC respectively (Markakis and 
Swanson, 1997). Thus, SS, TRH, CRH, DA, and GHRH PCNs are distributed along a 
continuous periventricular zone that includes the aPV, parvocellular PVN, and ARC.  
As a result of their unusual embryonic origins and in contrast to the other five, GnRH PCNs are 
displaced rostrally rostral, clustered in the medial preoptic area of the hypothalamus (MPOA) 
and in the medial septal-diagonal band complex of the telencephalic septal region (Barry et al., 
1973, Markakis and Swanson, 1997).  
2.1.2.2 The median eminance  
Anatomically the ME lies immediately below the third cerebral ventricle, posterior to the optic 
chiasm and rostral to the infundibulum. It is composed of an extensive array of blood vessels 
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and nerve endings. Its blood supply arises from the superior hypophyseal artery, which sends 
off many small branches that form capillary loops (Figure 2.1). The small capillary loops 
anastomose and drain into the pituitary portal veins that enter the vascular pool of the 
adenohypophysis (Knigge and Scott, 1970). The vascular arrangement connecting the 
hypothalamus and the adenohypophysis is termed the hypophyseal portal circulation. 
There are two distinct compartments within the ME, the internal zone and the external zone 
(Evans et al., 1994). The internal zone contains the axons of magnocellular and parvocellular 
destined for the neurohypophysis and external zone of the ME respectively. The external zone 
contains PCN terminals and the blood vessels of the hypophyseal portal system (Evans et al., 
1994). The ME is a circumventricular organ (CVO); its ventral surface is exposed to the 
perivascular space of capillaries allowing the passage of hypophysiotrophic hormones into the 
hypophyseal portal circulation (Knigge and Scott, 1970, Norsted et al., 2008). 
2.1.2.3 The adenohypophysis 
The adenohypophysis consists of the anterior lobe (pars distalis), the intermediate lobe (pars 
intermedia), and the pars tuberalis. Both the anterior and intermediate lobes of the pituitary 
derive from a dorsal invagination of the pharyngeal epithelium, called Rathke’s pouch, in 
response to inductive signals from the overlying neuroepithelium of the ventral diencephalon 
(Zhu et al., 2005). The main function of the anterior pituitary is the regulation of peripheral 
endocrine organ function through the secretion of trophic hormones.  
2.1.2.3.1 The intermediate lobe 
A well-developed intermediate lobe is found in most mammals, however, only rudimentary 
vestiges are detectable in adult humans, with the bulk of intermediate lobe cells being dispersed 
in the anterior and posterior lobes (Wingstrand, 1966). The intermediate lobe contains 
melanotroph cells that process the prohormone proopiomelanocortin (POMC) into β-endorphin 
and α-melanocyte-stimulating hormone (α-MSH) (Mains and Eipper, 1979, Chang and Loh, 
1984). The physiological function of the intermediate lobe is poorly understood. 
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2.1.2.3.2 The anterior lobe 
The anterior lobe is the largest part of the adenohypophysis. In the rat it surrounds all but the 
dorsal aspect of the posterior lobe of the neurohypophysis. The anterior lobe secretes ‘trophic’ 
hormones, under the regulation of the hypothalamus. Five distinct hormone-secreting cell types 
are present in the mature anterior pituitary gland. Corticotrophs express POMC peptides 
including adrenocorticotrophic hormone (ACTH); somatotrophs express growth hormone (GH); 
lactotrophs expresses prolactin (PRL); thyrotrophs express the common glycoprotein α-subunit 
and the specific thyroid-stimulating hormone (TSH) β-subunit, while gonadotrophs express the 
same α-subunit but β subunits for follicle-stimulating hormone (FSH) and luteinising hormone 
(LH). 
The distinct endocrine cell types are heterogeneously distributed in the anterior lobe (Larsen, 
2003). Somatotrophs account for 35-45% of pituitary cells and are concentrated laterally. 
Thyrotrophs are also concentrated laterally and these make up roughly 5% of anterior pituitary 
cells. Corticotrophs are found more medially and comprise 15-20% cells (Moriarty and Garner, 
1977). Lactotrophs and gonadotrophs are both randomly distributed and make up 25 and 10% 
respectively (Larsen, 2003).  
2.1.3 THE ANTERIOR HYPOTHALAMO-PITUITARY AXES 
The five classical anterior hypothalamo-pituitary axes are the hypothalamo-pituitary-adrenal 
(HPA) axis, hypothalamo-pituitary-thyroid (HPT) axis, hypothalamo-pituitary-gonadal (HPG) 
axis, hypothalamo-pituitary-prolactin axis, and the hypothalamo-pituitary-somatotrophic axis 
(Figure 2.3). They all share a common schematic whereby neural and humoral signals converge 
on specific PCNs and modulate their secretion of hypophysiotrophic hormones into the ME. 
Hypophysiotrophic hormones travel via the hypophyseal portal circulation to the anterior 
pituitary lobe, where they regulate trophic hormone secretion. Anterior lobe trophic hormones 
in turn regulate the secretion of circulating hormones by target endocrine organs, with the 
exception of prolactin. Control of secretion is exerted through negative feedback at multiple 
levels by circulating, trophic, and hypophysiotrophic hormones.  
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Figure 2.3: Diagrammatic representation of five classical anterior hypothalamo-pituitary axes. Although sex steroids act predominantly via negative feedback as 
shown, in females a transient positive feedback loop occurs during the late follicular phase (discussed in 2.1.3.4). 
Abbreviations: ACTH, adrenocorticotrophic hormone; CRH, corticotrophin-releasing hormone; FSH, follicle-stimulating hormone; GH, growth hormone; GHRH, 
growth hormone-releasing hormone; GnRH, gonadotrophin-releasing hormone; IGF, insulin-like growth factor; LH, luteinising hormone; T4, 
3,5,3’,5’-tetraiodo-L-thyronine; T3, 3,5,3’-triiodo-L-thyronine; TRH, thyrotrophin-releasing hormone; TSH, thyroid-stimulating hormone. Taken from (Melmed, 
2003) 
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2.1.3.1 The hypothalamo-pituitary-adrenal axis 
Internal or external stimuli that are perceived to challenge homeostasis are termed stressors (De 
Kloet et al., 2005). The HPA axis is the humoral component of an integrated neural and 
endocrine system that functions to orchestrate the response to stressors and maintain 
homeostasis. Activation of the HPA axis culminates in the secretion of glucocorticoids which 
act at multiple levels, temporarily redirecting resources to restorative processes (Selye, 1936). 
Much of the data presented in this chapter describes the effects of augurin on the HPA axis.  
The CRH system in the hypothalamus is vitally important for the integrated behavioural, 
endocrine, and autonomic response to stressors. In addition to CRH, there are three CRH-like 
peptides (urocortin I, urocortin II, and urocortin III), at least two cognate receptors (CRHR1 and 
CRHR2), and a high-affinity CRH-binding protein, each with distinct distribution in the CNS 
(Behan et al., 1989, Chen et al., 1993, Chalmers et al., 1995).  
At the hypothalamic level, CRH PCNs within the PVN control glucocorticoid secretion, and are 
the focal point for stress neurocircuitry (Whitnall, 1993). Under basal conditions, a circadian 
pulsatility of glucocorticoid secretion is maintained by direct projections from the SCN 
(Reppert and Weaver, 2002). In response to stressors however, a complex neural network that 
converges on the PVN initiates a surge in glucocorticoid levels (Ulrich-Lai and Herman, 2009). 
The PVN receives direct and indirect afferents from multiple sources including hypothalamic, 
brainstem, and limbic forebrain structures which modulate the activity of CRH PCNs (Herman 
et al., 2003).  
CRH is a 41-amino-acid peptide that stimulates the release of ACTH from pituitary 
corticotrophs (Vale et al., 1981). Two CRH G-protein-coupled receptors (GPCRs) have been 
identified; CRHR1 and CRHR2 (Bale and Vale, 2004). CRHR1 is expressed on pituitary 
corticotrophs and widely throughout the brain, while CRHR2 is less broadly expressed and 
predominantly found in the CNS (Chalmers et al., 1995). The nonapeptide AVP is co-expressed 
by a by a subset of CRH PCNs and it synergistically enhances the stimulation of ACTH release 
by CRH (Gillies and Lowry, 1979, Gillies et al., 1982).  
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ACTH is a 39-amino-acid peptide produced by cleavage of POMC (Lee et al., 1961). 
Circulating ACTH acts via the melanocortin 2 receptor (MC2R) to stimulate glucocorticoid 
synthesis and secretion from the adrenal gland (Ramachandran, 1984). The adrenal gland 
contains two endocrine components. The adrenal medulla is located at the centre of the adrenal 
gland and secretes catecholamines into the circulation. Surrounding the adrenal medulla is the 
cortex of the adrenal gland, which synthesises and secretes steroid hormones. The adrenal 
cortex is functionally and histologically comprised of three subdivisions. From exterior to 
interior they are the zona glomerulosa, zona fasciculate, and the zona reticularis (Mitani et al., 
1999). Glucocorticoids (predominantly cortisol in humans, corticosterone in rats) are secreted 
from the zona fasciculata under the control of ACTH, whereas mineralocorticoids 
(predominantly aldosterone) are secreted from the zona glomerulosa under the principal control 
of angiotensin II (Brecher et al., 1974). Cells of the zona reticularis secrete adrenal androgens 
that exert minor effects on reproductive function under physiological conditions (Migeon, 
1972).  
Glucocorticoids and mineralocorticoids exert their effects predominantly via the glucocorticoid 
and mineralocorticoid receptors (GR and MR) (Lu et al., 2006). Both receptors are members of 
the nuclear receptor superfamily (Chambon, 2005). They reside in the cytoplasm complexed 
with molecular chaperone proteins (Pratt and Toft, 1997). On ligand binding, the receptors 
translocate into the nucleus where they interact with specific responsive elements within the 
DNA, thus modulating the transcription of hormone responsive genes (Lu et al., 2006). The MR 
and GR share considerable homology and as a result, there is substantial promiscuity of ligand 
binding. While the GR is specifically activated by glucocorticoids, data from in vitro studies 
suggest aldosterone, corticosterone, and cortisol all bind to and activate the MR with equal 
affinity (Arriza et al., 1987, Lu et al., 2006). The average plasma glucocorticoid concentration is 
several orders of magnitude higher than plasma mineralocorticoid levels, however, tissue 
specificity at the MR and GR is conferred through the “pre-receptor” metabolism of steroid 
hormones via the 11β-hydroxysteroid dehydrogenase enzyme family (Edwards et al., 1988, 
Funder et al., 1988). Although the GR is encoded by single a gene, splice variants have been 
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described which, together with tissue specific post-translational modification are thought to 
account for many of the diverse actions of glucocorticoids (Pascual-Le Tallec and Lombes, 
2005, Zhou and Cidlowski, 2005). Like many of the steroid hormones, there is evidence 
glucocorticoids also exert rapid nongenomic effects, not mediated by the GR or MR (Evanson et 
al., 2010). 
Glucocorticoids regulate a wide range of physiological functions including intermediate 
metabolism, growth, immune function and bone and calcium metabolism (Buckingham, 2006). 
Circulating glucocorticoids negatively feedback on the HPA axis, acting on both the pituitary 
corticotrophs and the hypothalamic neurons that secrete CRH and AVP (Ulrich-Lai and 
Herman, 2009). 
2.1.3.2 The hypothalamo-pituitary-somatotrophic axis 
At the hypothalamic level GHRH and SS PCNs regulate the secretion of GH from pituitary 
somatotrophs. Post-translational processing of a single preproGHRH precursor yields several 
molecular forms of GHRH in the rat and human hypothalamus, and bioactivity lies in the 
N-terminal 29-amino-acids (Rivier et al., 1982, Mayo et al., 1983, Frohman et al., 1989). 
Somatostatin occurs in two major forms; a 14-amino-acid cyclic peptide (SS-14), and a 
28-amino-acid N-terminally extended form (SS-28). SS-14 is the predominant form in the CNS, 
whereas SS-28 is the major form in the gastrointestinal tract (Bloom and Polak, 1987).  
Pituitary somatotrophs expresses the GHRH receptor, GH secretagogue receptor (GHSR), and 
SS receptor subtypes 2 and 5, all of which regulate GH secretion (Shimon et al., 1997a, Mayo et 
al., 2000). GHRH selectively induces GH gene transcription and hormone release (Barinaga et 
al., 1983, Mayo et al., 2000), while SS suppresses basal and GHRH-stimulated GH release, and 
also supresses the release of TSH, ACTH, and PRL (Shimon et al., 1997a, Shimon et al., 
1997b). The hypophyseal release of SS and GHRH oscillate 180 degrees out of phase, resulting 
in pulsatile hormone secretion characteristic of GH (Plotsky and Vale, 1985, Vance et al., 
1985). Acyl-ghrelin, a 28-amino-acid peptide, is the only known endogenous ligand for the 
GHSR (Kojima et al., 1999). Acyl-ghrelin dose-dependently evokes GH release from 
somatotrophic cells (Kojima et al., 1999). 
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GH is an anabolic hormone that stimulates increased protein synthesis, promotes lipolysis and 
gluconeogenesis and increases bone mineralisation (Davidson, 1987, Moller and Jorgensen, 
2009). The principal form of GH is a 191-amino-acid single-chain polypeptide, accounting for 
90% of pituitary and 75% of plasma GH (Baumann et al., 1983). GH mediates its pleiotropic 
effects through the GH receptor (GHR), both directly by agonising GHRs on target organs, and 
indirectly through stimulation of insulin-like growth factor-1 (IGF-1) secretion by the liver 
(Lupu et al., 2001).  
2.1.3.3 The hypothalamo-pituitary-thyroid axis 
The HPT axis directly regulates energy expenditure and metabolic rate, and has a much broader 
permissive role in development, growth, reproduction, and metabolism. TRH PCNs determine 
the set-point of feedback control, and therefore HPT axis tone (Nikrodhanond et al., 2006). 
TRH, a tripeptide, is the smallest known NEP (Boler et al., 1969). Rat preproTRH contains five 
TRH peptides (six in humans) flanked by dibasic residue cleavage sites (Lee et al., 1988). Two 
TRH GPCRs have been identified in rodents, TRHR1 and TRHR2, however humans appear to 
lack a functional TRHR2 gene (Straub et al., 1990, Heuer et al., 2000, Sun et al., 2003). TRH 
stimulates the secretion of TSH via TRHR1 on thyrotrophs, while DA and SS have modest 
inhibitory effects (Arimura and Schally, 1976, Morley, 1981, Jackson, 1982). 
TSH is a glycoprotein heterodimer of two non-covalently linked α and β subunits (Pierce and 
Parsons, 1981). TSH, LH, FSH and human chorionic gonadotrophin share a common α-subunit, 
and each has a unique β-subunit that confers specificity of action (Fiddes and Goodman, 1981, 
Grossmann et al., 1997). TSH acts via a single TSH receptor expressed by thyroid follicular 
cells, stimulating the synthesis and release of 3,5,3’,5’-tetraiodo-L-thyronine (T4) and 
3,5,3’-triiodo-L-thyronine (T3) (Vassart et al., 1995, Rapoport et al., 1998). Normal plasma T4 
levels are roughly 40 fold higher than plasma T3, and the vast majority of both are bound and 
sequestered in the plasma by thyroxine-binding globule, transthyretin, or albumin (Robbins, 
1992, Schussler, 2000). Only free T4 and T3 are bioactive (fT4 and fT3 respectively), the latter 
15-fold more active than the former (Brent, 1994). Both fT4 and fT3 circulate in equilibrium 
with the bound fraction so that roughly 0.02% and 0.3% of total plasma T4 and T3 are in the free 
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form (Robbins and Rall, 1957, Schussler, 2000). Negative feedback on thyrotrophs and TRH 
PCNs maintains plasma fT4 and fT3 within a remarkably narrow range (Reichlin and Utiger, 
1967, Segerson et al., 1987, Dyess et al., 1988).  
Intracellular transport of T4 and T3 is near universal but tissue specificity is conferred by 
expression of particular membrane transporter, iodothyronine deiodinase, and thyroid hormone 
receptor subtypes (Brent, 1994, Gereben et al., 2008, Van Der Deure et al., 2010). The 
iodothyronine deiodinases are a family of selenoprotein enzymes that catalyse the 
dehalogenation of iodothyronines (Gereben et al., 2008). Intracellular T4 is metabolised into T3 
by type 1 and type 2 deiodinase, or inactive rT3 by type 3 deiodinase (St Germain and Galton, 
1997). T3 is the principal ligand for the ubiquitously expressed thyroid hormone receptors 
(TRs), which are members of the nuclear receptor superfamily. There are four TRs, TRα1 and 
TRβ1, TRβ2, and TRβ3 (Lazar, 2003). Ligand binding alters the affinity of the TR complex for 
thyroid hormone response elements in the DNA, thereby regulating transcription (Lazar, 2003).  
2.1.3.4 The hypothalamo-pituitary-gonadal axis 
The physiology of the mammalian HPG axis is a highly complex, sexually dimorphic, and 
changes dramatically depending on reproductive status. Plasma reproductive hormone levels, 
and thus fertility and reproductive behaviour, are regulated by GnRH PCNs (Seeburg and 
Adelman, 1984). There are two mammalian GnRH genes; Gnrh1 and Gnrh2 (Sherwood et al., 
1993). GnRH-I, encoded by the Gnrh1 gene, is expressed by GnRH PCNs, and this form 
regulates gonadotroph function (Fernald and White, 1999). GnRH-I is a decapeptide produced 
from a 92-amino-acid preproGnRH1 precursor (Seeburg and Adelman, 1984). Following 
cleavage by PC enzymes, the N-terminal Gln is cyclised, while the C-terminal Gly is amidated 
(Amoss et al., 1971, Baba et al., 1971, Matsuo et al., 1971, Schally et al., 1971). The 
N-terminal pGlu-His-Trp-Ser and C-terminal Pro-Gly-NH2 are critical for biological activity, 
and are highly conserved throughout vertebrates (Fernald and White, 1999, Millar, 2005). 
GnRH-I stimulates the release of LH and FSH via the GnRHR1, a GPCR expressed by pituitary 
gonadotrophs (Cheng and Leung, 2005).  
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GnRH PCNs fire in coordinated and episodic manner, producing distinct pulses of GnRH-I in 
the hypophyseal circulation (Carmel et al., 1976). The regulation of GnRH-I pulses is highly 
complex; their amplitude and frequency determine the pattern of LH and FSH secretion, and 
vary depending on pubertal development, circadian rhythms, and the stage of the oestrus cycle 
in females (Crowley et al., 1991, Krsmanovic et al., 2009). The pulsatile release of GnRH is 
critical for fertility because continuous GnRH administration down-regulates pituitary 
gonadotroph activity, leading to suppression of gonadotrophin secretion and subsequent 
infertility (Belchetz et al., 1978). The determinants of GnRH-I secretion are collectively termed 
the ‘GnRH pulse generator’, and their identity is a fundamental, unsolved question in 
reproductive biology. There is evidence GnRH PCNs are inherently pulsatile (Wetsel et al., 
1992, Suter et al., 2000), but they also receive peptidergic inputs from neurons expressing 
kisspeptin (KISS) (Cravo et al., 2011), nesfatin (Garcia-Galiano et al., 2010), neurokinin B 
(NKB) (Goodman et al., 2007), dynorphin A (DYN) (Wakabayashi et al., 2010), gonadotrophin 
inhibitory hormone (GnIH) (Kriegsfeld et al., 2006), neuropeptide Y (Klenke et al., 2010), 
galanin (Rajendren and Gibson, 2001), galanin-like peptide (Matsumoto et al., 2001), and 
POMC (Hill et al., 2010), as well as classical neurotransmitters such as glutamate and GABA 
(Chen and Moenter, 2009, Khan et al., 2010), all of which regulate hypophysiotrophic GnRH 
release. 
Of the aforementioned neuronal projections those expressing KISS and those expressing GnIH 
have received considerable attention recently (Clarke, 2011). KISS neurons reside within the 
preoptic region and ARC (Mikkelsen and Simonneaux, 2009). ARC KISS neurons co-express 
NKB and DYN (KNDy neurons) and project directly to GnRH PCNs (Goodman et al., 2007, 
Lehman et al., 2010). Although there is some variability between species considerable evidence 
suggests KNDy neurons are important regulators of the mammalian HPG axis. Hypothalamic 
injection of KISS or NKB stimulates the release of GnRH into the hypophyseal circulation 
(Thompson et al., 2004b, Navarro et al., 2011). Furthermore loss-of-function mutations in the 
genes encoding KISS (Kiss1), NKB (Tac3), or their cognate receptors (Gpr54 and Tacr3 
respectively), cause congenital isolated hypogonatrophic hypogonadism (Seminara et al., 2003, 
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D'anglemont De Tassigny et al., 2007, Topaloglu et al., 2009). GnIH was identified as a 
hypothalamic neuropeptide that inhibits HPG axis activity in the quail and a large body of work 
has established this is as a bone fide regulatory peptide in avian species (Tsutsui et al., 2000, 
Tsutsui et al., 2009). Nerveless, although an analogous effect has been described in mammals, 
discrepancies in the literature regarding the magnitude, sites, and relevance of its biological 
effects mean its physiological role is unclear (Pineda et al., 2010). 
Both LH and FSH are synthesised and intermittently secreted from gonadotrophs in response to 
the pulsatile release of GnRH (Evans, 1999). They act via their respective GPCRs on the gonads 
where they regulate gametogenesis and the production of sex steroids (Misrahi et al., 1996, 
Themmen and Huhtaniemi, 2000). In males, LH promotes the secretion of testosterone and 
other androgens from Leydig cells in the testes (Bhalla et al., 1992), while in females, LH and 
FSH act together to regulate the production of oestrogens and progesterones in the ovaries 
(Themmen and Huhtaniemi, 2000). Sex steroids act predominantly via negative feedback at the 
hypothalamic and pituitary levels to supress HPG axis tone (Damassa et al., 1976, Tilbrook and 
Clarke, 2001). In females however, prolonged exposure to oestrogens during the late follicular 
phase of the oestrous cycle results in a transient positive feedback loop that triggers ovulation 
(Moenter et al., 1990). 
2.1.3.5 Hypothalamo-pituitary-prolactin axis 
Human PRL is a 199-amino-acid polypeptide necessary for lactation in mammals (Li et al., 
1969, Ormandy et al., 1997). In contrast to the other trophic hormones, the hypothalamic 
regulation of PRL is predominantly inhibitory, mediated by DA PCNs (Ben-Jonathan, 1985). 
DA inhibits PRL secretion via type 2 dopamine receptors on pituitary lactotrophs (Ben-
Jonathan, 1985). No primary PRL releasing hormone has been identified, but numerous 
hypothalamic and systemic factors have been shown to stimulate PRL secretion, including 
vasoactive intestinal polypeptide (VIP), OXT, PRL-releasing peptide (PrRP), TRH, and 
oestrogen (Lloyd et al., 1975, Bjoro et al., 1984, Liu and Ben-Jonathan, 1994, Hinuma et al., 
1998). 
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Circulating PRL is a mixture of monomeric and polymeric forms with varying bioactivity (Suh 
and Frantz, 1974, Farkouh et al., 1979). All forms of PRL act via a single PRL receptor (PRLR) 
that is similar in structure and function to the GHR (Arden et al., 1990, Bazan, 1990, Goffin and 
Kelly, 1997). PRLRs are broadly expressed, and in addition to stimulating lactation, prolactin 
has been implicated in the regulation of fluid and electrolyte balance, growth and development, 
behaviour, and immune function (Bole-Feysot et al., 1998).  
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2.2 HYPOTHESIS AND AIMS 
Augurin is a putative neuroendocrine peptide of unknown function, and is expressed in the 
CNS, pituitary, and endocrine organs. I hypothesise that augurin may play a role in the 
neuroendocrine system. As the hypothalamus and pituitary are sites at which many NEPs have 
biological activity, and are pivotal components of the neuroendocrine system, I began by 
investigating the effects of augurin on the hypothalamo-pituitary axes in male Wistar rats. 
2.2.1 AIMS 
1. Investigate the effects of augurin on plasma hormone levels following central or 
peripheral injection in vivo.  
2. Investigate the direct effect of augurin on the release of neurohypophyseal 
hormones from the hypothalamus. 
3. Investigate the direct effect of augurin on trophic hormone release from the 
pituitary. 
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2.3 METHODS 
2.3.1 PEPTIDES 
A synthetic fragment of human augurin corresponding to amino acids 71 to 148 of 
preproaugurin protein was synthesised by Bachem UK Ltd. (Merseyside, UK). The synthesis 
was performed using a Symphony automated peptide synthesiser (Protein Technology, Inc., 
USA). The product was initially purified by flash chromatography with a reversed phase resin 
(Daisogel, Daiso Ltd. Japan), followed by reversed phase high-pressure liquid chromatography 
(HPLC). Analyses of the purified peptide by matrix-assisted laser desorption/ionisation mass 
spectroscopy, HPLC, and amino acid analysis showed above 91% purity (average molecular 
weight 9689). Rat neuromedin U (NMU) 23, angiotensin II (AII), and astressin 
(cyc30-33[D-Phe12,Nle21,38,Glu30,Lys33]CRH-(12-41)) were purchased from Bachem UK Ltd.  
Augurin is poorly soluble in water, therefore, for all studies lyophilised augurin was first 
dissolved in a small amount of 0.05M HCl, and then diluted in saline (in vivo studies) or 
artificial cerebrospinal fluid (aCSF; hypothalamic and pituitary explant studies) containing 
sufficient NaOH to neutralise the HCl. Vehicle was prepared by mixing the same amounts of 
0.05M HCl, 0.05M NaOH, and saline/aCSF. The pH of vehicle and peptide solutions was 
checked prior to injection by pipetting a small amount onto pH indicator paper. AII, astressin, 
and NMU were dissolved into a minimal quantity of sterile water, and then diluted into sterile 
saline (AII and astressin) or vehicle (NMU 23) prior to injection. 
2.3.2 ANIMALS 
Male Wistar rats (specific pathogen free; Charles River, Margate, UK), weighing 250-300g 
were maintained in individual cages under controlled temperature (21-23 C) and light (12 hour 
light, 12 h dark cycle; lights on at 0700 h) conditions with ad libitum access to food (RM1 diet, 
SDS Ltd., Witham, UK) and water. Animal procedures were approved under the British Home 
Office Animals Scientific Procedures Act 1986 (Project Licence 70/6402). 
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2.3.3 INTRACEREBROVENTRICULAR CANNULATION AND INJECTIONS 
Intracerebroventricular (ICV) cannulation was carried out using an established protocol (Rossi 
et al., 1997). Prophylactic antibiotics were administered to prevent post-operative infection. An 
ip injection of a mixture of amoxycillin (37.5mg/kg) and flucloxacillin (37.5mg/kg) was given 
prior to surgery. Animals were anaesthetized by ip injection of a mixture of xylazine (10mg/kg) 
(Rompun, Bayer UK Ltd.) and ketamine (100mg/kg) (Ketalar, Parke-Davis, Pontypool, UK) in 
a 2:5 ratio. The head was cleaned with 10% w/v povidone/iodine solution (Betadine, Seton 
Healthcare) and the animal placed in a stereotaxic frame (David Kopf instruments, supplied by 
Clark Electromedial Instruments) with the incisor bar set at 3mm below the interaural line. Prior 
to commencement of surgery, each rat received a single sub-cutaneous injection of 
buprenorphine (45µg/kg; Schering-Plough, Welwyn Garden City, UK) for analgesia. A 1.5cm 
incision was made in the scalp and the skull surface exposed by removal of the periosteum. A 
hole was drilled 0.8mm posterior to the bregma on the midline. A permanent 22-gauge 
intracerebroventricular (ICV) stainless steel cannula (Plastics One Inc. USA) was 
stereotaxically implanted 6.5mm below the outer surface of the skull projecting to the third 
cerebral ventricle. Co-ordinates were calculated from the Rat Brain Atlas (Paxinos, 2007). 
Three stainless steel screws were secured in the skull in three additional drill holes to anchor the 
dental cement (Associated Dental Products Ltd) used to hold the cannula in position. A 
plastic-topped obturator (Plastic One Inc.) was then inserted into the cannula to prevent 
blockage. Following surgery 5ml 0.9% sodium chloride was injected ip to prevent hypovolemia.  
Following surgery, rats were allowed a seven-day recovery period during which time they were 
checked daily. Prior to the studies, each rat received two sham injections (one of AII and one of 
saline) to acclimatise them to the procedure. Only animals with correct cannula placement, as 
confirmed by a sustained drinking response to ICV AII (50ng/rat), were included in the studies. 
Peptide/vehicle was administered in 5µl volume to conscious, freely moving rats using a 
stainless steel injector (Plastics One Inc.) placed into, and projecting 1mm below, the cannula 
tip. The injector was connected by polythene tubing to a Hamilton gas tight syringe (Fischer 
Scientific, UK) in a Harvard infusion pump (Harvard Apparatus, USA). The tubing was filled 
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with water and a 1µl bubble drawn up into it to separate the experimental compound from the 
water. Injections were given over 1 minute, and the injector left in place for a further 30 seconds 
to allow diffusion of the compound and to prevent retrograde flow. Rats were returned to their 
own cages following the injection procedure.  
2.3.4 INTRAPARAVENTRICULAR CANNULATION AND INJECTIONS 
Unilateral intrahypothalamic cannulation directed at the PVN (iPVN) was carried out using an 
established protocol (Abbott et al., 2003). Animals were maintained and handled for iPVN 
cannulation as in 2.3.3. Anaesthesia, surgical equipment, and post cannulation recovery were 
the same as in 2.3.3. Only the site and cannula gauge differed. Permanent 26-gauge stainless 
steel guide cannulae (Plastics One Inc.) were stereotaxically implanted using established 
coordinates obtained from the Rat Brain Atlas (1.8mm posterior to the bregma, 0.3mm laterally 
and implanted 7.5mm below the outer surface of the skull) (Paxinos, 2007). 
For iPVN injections, peptides were dissolved as described in 2.3.1 and administered in 1µl 
volume via a stainless steel injector projecting 1mm beyond the tip of the cannula. Correct 
cannula placement was confirmed histologically at the end of the study period by injection of 
India ink using an established protocol (Abbott et al., 2003). Following decapitation 1µl of India 
ink was injected into the cannula using the same protocol as iPVN injection of peptide. The ink 
was allowed to diffuse for 5 minutes, following which the guide cannula was removed. The 
brain was rapidly dissected out, fixed overnight in 4% formaldehyde, cryoprotected in 40% 
sucrose, and frozen in an isopentane/dry ice bath. Brains were stored at -70 C until sectioning. A 
freezing sled microtome (Shandon Southern Products Ltd, Cheshire, UK) was used to take 
40µm coronal sections. Sections were stained with cresyl violet and compared with the 
corresponding section from the rat brain atlas (Nissl, 1894, Paxinos, 2007).  
Data from rats were excluded if the injection site extended more than 0.4mm outside the 
intended injection site, or if any ink was detected in the cerebroventricular system. In total 71% 
of cannulae were correctly positioned. Figure 2.4 shows a representative section of the PVN 
containing India ink.  
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Figure 2.4: Photomicrograph of the spread of 1µl India ink injected into the PVN. The section 
was not stained so that the ink could be clearly seen. 
Abbreviations: 3V, 3rd ventricle; ot, optic tract. 
3V 
ot 
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2.3.5 THE EFFECT OF ICV AUGURIN ON PLASMA HORMONE LEVELS 
Each rat received a single ICV injection of vehicle or 5 nmol augurin (n = 9-10 per group) in the 
early light phase (0900-1200 h). Rats were killed by decapitation 60 minutes after injection. 
Trunk blood was collected in plastic lithium heparin tubes containing 4200 kallidinogenase 
inactivator units of aprotinin (Bayer Corp., Haywards Heath, UK) for LH, FSH, GH, TSH, PRL, 
testosterone, fT3, fT4, and corticosterone assays, and in plastic ethylenediaminetetraacetic acid 
(EDTA) tubes for ACTH assays. Plasma was immediately separated by centrifugation at 1600g 
for 10 minutes, frozen on dry ice, and stored at -20 C (lithium heparin tubes) or -80 C (EDTA 
tubes). 
2.3.6 THE EFFECT OF ICV AUGURIN ON PLASMA CORTICOSTERONE 
AND ACTH 
Each rat received a single ICV injection of vehicle, 0.6, 1.7, or 5 nmol augurin in the early light 
phase (0900-1200 h). Rats were killed by decapitation 20 or 60 minutes post injection (n = 8-10 
per group per time point). Trunk blood was collected and stored as in 2.3.5. 
2.3.7 THE EFFECT OF IPVN AUGURIN ON PLASMA CORTICOSTERONE 
AND ACTH 
Each rat received a single iPVN injection of vehicle, 0.1, 0.3, or 1 nmol augurin in the early 
light phase (0900-1200 h). Rats were killed by decapitation 20 or 60 minutes post injection (n = 
5-8 per group per time point). Trunk blood was collected and stored as in 2.3.5. 
2.3.8 THE EFFECT OF IPVN AUGURIN ON BEHAVIOUR 
The acute effects of iPVN augurin on behaviour were formally assessed by blinded observers 
using an established protocol (Smith et al., 2006). Each rat received a single iPVN injection of 
vehicle, 1 nmol augurin, or 0.3 nmol NMU 23 (n = 6-8 per group) in the early light phase 
(0900-1200 h). Behavioural patterns were monitored for 120 minutes following injection by 
observers blinded to the experimental treatment. Behaviour was classified into eight different 
categories; feeding, drinking, grooming, burrowing, rearing, locomotion, head down, and 
sleeping, adapted from Fray et al (Fray et al., 1980). These methods have previously been used 
to demonstrate abnormal behaviour following iPVN injection of peptides (Wren et al., 2002). 
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During the analysis, each rat was observed for 15 seconds every 5 minutes. Each 15-second 
period was further subdivided into three and the predominant behaviour of the rat during each 
5-second episode was noted. NMU was used as a positive control as it is known to increase 
grooming behaviour and decrease sleeping (Wren et al., 2002). 
2.3.9 THE EFFECT OF AUGURIN ON CRH AND AVP RELEASE FROM 
HYPOTHALAMIC EXPLANTS 
Static incubation of hypothalamic explants was carried out using an established technique 
(Dhillo et al., 2002). Ad libitum fed male Wistar rats were killed by decapitation and the whole 
brain immediately removed. The brain was mounted with the ventral surface uppermost and 
placed in a vibrating microtome (Microfield Scientific Ltd., Dartmouth, UK). A 1.9mm slice 
was taken from the basal hypothalamus and blocked lateral to the circle of Willis. The 
hypothalamic slices were incubated in individual chambers containing 1ml aCSF (20mM 
NaHCO3, 126mM NaCl, 0.09mM Na2HPO4, 6mM KCl, 1.4mM CaCl2, 0.09mM MgSO4, 5mM 
glucose, 0.18mg/ml ascorbic acid, and 100µg/ml aprotinin) equilibrated with 95% O2 and 5% 
CO2. 
The tubes were placed on a platform in a water bath maintained at 37 C. After an initial 2 h 
equilibration period, hypothalami were incubated for 45 min in 600µl aCSF (basal period), 
before being treated with 1, 10, or 100nM augurin in 600µl aCSF for 45 min (n = 13-15 
hypothalamic slices per group). Finally, tissue viability was assessed by incubation for 45 min in 
aCSF containing 56mM KCl. Isotonicity was maintained by substituting K+ for Na+. Explanted 
hypothalami that failed to show peptide release above the basal level in response to aCSF 
containing 56mM KCl were excluded from the data analysis. At the end of each period, aCSF 
was collected and stored at -20 C until measurement of CRH and AVP by radioimmunoassay 
(RIA).  
2.3.10 THE EFFECT OF PERIPHERAL CRHR ANTAGONISM ON AUGURIN 
INDUCED ACTH AND CORTICOSTERONE SECRETION  
ICV cannulated rats were injected ip with 100µg/kg astressin or vehicle 15 minutes before 
receiving an ICV injection of 5 nmol augurin or vehicle. Astressin is a CRHR1/2 receptor 
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antagonist (Gulyas et al., 1995), not known to cross the blood-brain barrier. This dose of 
astressin has previously been used to block the increase in plasma ACTH and corticosterone 
caused by ICV injection of GLP-1 (Kinzig et al., 2003). Rats were decapitated 30 minutes after 
the ICV injection (n = 7-9 per group). Trunk blood was collected and stored as in 2.3.5. 
2.3.11 THE EFFECT OF PERIPHERALLY ADMINISTERED AUGURIN ON 
PLASMA HORMONE LEVELS 
Rats were handled daily and received twice-weekly ip injections to acclimatise them to the 
procedure. On the day of the study, rats were injected ip with 100 nmol/kg augurin or vehicle 
during the early light phase (0900-1200 h). Rats were decapitated 30 minutes after the ip 
injection (n = 7-9 per group). Trunk blood was collected and stored as in 2.3.5. 
2.3.12 THE EFFECT OF AUGURIN ON ACTH RELEASE FROM PITUITARY 
SEGMENTS 
Static pituitary explants were performed using an established technique (Smith et al., 2006). 
The anterior pituitaries of ad libitum fed rats were harvested immediately following 
decapitation. The posterior pituitary was removed from the anterior pituitary which was bisected 
along the mid-sagittal line and then divided into four pieces of approximately equal size. After 
an acclimatisation period, the segments were then incubated in one of aCSF alone, or aCSF 
containing 10nM augurin, 100nM augurin, 1000nM augurin or 100nM CRH for 4 h (n = 17-19 
per group). At the end of this period the incubation medium was collected and stored at -20 C 
until assayed for ACTH by RIA. 
2.3.13 RADIOIMMUNOASSAYS 
RIAs for CRH and AVP were performed using established protocols (Dhillo et al., 2003). The 
intra and interassay coefficient of variation (!!) were <10% for the CRH RIA, and 11% and 
20% respectively for the AVP RIA. Plasma corticosterone was measured using an RIA kit from 
MP Biomedicals, Inc. (Orangeburg, NY, USA), for which the intra and interassay !! were less 
than 10% and 7% respectively. For studies 2.3.5, 2.3.6, and 2.3.7, plasma ACTH was measured 
by immunoradiometric assay purchased from Euro-Diagnostica B.V. (Arnhem, The 
Netherlands). The intra and interassay !! were both less than 4%. For study 2.3.10 plasma 
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ACTH was measured by immunoradiometric assay purchased from BioSource Europe S.A. 
(Nivelles, Belgium) because the previously used kit was no longer available. The intra and 
interassay !!  were 6.4% and 6.2% respectively. Plasma TSH, LH, FSH, PRL, GH, were 
measured, using methods and reagents provided by the National Hormone and Pituitary 
program, as was and ACTH release from pituitary segments. Total plasma testosterone, fT3 and 
fT4 were measured using commercial Coat-a-Count RIA kits (Euro/DPC Limited, Caenarfon, 
UK). The relevant theoretical and practical aspects of RIAs are described in more detail in 
appendix I. 
2.3.14 STATISTICS 
Data from hypothalamic explant, pituitary explant, and terminal studies are presented as mean ± 
SEM. Data from behavioural analyses are presented as median frequency and interquartile range 
for each behaviour Data from hypothalamic explant release were analysed using paired Student t 
test between the basal period and the test period. Data from pituitary explant release were 
analysed using one-way ANOVA followed by post hoc Holm-Sidak test (SigmaStat 3.5, San 
Jose, CA, USA). Data from the behavioural study were analysed using Kruskal-Wallis one-way 
ANOVA on ranks (Systat 11, San Jose, CA, USA).  
The normal distributions of plasma ACTH and corticosterone levels are positively-skewed 
(Ganong and Systems, 1995). Therefore plasma ACTH and corticosterone values were log 
transformed to homogenise variances among groups, and to improve the normality of residuals 
(Bland and Altman, 1996). Transformed values were then analysed by Student t test, or one- or 
two-way ANOVA followed by post hoc Holm-Sidak test (SigmaStat 3.5, San Jose, CA). 
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2.4 RESULTS 
2.4.1 THE EFFECT OF ICV AUGURIN ON PLASMA HORMONE LEVELS 
Augurin significantly increased plasma ACTH 60 minutes post injection (ACTH pg/ml; vehicle 
21.3 ± 3.2, 5 nmol augurin 66.7 ± 16.3, p<0.001). Plasma corticosterone was raised but failed to 
reach statistical significance (corticosterone ng/ml; vehicle 152.8 ± 25.9, augurin 5 nmol 300.0 
± 65.1). There were no significant changes in plasma LH, FSH, GH, TSH, prolactin, 
testosterone, fT3, or fT4 (Table 2.1). 
2.4.2 THE EFFECT OF ICV AUGURIN ON PLASMA CORTICOSTERONE 
AND ACTH 
Plasma ACTH and corticosterone levels were significantly elevated following ICV injection of 
augurin compared with vehicle injected controls (Figure 2.5). In the case of ACTH, two-way 
ANOVA revealed that there was a significant main effect of dose (F(3,60) = 11.789; p<0.001), a 
significant main effect of time (F(1,60) = 7.956; p<0.01), and a significant interaction (F(3,60) = 
3.181; p<0.05). Post hoc analysis demonstrated that ICV injection of 5 nmol augurin 
significantly increased plasma ACTH 20 minutes post injection (p<0.001). All doses of augurin 
significantly increased plasma ACTH 60 minutes post injection (p<0.01 for all doses). 
In the case of corticosterone, two-way ANOVA revealed that there was a significant main effect 
of dose (F(3,68) = 8.510; p<0.001), a significant main effect of time (F(1,68) = 3.799; p<0.05), and 
no significant interaction (F(3,68) = 0.954; p=0.420). Post hoc analysis demonstrated that ICV 
injection of 5 nmol augurin significantly increased plasma corticosterone 20 minutes post 
injection (p<0.001). 
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Table 2.1: Effect of a single ICV injection of augurin (5 nmol) or vehicle in ad libitum fed rats 
on plasma hormone concentrations at 60 minutes post injection. *** p<0.001 vs. vehicle, n = 9-
10 per group. Results are mean ± SEM 
 Vehicle Augurin  (5 nmol) 
 Mean SEM Mean SEM 
ACTH (pg/ml) 21.3 3.2 66.7*** 16.3 
Corticosterone (ng/ml) 152.8 25.9 300.0 65.1 
LH (ng/ml) 0.60 0.09 0.54 0.12 
FSH (ng/ml) 8.97 0.65 7.18 0.88 
Testosterone (ng/dL) 425.4 87.2 495.7 139.2 
TSH (ng/ml) 2.38 0.14 2.21 0.37 
Free T4 (ng/dL) 2.05 0.11 2.27 0.12 
Free T3 (pg/dL) 1.28 0.11 1.21 0.13 
PRL (ng/ml) 5.28 0.79 5.15 0.81 
GH (ng/ml) 20.27 4.38 22.39 11.54 
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Figure 2.5: Effect of a single ICV injection of augurin (0.6, 1.7, or 5 nmol) or vehicle in ad 
libitum fed male Wistar rats on plasma ACTH and corticosterone at 20 (A and C) and 60 (B and 
D) minutes post injection. **p<0.01, ***p<0.001 vs. vehicle, n = 8-10 per group per time point. 
Results are mean ± SEM. 
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2.4.3 THE EFFECT OF IPVN AUGURIN ON PLASMA CORTICOSTERONE 
AND ACTH 
Plasma ACTH and corticosterone levels were significantly elevated following iPVN 
microinjection of augurin compared with vehicle-injected controls (Figure 2.6). In the case of 
ACTH, two-way ANOVA revealed that there was a significant main effect of dose (F(3,45) = 
9.891; p<0.001), a significant main effect of time (F(1,45) = 5.363; p<0.05), and no significant 
interaction (F(3,45) = 0.600; p=0.618). Post hoc analysis demonstrated that iPVN microinjection 
of 1 nmol augurin significantly increased plasma ACTH 20 and 60 minutes post injection 
(p<0.01 for both time points).  
In the case of corticosterone, two-way ANOVA revealed that there was a significant main effect 
of dose (F(3,45) = 6.247; p<0.001), no significant main effect of time (F(1,45) = 2.275; p=0.138), 
and no significant interaction (F(3,45) = 1.129; p=0.347). Post hoc analysis demonstrated that 
iPVN microinjection of 1 nmol augurin significantly increased plasma corticosterone 20 
minutes post injection (p<0.01). 
2.4.4 THE EFFECT OF IPVN AUGURIN ON BEHAVIOUR 
There were no significant behavioural differences between iPVN augurin or vehicle injected 
rats. Injection of 0.3 nmol NMU significantly increased time spent grooming, and decreased 
time spent sleeping or feeding (Table 2.2). 
2.4.5 THE EFFECT OF AUGURIN ON CRH AND AVP RELEASE FROM 
HYPOTHALAMIC EXPLANTS 
Augurin caused a significant increase in CRH and AVP release from hypothalamic explants. 
Neither assay demonstrated cross-reactivity with aCSF, aCSF containing 1, 10, or 100 nM 
augurin, nor the high potassium aCSF. CRH and AVP release is presented in Table 2.3 and 
graphically as a percent of basal in Figure 2.7. 
2.4.6 THE EFFECT OF PERIPHERAL CRHR ANTAGONISM ON AUGURIN 
INDUCED ACTH AND CORTICOSTERONE SECRETION  
Pre-treatment with astressin completely blocked the increase in plasma ACTH and 
corticosterone 30 minutes post ICV injection of 5nmol augurin (Figure 2.8).  
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Figure 2.6: Effect of a single iPVN injection of augurin (0.1, 0.3, or 1 nmol) or vehicle in ad 
libitum fed male Wistar rats on plasma ACTH and corticosterone at 20 (A and C) and 60 (B and 
D) minutes post injection. *p<0.05, **p<0.01, ***p<0.001 vs. vehicle, n = 5-8 per group per 
time point. Results are mean ± SEM. 
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Table 2.2: Effect of a single iPVN injection of augurin (1 nmol), NMU (0.3 nmol), or vehicle in ad libitum fed male rats on behaviour. *p<0.05, **p<0.01, 
***p<0.001 vs. vehicle, n = 6-8 per group. Data presented are median frequency and interquartile range.   
0-60 minutes  Feeding  Rearing  Drinking  Locomotion  Grooming  Burrowing  Head down  Sleeping  
Vehicle  2 [0:4]  8 [6:15]  0 [0:0]  5 [3:7]  6 [4:8]  0 [0:1]  1 [0:1]  11 [7:14]  
Augurin 1 nmol 7 [4:9]  10 [8:13]  0 [0:0]  8 [6:9]  5 [4:8]  0 [0:0]  1 [0:3]  2 [0:9]  
NMU 0.3 nmol  0 [0:0]  7 [6:9]  0 [0:0]  5 [3:6]  21 [18:24]**  1 [0:4]  1 [0:3]  0 [0:0]**  
61-120 minutes  
        
Vehicle  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:2]  35 [31:36]  
Augurin 1 nmol 0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:0]  2 [0:4]  32 [30:36]  
NMU 0.3 nmol  0 [0:0]  0 [0:0]  0 [0:0]  0 [0:1]  10 [2:18]*  0 [0:0]  1 [0:4]  23 [17:24]*  
0-120 minutes  
        
Vehicle  3 [1:4]  8 [6:16]  0 [0:0]  5 [3:8]  6 [4:8]  0 [0:1]  3 [0:5]  47 [38:48]  
Augurin 1 nmol 7 [4:9]  10 [8:14]  0 [0:0]  8 [6:9]  6 [4:9]  0 [0:0]  3 [3:6]  32 [30:45]  
NMU 0.3 nmol  0 [0:0]*  7 [6:9]  0 [0:0]  5 [3:6]  30 [20:40]***  1 [0:4]  2 [1:8]  23 [17:24]*  
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Table 2.3: Effect of augurin (1, 10 or 100nM) on CRH and AVP release from hypothalamic explants. *p<0.05 vs. basal release. Results are mean ± SEM 
 
Concentration of augurin in aCSF 
1nM 10nM 100nM 
Basal Augurin Basal Augurin Basal Augurin 
CRH (pmol/explant) 1.3 ± 0.35 2.1 ± 0.59 1.8 ± 0.51 3.4 ± 0.88* 2.3 ± 0.73 5.5 ± 1.27* 
AVP (fmol/explant) 700.3 ± 151.82 1169.8 ± 633.97 655.6 ± 143.33 1142.2 ± 145.39 759.9 ± 148.81 1487.5 ± 304.77* 
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Figure 2.7: Effect of augurin (1, 10, or 100nM) on CRH (A) and AVP (B) release from 
hypothalamic explants. Data presented as percent of basal release. *p< 0.05 vs. basal release, n 
= 13-15 hypothalami per group. Results are mean ± SEM. 
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Figure 2.8: Effect of a single ICV injection of augurin (5 nmol) or vehicle in ad libitum fed male 
Wistar rats pre-treated with 100nmol/kg astressin on plasma ACTH (A) and corticosterone (B) 
30 minutes post ICV injection. **p<0.01, ***p<0.001 vs. vehicle, n = 7-9 per group. Results are 
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2.4.7 THE EFFECT OF PERIPHERALLY ADMINISTERED AUGURIN ON 
PLASMA HORMONE LEVELS 
There were no significant differences in plasma corticosterone, LH, FSH, GH, TSH, PRL, fT3, 
or fT4 at 30 minutes post ip injection of 100nmol/kg augurin (Table 2.4). 
2.4.8 THE EFFECT OF AUGURIN ON ACTH RELEASE FROM PITUITARY 
SEGMENTS 
No significant change in ACTH release was seen following incubation of pituitary segments 
with 10, 100, or 1000nM augurin, compared with aCSF alone. Incubation with 100nM CRH 
resulted in a significant increase in ACTH release (ACTH ng/explant; vehicle 192.9 ± 23.1; 
CRH 100nM 296.7 ± 36.2, p<0.01) (Figure 2.9). 
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Table 2.4 Effect of a single ip injection of augurin (100 nmol/kg) or vehicle in ad libitum fed 
rats on plasma corticosterone, LH, FSH, GH, TSH, prolactin, free T3, and free T4 at 30 minutes 
post injection. Results are mean ± SEM, n = 7-9 per group. 
 Vehicle Augurin  (100 nmol/kg) 
 Mean SEM Mean SEM 
Corticosterone (ng/ml) 34.5 12.6 22.3 4.45 
LH (ng/ml) 0.84 0.11 0.59 0.05 
FSH (ng/ml) 9.40 0.67 7.74 0.58 
TSH (ng/ml) 2.21 0.19 2.25 0.15 
Free T4 (ng/L) 22.5 1.1 21.1 1.0 
Free T3 (pg/L) 10.8 1.5 12.3 1.0 
PRL (ng/ml) 3.87 0.66 2.29 0.38 
GH (ng/ml) 105.9 33.1 64.7 23.5 
     
 74  
 
Figure 2.9: Effect of augurin (10, 100, or 1000nM) or CRH (100nM) on ACTH release from 
pituitary segments. **p<0.01, n = 17-19 per group. Results are mean ± SEM. 
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2.5 DISCUSSION 
Augurin is a recently identified secreted peptide of unknown function. It is expressed in the 
CNS and endocrine organs. I therefore examined the effects of augurin on the 
hypothalamo-pituitary axes. Both ICV and iPVN injection of augurin elevated plasma ACTH 
and corticosterone compared with vehicle-injected controls, and augurin increased the release of 
CRH and AVP from hypothalamic explants. The rise in plasma ACTH and corticosterone 
following ICV injection of augurin was blocked by pre-treatment with a CRH receptor 
antagonist.  
ICV injection of 5 nmol augurin increased plasma ACTH three fold 20 minutes after injection, 
versus vehicle injected controls. Plasma corticosterone also increased three fold over the same 
period. Interestingly, ICV injection of 0.6 or 1.7 nmol augurin caused a delayed rise in plasma 
ACTH, evident only at 60 minutes (Figure 2.5). The reason for this delay is unclear; it is 
possible that it represents the time taken for the peptide to diffuse to its site or sites of action. 
Alternatively, small differences in plasma ACTH at 20 minutes may have been masked by the 
stress of the experimental procedure. ICV injection of 5 nmol augurin had no effect on plasma 
LH, FSH, testosterone, TSH, fT3, fT4, PRL, or GH at 60 minutes post injection, compared with 
vehicle injected controls, suggesting the neuroendocrine effects of augurin are specific to the 
HPA axis. 
CRH and AVP are the main regulators of ACTH levels; they act synergistically on the pituitary 
to stimulate ACTH secretion (Whitnall, 1993). Augurin increased the release of CRH and AVP 
from explanted hypothalami, and pre-treatment with the non-selective CRHR antagonist 
astressin blocked the rise in plasma ACTH and corticosterone caused by ICV injection of 
augurin. This suggests augurin stimulates the secretion of ACTH by stimulating the release of 
CRH and AVP from hypothalamic PCNs, although the relative contribution of AVP cannot be 
determined from the antagonist study as CRH is necessary for AVP stimulated ACTH release 
(Whitnall, 1993).  
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CRH neurons in the PVN are the major conduit for endocrine, autonomic, and behavioural 
responses to stress (Herman, 1997). The PVN contains a subpopulation of hypophysiotrophic 
neurons that constitute the primary source of CRH and AVP (Hashimoto et al., 1982, 
Sawchenko et al., 1993). I therefore examined the effects of injecting augurin directly into the 
PVN on the HPA axis. Intranuclear injection of lower doses minimises any nonspecific side 
effects of peptide administration that may occur following ICV injection (Dhillo et al., 2002).  
Microinjection of 1 nmol augurin iPVN significantly increased plasma ACTH and 
corticosterone; a much lower dose than required for a similar effect ICV. This could indicate 
receptors for augurin are found within or close to the PVN. It is, however, possible that lower 
concentrations of augurin could diffuse into adjacent nuclei, and I cannot therefore discount 
administration of augurin to other hypothalamic areas having a similar effect. There were no 
significant effects on ACTH or corticosterone following iPVN injection of 0.1 or 0.3 nmol 
augurin. There were no significant differences in behaviour in the two hours following iPVN 
microinjection of 1 nmol augurin, compared with vehicle injected controls. In particular, no 
adverse behaviours such as hunched posture or tremors were observed in the augurin group, 
indicating that nonspecific activation of the HPA axis secondary to a noxious effect is unlikely 
(Deacon, 2006, Kalueff et al., 2007).  
Basal and augurin-stimulated levels of ACTH and corticosterone varied somewhat between 
studies. In study 2.4.2 basal ACTH is 41.1 ± 9.6pg/ml at 20 min and 14.9 ± 2.1pg/ml at 60 min, 
in study 2.4.3 the values are 72.8 ± 18.1pg/ml and 56.7 ± 16.6pg/ml, while in study 2.4.6 basal 
ACTH is 16.3 ± 2.6pg/ml at 30 min. Unfortunately it was necessary to measure ACTH levels 
using a different assay kit for study 2.4.6 because the previously used assay kit was no longer 
being manufactured. For studies 2.4.2 and 2.4.3 plasma ACTH was measured by 
immunoradiometric assay manufactured by Euro-Diagnostica B.V. whereas for study 2.4.6, 
plasma ACTH was measured by immunoradiometric assay manufactured by BioSource Europe 
S.A. It is common to see variations in levels measured by different assay kits and this may 
account for the differences between studies (Bieling et al., 1988).  
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Peripheral administration of augurin at doses of 100nmol/kg had no effect on plasma 
corticosterone at 30 minutes post injection. This dose is relatively high; ip injection of 4.2 
nmol/kg of CRH causes a significant rise in plasma ACTH (Watanabe et al., 1991). 
Furthermore, incubation of pituitary segments with augurin at concentrations of up to 1000nM 
had no effect on ACTH release. It therefore appears unlikely that peripheral augurin acts 
directly on the pituitary to release ACTH, unless it is released into the circulation at very high 
concentrations. To date, the presence of augurin in the circulation has not been investigated.  
The data presented in this chapter indicate hypothalamic injection of augurin (preproaugurin 
71-148) stimulates the HPA axis. It is also possible shorter fragments of augurin will be 
biologically active. The N-terminal segment of augurin adjacent to the Lys69/Arg70 dibasic 
cleavage site has substantially higher interspecies conservation than the rest of the peptide 
(Figure 1.1). I hypothesise that the increase in conservation implies the N-terminal segment is 
important for biological activity. Identifying the endogenous forms of augurin and determining 
the minimum biologically active sequence would provide a basis for developing structural 
analogues acting as antagonists or agonists of the augurin system. 
Hypophysiotrophic CRH neurons within the PVN control glucocorticoid secretion and are the 
focal point for neurocircuitry projecting from hypothalamic, brainstem and forebrain nuclei 
conveying information regarding stressors (Ulrich-Lai and Herman, 2009). In response to 
stressors, a surge in plasma glucocorticoids is initiated by the activity of stress responsive 
neurocircuitry directly or indirect on PVN CRH neurons (Ulrich-Lai and Herman, 2009). The 
studies in this chapter suggest that hypothalamic injection of augurin stimulates the HPA axis in 
rats, and that this effect is likely mediated by the release of CRH from neurons in the PVN. 
Nevertheless, these studies show a pharmacological rather than physiological effect. Two 
studies published during the preparation of this thesis indicate that endogenously 
preproaugurin-like immunoreactivity (LI) is present within neurons of the CNS, suggesting 
augurin could play a physiological role in the HPA axis (Roberton et al., 2009, Kujuro et al., 
2010). 
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Early studies of hypocretin (HCRT) illustrate the accuracy with which neuropeptide function 
can be inferred from its neuroanatomy. Based on the distribution of HCRT neurons, a role in the 
regulation of food intake, blood pressure, body temperature, and the sleep-waking cycle were 
hypothesised, all of which have since been confirmed (Peyron et al., 1998, Tsujino and Sakurai, 
2009, Scammell and Winrow, 2011). A similarly detailed analysis of the distribution of augurin 
neurons, their projections, and their neurochemical identity might indicate possible 
physiological roles within the CNS. Furthermore, differences in the distribution or intensity of 
preproaugurin-LI or mRNA in response to a stressor, or following suppression or elevation of 
circulating glucocorticoids would suggest a physiological role for augurin in the regulation of 
the HPA axis. 
Multiple neuropeptides including HCRT, neuropeptide Y, cocaine-and amphetamine-regulated 
transcript protein, glucagon-like peptide-1, melanocortin-concentrating hormone, and PrRP are 
all released into the PVN and peri-PVN area where they contribute to the PVN peptidergic 
microenvironment (Rinaman, 1999, Stanley et al., 2001, Lin et al., 2002, Mihaly et al., 2002, 
Sarkar and Lechan, 2003, Swaab, 2004, Pissios et al., 2006). Neuropeptides released in this 
manner regulate HPA axis activation, and particularly the intra-hypothalamic processing of 
stressful stimuli (Herman et al., 2002). The extent of intra-hypothalamic processing depends on 
the precise nature of the ‘stressful’ stimulus and ensures that stimuli are interpreted in the 
context of cardiovascular, nutritional, immune, and reproductive status, in order that the 
appropriate response ensues (Herman et al., 2002, Swaab, 2004). It is possible augurin my have 
a similar role to the aforementioned neuropeptides. Further characterisation of the 
neuroanatomy, identification of receptors, and the development of specific antagonists are 
important to establish whether augurin has a physiological role in the regulation of the HPA axis 
and whether it may represent a novel target for the treatment of stress related diseases. 
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3 THE EFFECTS OF AUGURIN ON 
FOOD INTAKE 
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3.1 INTRODUCTION 
The rise in obesity and its comorbid associations is one of the most pressing issues facing the 
medical and scientific community. The prevalence of obesity amongst adults worldwide has 
risen by 75% since 1980, and has been rising even faster in children (Bray, 1998, Flegal, 2005). 
The threat to public health services is unparalleled and obesity has become a socioeconomic 
time bomb because of its well known cardiovascular, metabolic, reproductive, neoplastic, 
musculoskeletal, and psychosocial complications (Ogden et al., 2006, Welborn and Dhaliwal, 
2011). 
Despite the alarming figures, the increasing incidence of obesity is not reflected by a 
proportionate increase in body weight (Friedman, 2003). Body weight is kept remarkably 
constant during most of adult human life, in spite of large variations in daily energy intake and 
expenditure (Jéquier and Tappy, 1999). The regulation of body weight is incredibly precise, 
typically food intake matches expenditure to within 0.17% over a decade (Harris, 1990). This 
degree of precision implies the active regulation or defence of energy intake and expenditure. 
Indeed, evidence suggests humans and rodents have a complex “adipostatic” system that 
defends body weight in the face of positive or negative energy balance (Bandini et al., 1989, 
Keesey and Corbett, 1990).  
3.1.1 THE HYPOTHALAMUS AND THE REGULATION OF FOOD INTAKE 
Food intake is controlled by a complex and diverse neural network, within which the 
hypothalamus plays a critical and largely non-redundant role. The hypothalamus integrates both 
long- and short-term signals about energy flux, and orchestrates the compensatory responses to 
positive or negative energy balance (Morton et al., 2006). Although simplistic, the melanocortin 
model, in which orexigenic agouti-related protein (AgRP) and anorexigenic 
proopiomelanocortin (POMC) neurons within the hypothalamic arcuate nucleus (ARC) take 
centre stage, is the most widely accepted framework for explaining hypothalamic regulation of 
food intake.  
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Figure 3.1: The melanocortin model. Activation of AgRP neurons promotes food intake and 
reduces energy expenditure, whereas activation of POMC neurons reduces food intake and 
increases energy expenditure. Insulin and leptin inhibit AgRP neurons and stimulate POMC 
neurons, thereby reducing food intake, whereas ghrelin activates AgRP neurons and thereby 
increases food intake.  
Abbreviations: AgRP, agouti-related protein; CART, cocaine-and amphetamine-regulated 
transcript protein; Ghsr, growth hormone secretagogue receptor; Lepr, leptin receptor; 
Mc3r/Mc4r, melanocortin 3/4 receptor; NPY, neuropeptide Y; POMC, proopiomelanocortin; 
Y1r, Y1 receptor. Adapted from (Barsh and Schwartz, 2002). 
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3.1.1.1 The melanocortin model 
The hypothalamic melanocortin system comprises two opposing populations of ‘first order’ 
peptidergic neurons in the ARC (Figure 3.1) (Cone, 2005). One population express POMC and 
their activity suppresses food intake (POMC neurons), while the other subset co-express AgRP 
and neuropeptide Y (NPY), and their activity stimulates food intake (AgRP neurons) (Cowley et 
al., 2001, Aponte et al., 2011). Within the ARC, POMC neurons are located lateral to AgRP 
neurons, and in rodents roughly 50% of POMC neurons co-express cocaine-and 
amphetamine-regulated transcript protein (CART) (Elias et al., 1998, Hahn et al., 1998). In 
humans, however, CART co-localises with AgRP, and is absent from POMC neurons 
(Menyhert et al., 2007).  
3.1.1.1.1 POMC neurons  
The majority of POMC neurons in the CNS are located in the hypothalamus and nucleus of the 
tractus solitarius (Civelli et al., 1982, Joseph et al., 1983). Within the hypothalamus, POMC is 
expressed exclusively in the ARC (Jacobowitz and O'donohue, 1978, Gee et al., 1983). The 
melanocortins α- and γ-melanocyte-stimulating hormone (MSH) are the major products of 
POMC processing in the rodent central nervous system (CNS), and both are potently 
anorexigenic when injected ICV (Panskepp et al., 1976, Jacobowitz and O'donohue, 1978, 
Emeson and Eipper, 1986). Subsets of ARC POMC neurons also synthesise and release the 
neurotransmitters γ-amino butyric acid (GABA) or glutamate (Horvath et al., 1997, Hentges et 
al., 2004, Hentges et al., 2009).  
Of the five melanocortin receptors, subtype 4 (MC4R), and to a lesser extent subtype 3 
(MC3R), are important for the regulation of feeding (Cone, 2006). The CNS distribution of 
MC4Rs is broader than that of MC3Rs, but both receptors highly expressed in hypothalamic 
nuclei, the paraventricular nucleus (PVN), lateral hypothalamic area (LHA), and ventromedial 
nucleus (VMN) (Roselli-Rehfuss et al., 1993, Mountjoy et al., 1994). The orexigenic peptide 
AgRP acts as a competitive antagonist at both receptors, and has also been shown to inhibit 
constitutive activity in the MC4R (Ollmann et al., 1997, Nijenhuis et al., 2001). In the rodent 
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hypothalamus, α-MSH is believed to be the main endogenous agonist of the MC3R and MC4R 
(Panskepp et al., 1976, Adan et al., 1994, Oosterom et al., 1998). 
Studies of genetic defects that impair α-MSH signalling clearly demonstrate the critical role of 
the melanocortin system in energy homeostasis. In both humans and mice, homozygous 
loss-of-function mutations in the gene encoding the α-MSH precursor (Pomc), the enzymes 
required for post translational processing into α-MSH (Pcsk1, Cpe), it’s receptor (Mc4r), or 
several downstream targets of the melanocortin system (Sim1, Bdnf, and Ntrk2), each cause 
marked hyperphagia and adiposity (Cool et al., 1997, Huszar et al., 1997, Jackson et al., 1997, 
Krude et al., 1998, Vaisse et al., 1998, Yeo et al., 1998, Farooqi et al., 2000, Holder et al., 
2000, Xu et al., 2003, Yeo et al., 2004, Han et al., 2008). It is noteworthy that heterozygous 
mutations result in an intermediate phenotype, suggesting there is little redundancy in anorectic 
tone from the melanocortin system (Huszar et al., 1997, Jackson et al., 1997, Farooqi et al., 
2000, Holder et al., 2004, Farooqi et al., 2006). 
3.1.1.1.2 AgRP neurons  
AgRP neurons in the ARC co-express NPY, a potent orexigen (Stanley and Leibowitz, 1985, 
Hahn et al., 1998). NPY is a member of the PP-fold peptide family, all of which bind and 
activate members of the Y-receptor family (Lin et al., 2004). NPY is abundant throughout the 
CNS, and particularly within the hypothalamus (Adrian et al., 1983, Allen et al., 1983). Of the 
five known Y-receptors, evidence suggests Y1R and Y5R mediate the orexigenic effect of NPY, 
and both receptors are expressed throughout the hypothalamus (Gerald et al., 1996, Kanatani et 
al., 1996, Parker and Herzog, 1999). 
Although hypothalamic injection of NPY stimulates feeding, blockade of NPY signalling has 
minor effects, if any, on energy homeostasis, and its precise physiological role in regulating 
feeding is therefore unclear. Mice with homozygous loss-of-function mutations in Npy, Npy1r, 
or Npy5r have normal food intake and body weight, or, paradoxically, a slight increase in 
adiposity and mild hyperphagia (Erickson et al., 1996a, Marsh et al., 1998, Pedrazzini et al., 
1998, Ishihara et al., 2006). Genetic or pharmacological blockade of NPY signalling in adults 
has a similarly innocuous effect, suggesting the mild phenotype in Npy-, Npy1r-, or 
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Npy5r- knockout (KO) mice is not a result of developmental compensation (Ste Marie et al., 
2005, Erondu et al., 2006). Nevertheless, ARC NPY expression is elevated during negative 
energy balance and in most genetic models of obesity (Sanacora et al., 1990, Kalra et al., 1991, 
Wilding et al., 1993, Kesterson et al., 1997, Schwartz et al., 1998). Furthermore, loss of Npy 
attenuates the hyperphagia caused by leptin deficiency and fasting, suggesting a specific role for 
NPY in the acute response to starvation (Erickson et al., 1996b, Segal-Lieberman et al., 2003). 
A series of elegant experiments over the last decade have shed considerable light on the role of 
AgRP neurons in energy homeostasis, and demonstrate that, in contrast to POMC neurons, the 
AgRP neurons themselves, rather than their characteristic neuropeptides, play an essential role 
in feeding behaviour. Firstly, transgenic mouse models enabling the ablation or depolarisation 
of AgRP neurons demonstrate their activity is both necessary and sufficient for feeding (Gropp 
et al., 2005, Luquet et al., 2005, Aponte et al., 2011, Krashes et al., 2011). Secondly, although 
AgRP neurons project to and hyperpolarise POMC neurons, and AgRP antagonises MC3/4Rs, 
the acute stimulation of feeding by AgRP neurons appears to be independent of 
melanocortinergic signalling (Horvath et al., 1992, Cowley et al., 2001, Cowley et al., 2003, 
Tong et al., 2008, Wu et al., 2008, Aponte et al., 2011). And thirdly, that the release of GABA 
by AgRP neurons is necessary for energy homeostasis, while null mutations in Npy, Agrp, or 
both have little effect on appetite (Qian et al., 2002, Wortley et al., 2005, Phillips and Palmiter, 
2008, Tong et al., 2008, Wu et al., 2009). 
3.1.1.2 The regulation of the melanocortin system by the periphery 
The ARC integrates a number of peripheral signals as part of its role in regulating energy 
homeostasis. Peripheral signals can be classified into a short-term feedback signals that regulate 
the initiation and termination of meals depending on the contents of the gastrointestinal tract, 
and long-term feedback signals of energy stores such as leptin and insulin (Morton et al., 2006, 
Suzuki et al., 2010).  
3.1.1.2.1 Long-term feedback signals 
Leptin is the archetypal adipostatic hormone; mathematical modelling of both food intake and 
energy expenditure over time as a function of plasma leptin alone matches experimental data 
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from numerous in vivo studies with remarkable accuracy (Tam et al., 2009). Leptin is secreted 
by primarily by white adipocytes and circulates in approximately direct proportion to adipose 
mass (Frederich et al., 1995, Considine et al., 1996). During acute starvation, however, plasma 
leptin levels decrease excessively relative to the mass of adipose lost (Weigle et al., 1997). 
Leptin insufficiency profoundly affects whole body physiology to promote positive energy 
balance at the expense of reproductive, immune, and anabolic processes (Friedman and Halaas, 
1998). Loss-of-function mutations in the gene encoding leptin or the gene encoding the leptin 
receptor cause extreme hyperphagia and adiposity in both rodents (Lepob/ob and Leprdb/db mice 
respectively) and humans (Zhang et al., 1994, Lee et al., 1996, Phillips et al., 1996, Montague 
et al., 1997, Clement et al., 1998).  
Circulating leptin acts in the CNS to promote negative energy balance by supressing food intake 
and increasing energy expenditure (Cohen et al., 2001). Leptin traverses the blood brain barrier 
(BBB) via a specific transport system, and has direct effects on disparate neuronal targets within 
the hypothalamus, brainstem, hippocampus, cortex, and limbic system (Balthasar et al., 2004, 
Dhillon et al., 2006, Leinninger et al., 2009, Yadav et al., 2009, Hayes et al., 2010). 
Administration of leptin to fasted mice reverses many of the neuroendocrine consequences of 
starvation, suggesting that the physiological role of leptin is to inhibit the starvation response 
(Ahima et al., 1996). 
Insulin also meets the criteria for an adipostatic hormone. Secreted by pancreatic β-cells, plasma 
insulin correlates positively with adiposity (Polonsky et al., 1988). Insulin crosses the BBB via 
receptor-mediated transport process, and acts in the hypothalamus to promote negative energy 
balance (Bagdade et al., 1967, Schwartz et al., 1991, Baura et al., 1993). Blockade of 
hypothalamic insulin signalling by injection of anti-insulin antibodies, by neuron-specific 
insulin receptors (IRS) knockout, or by antisense mediated IRS knockdown, results in 
hyperphagia and increased adiposity (Strubbe and Mein, 1977, Brüning et al., 2000, Obici et al., 
2002). These data support a physiological role for hypothalamic insulin signalling in the 
regulation of energy homeostasis.  
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3.1.1.2.2 Short-term feedback signals from the gut 
The ingestion of food gives rise to mechanical and chemical stimulation of the gastrointestinal 
tract (GIT) and, in turn, to the secretion of numerous gut hormones. These neurohormonal 
signals are primarily implicated in the regulation of meal initiation and termination. Gut 
hormones are produced from several different regions of the GIT, and include cholecystokinin 
(CCK), peptide YY3-36 (PYY3-36), glucagon-like peptide-1, oxyntomodulin, and pancreatic 
polypeptide (PP) (Suzuki et al., 2010). Plasma gut hormone levels rise rapidly after food is 
ingested, and in general they act to inhibit further food intake (Suzuki et al., 2010). Gut 
hormones signal to the CNS either indirectly via the vagus nerve and circumventricular organs, 
or cross the BBB and act directly on brainstem, hypothalamic, and limbic areas (Cummings and 
Overduin, 2007, Kastin and Pan, 2008, Price et al., 2008).  
Ghrelin is the only known gut hormone which is orexigenic (Kojima et al., 1999). It is secreted 
primarily by the stomach and has a role in both long- and short-term energy homeostasis. 
Circulating levels of the ghrelin increase before each meal and decline rapidly afterwards, 
implicating it in meal initiation (Cummings et al., 2001, Tschop et al., 2001a). In addition, 
plasma ghrelin is inversely proportional to body mass index, and is altered by changes in body 
weight (Tschop et al., 2001b, Purnell et al., 2007). In rodents, central or peripheral injection of 
ghrelin increases food intake and adiposity, while peripheral injection of a ghrelin receptor 
antagonist has the opposite effect (Tschop et al., 2000, Esler et al., 2007).  
3.1.1.3 The regulation of the melanocortin system by the CNS 
In addition to neurohormonal signals from the periphery, the ARC reciprocally innervates 
structures throughout the CNS that play a role in feeding. Efferent projections from the 
brainstem, LHA, and VMN to the melanocortin system are amongst the most important and 
best-characterised CNS pathways. 
3.1.1.3.1 Brainstem 
Within the caudal brainstem, the dorsal vagal complex (DVC) is crucial in the interpretation and 
relaying of peripheral signals of energy balance to the hypothalamus. Vagal nerve endings are 
found throughout the oesophagus, stomach, liver, and both small and large intestines, the 
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majority of which are afferent sensory fibres (Powley et al., 2005). The vagus conveys 
information from mechano- and chemoreceptors activated by the presence of nutrients in the 
stomach and the intestine to the DVC (Gao and Horvath, 2008). In addition, vagal nerves 
express receptors for several gut hormones, and the effects of CCK, ghrelin, GLP-1, and 
PYY3-36 on food intake appear to be mediated in part via the vagus nerve (Abbott et al., 2005, 
Le Roux et al., 2005, Berthoud, 2008). 
The DVC consists of the dorsal motor nucleus of vagus (DMX), area postrema (AP), and the 
nucleus of the tractus solitarius (NTS). Specific subnuclei of the NTS are the first central 
neurons to process ingestion-related vagal afferent signals (Sawchenko, 1983). The NTS 
receives and integrates information about energy status from numerous sources as well as the 
vagus. NTS neurons also express receptors for, and alter their firing in response to, peripheral 
hormones such as ghrelin and leptin (Mercer et al., 1998, Grill et al., 2002, Ellacott et al., 2006, 
Hisadome et al., 2010, Cui et al., 2011). Additional blood-borne signals related to nutrient 
status are relayed via dense projections from the AP, a sensory circumventricular organ (CVO) 
immediately adjacent to the NTS (Berthoud et al., 2006, Price et al., 2008, Wang et al., 2008). 
Efferents from the NTS project caudally to the ascending visceral afferent pathway, which 
includes neurons located in the parabrachial nucleus, ARC, PVN, ventral forebrain, thalamus, 
and insular cortex (Berthoud et al., 2006, Grill, 2010).  
3.1.1.3.2 The VMN 
Classic lesioning studies in the 1940s and 1950s fostered the ‘dual centre’ model, whereby 
appetite was regulated by the LHA feeding and VMN satiety centres (Hetherington and Ranson, 
1940, Anand and Brobeck, 1951, Stellar, 1954). However, the role of the VMN was 
subsequently questioned because the process of lesioning also damaged nearby nuclei and 
traversing neuronal fibres (Gold, 1973, Parkinson and Weingarten, 1990). More recent studies 
of the molecular biology, neurochemistry, and neurophysiology of VMN neurons have in large 
part validated the conclusions drawn from the early lesions studies, and suggest the VMN is 
indeed a satiety centre.  
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Within the CNS, the transcription factor steroidogenic factor-1 (SF1) is expressed exclusively 
by VMN neurons (Ikeda et al., 1995). Deletion of SF1 in mice results in agenesis of the VMN 
and leads to hyperphagia and increased adiposity (Dellovade et al., 2000, Majdic et al., 2002). 
Leptin has been shown to directly activate SF1 neurons in the VMN, and deletion of Lepr from 
SF1 lineage neurons causes hyperphagia and increased adiposity (Dhillon et al., 2006). 
Although these studies demonstrate an important role for the VMN in supressing food intake, 
how the VMN regulates output from the ARC is poorly understood. The recent identification of 
neuronal projections from the VMN to the ARC implies the VMN might promote negative 
energy balance by directly regulating the activity of melanocortin system neurons (Sternson et 
al., 2005). Using a combination of laser scanning photo-stimulation and slice electrophysiology, 
Sternson et al. demonstrated neurons within the lateral and medial VMN project to the ARC 
where they predominantly synapse POMC neurons. Furthermore, while VMN-to-ARC 
inhibitory projections were essentially absent, VMN-to-POMC neuron projections were almost 
universally excitatory, and were markedly reduced by fasting (Sternson et al., 2005). These data 
suggest VMN neurons regulate energy homeostasis via direct excitatory stimulation of POMC 
neurons. 
3.1.1.3.3 The LHA 
Within the LHA, two intermingled but distinct cell populations express the orexigenic 
neuropeptides melanin-concentrating hormone (MCH) and the hypocretins (HCRT) (Qu et al., 
1996, Broberger et al., 1998, Sakurai et al., 1998). Although primarily implicated in arousal, 
MCH and HCRT neurons play a prominent role in the coordinated behavioural responses to 
negative energy balance (Van Den Pol et al., 2004, Williams et al., 2008, Silva et al., 2009). 
MCH- and HCRT-LI fibres directly synapse neurons throughout the hypothalamus and CNS, 
including the majority of structures involved in energy homeostasis (Bittencourt et al., 1992, 
Peyron et al., 1998, Yamanaka et al., 2003). Despite their similarities MCH and HCRT neurons 
interact with the melanocortin system essentially independent of each other. HCRT neurons are 
activated rapidly by fasting, and project heavily to AgRP, but not POMC, neurons within the 
ARC (Horvath et al., 1999, Diano et al., 2003). Furthermore, their activity and synaptic profiles 
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on AgRP neurons is regulated by peripheral feedback signals such as ghrelin, leptin, and insulin 
(Toshinai et al., 2003, Horvath and Gao, 2005, Louis et al., 2010). Feeding in response to ICV 
HCRT is dependant on Y1 and Y5 receptors, suggesting the orexigenic effects of HCRT are 
mediated by direct stimulation of AgRP neurons (Jain et al., 2000, Yamanaka et al., 2000). In 
contrast, MCH-LI projections in the ARC are relatively sparse, but MCH increases food intake 
by functionally antagonising the effects of α-MSH at ‘second order’ neurons (Abbott et al., 
2003, Croizier et al., 2010). The difference in phenotype between Hcrt-/- and Mch-/- mice 
illustrates the distinct roles of MCH and HCRT neurons in energy homeostasis. Hcrt-/- mice are 
overweight and hypophagic, while Mch-/- mice are lean and hypophagic (Shimada et al., 1998, 
Chemelli et al., 1999, Hara et al., 2001, Willie et al., 2003). 
3.1.1.4 Downstream targets of the melanocortin system 
Neuronal and hormonal signals converge on POMC and AgRP neurons in the ARC, which in 
turn project to ‘second order’ neurons throughout the CNS (Figure 3.1). Within the 
prosencephalon, the distribution of γ-MSH and AgRP fibres overlap, however, with the 
exception of the parabrachial and trigeminal nuclei, γ-MSH fibres innervate the mesencephalon 
and rhombencephalon in the absence of AgRP (Bagnol et al., 1999, Haskell-Luevano et al., 
1999). POMC and AgRP neurons also project extensively within the hypothalamus. Most nuclei 
contain some POMC and AgRP fibres, but the PVN receives by far the densest innervation and 
is recognised as a key downstream target of the melanocortin system (Elias et al., 1998, Bagnol 
et al., 1999, Haskell-Luevano et al., 1999, Atasoy et al., 2008). 
3.1.1.5 The PVN 
Evidence indicates the PVN is a critical node in neural circuitry that coordinates 
neuroendocrine, autonomic, and behavioural responses underlying energy balance. Firstly, the 
PVN receives peptidergic and non-peptidergic afferents from diverse regions of the CNS that 
regulate feeding, including prominent projections from hypothalamic and brainstem nuclei 
(Swanson and Sawchenko, 1983, Sawchenko et al., 1985, Elmquist et al., 1998, Patterson et al., 
2011). Secondly, PVN neurons express receptors for the majority of neurotransmitters, 
neuropeptides, and hormones that regulate feeding, including GABA, glutamate, leptin, insulin, 
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ghrelin, NPY, MCH, HCRT, and α-MSH (Baskin et al., 1993, Mountjoy et al., 1994, 
Hakansson et al., 1998, Trivedi et al., 1998, Cole and Sawchenko, 2002, Fetissov et al., 2004). 
Furthermore, microinjection of orexigenic or anorexigenic peptides directly into the PVN 
requires lower doses to elicit an effect then ICV (Stanley and Leibowitz, 1985, Rossi et al., 
1999, Kim et al., 2000, Kennedy et al., 2003, Olszewski et al., 2003). 
MC4R expressing PVN neurons are synapsed by both POMC and AgRP neurons, which 
stimulate and inhibit their activity respectively (Cowley et al., 1999, Cowley et al., 2003, 
Ghamari-Langroudi et al., 2011). Rodent models in which ARC-PVN signalling is disrupted 
demonstrate the importance of the PVN in for the regulation of energy homeostasis by the 
melanocortin system. Discrete lesions of the PVN cause marked hyperphagia and adiposity, as 
do loss-of-function mutations in the Sim1 gene, a haploinsufficient transcription factor 
necessary for the normal development of the PVN (Leibowitz et al., 1981, King et al., 1989, 
Holder et al., 2000, Michaud et al., 2001, Kublaoui et al., 2006). Furthermore, overexpression 
of AgRP in the PVN causes hyperphagia and adiposity, while restoration of MC4R expression 
in Sim1 lineage neurons is sufficient to normalise food intake in MC4R-/- mice (Balthasar et al., 
2005, De Backer et al., 2010). These data demonstrate the importance of the PVN in the 
regulation of energy homeostasis, and imply that net autonomous output from the PVN is 
anorexigenic and maintained under normal conditions by direct melanocortinergic tone. 
3.1.1.5.1 The regulation of food intake by the PVN 
There are three predominant efferent pathways from the PVN; endocrine via the pituitary; 
autonomic via direct projections to preganglionic neurons in the spinal cord (sympathetic) and 
the vagus (parasympathetic); and behavioural via projections to the brainstem and LHA (Saper 
et al., 1976, Thompson and Swanson, 2003, Geerling et al., 2010). Evidence suggests a subset 
of non-hypophysiotrophic CRH and OXT neurons, which form part of the behavioural output 
from the PVN, are important second order targets for both melanocortinergic and 
non-melanocortinergic pathways regulating appetite. 
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3.1.1.5.2 CRH 
A significant number of MC4R expressing neurons in the medial parvocellular PVN also 
express functional leptin receptors and the anorexigenic neuropeptides CRH and/or OXT 
(Hakansson et al., 1998, Lu et al., 2003, Ghamari-Langroudi et al., 2011). Hypothalamic CRHR 
agonism consistently causes a reduction of food intake and body weight, with greater attribution 
to the CRHR2 subtype (Morley and Levine, 1982, Krahn et al., 1988, Gardner et al., 1998, 
Cullen et al., 2001, Stengel et al., 2009). A physiological role for the CRH system is supported 
by the apposite variation of CRH and CRHR2 mRNA, and of CRH peptide, in response to 
exogenous leptin, food deprivation, or overfeeding (Schwartz et al., 1996, Gardner et al., 1998, 
Makino et al., 1998, Cullen et al., 2001). Furthermore, ICV co-injection of a CRHR antagonist 
attenuates the anorexigenic effects of α-MSH and leptin (Gardner et al., 1998, Uehara et al., 
1998, Lu et al., 2003).  
3.1.1.5.3 OXT 
OXT neurons in the PVN are necessary for energy homeostasis, and are important downstream 
targets of leptin’s effects on food intake. Firstly, mouse models in which CNS oxytocin 
signalling is disrupted, such as or loss-of-function mutation of the gene encoding oxytocin 
(Oxt), its receptor (Oxtr), or Sim1 or Syt4 which regulate the expression and release of OXT 
respectively, all result in hyperphagia (Kublaoui et al., 2008, Takayanagi et al., 2008, 
Camerino, 2009, Tolson et al., 2010, Zhang et al., 2011). Secondly, PVN OXT neurons express 
c-fos, a marker of neuronal activation, following ICV injection of leptin, and leptin’s effects on 
food intake are attenuated by ICV co-injection of an OXTR antagonist (Blevins et al., 2004). 
PVN OXT neurons project heavily to hindbrain nuclei that regulate satiety, the NTS and 
parabrachial nucleus in particular, where it is suggested OXT suppresses feed intake by 
enhancing the sensitivity to satiety signals from the GIT (Blevins et al., 2003, Blevins et al., 
2004, Geerling et al., 2010, Olszewski et al., 2010). 
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3.2 HYPOTHESIS AND AIMS 
Studies in chapter 2 suggest that ICV or iPVN injection of augurin stimulates the 
hypothalamo-pituitary-adrenal (HPA) axis in rats, and that this effect is likely mediated by the 
release of CRH from neurons in the PVN. As CRH is potently anorexigenic, I hypothesise that 
hypothalamic injection of augurin will acutely supress food intake in male Wistar rats by 
stimulating the central release of CRH.  
3.2.1 AIMS 
1. Investigate the effects of augurin on food intake following ICV injection. 
2. Investigate the effects of augurin on food intake following iPVN injection. 
3. Investigate whether the effects of augurin on food intake are mediated by CRH. 
 93  
3.3 METHODS 
3.3.1 PEPTIDES 
A synthetic fragment of human augurin corresponding to amino acids 71 to 148 of 
preproaugurin protein was synthesised and purified by Bachem UK Ltd. as described in 2.3.1. 
Angiotensin II (AII) and the non-specific CRHR antagonist α-helical CRH-(9-41) (α-hCRH) 
were purchased from Bachem UK Ltd. Augurin was prepared for injection as described in 2.3.1. 
Prior to injection, α-hCRH was dissolved into a minimal quantity of sterile water, and then 
diluted into vehicle. 
3.3.2 ANIMALS 
Male Wistar rats (specific pathogen free; Charles River), weighing 250-300 g were maintained 
in individual cages under controlled temperature (21-23 C) and light (12 h light, 12 h dark 
cycle; lights on at 0700 h) conditions with ad libitum access to food (RM1 diet, SDS Ltd.) and 
water. Animal procedures were approved under the British Home Office Animals Scientific 
Procedures Act 1986 (Project Licence 70/6402). 
3.3.3 INTRACEREBROVENTRICULAR CANNULATION AND INJECTIONS 
ICV cannulation and injections were carried out as described in 2.3.3. 
3.3.4 INTRAPARAVENTRICULAR CANNULATION AND INJECTIONS 
Unilateral iPVN cannulation, iPVN injections, and histological verification of cannula 
placement were carried out as described in 2.3.4. 
3.3.5 THE EFFECT OF ICV AUGURIN INJECTION DURING THE EARLY 
DARK PHASE ON FOOD INTAKE 
The effect of augurin on dark phase food intake was investigated first. Ad libitum fed rats 
received a single ICV injection of vehicle, 0.3, 1 or 3 nmol augurin in the early dark phase 
(1900-2000 hours, n = 8-10 per group). Animals were returned to their own cages with a 
preweighed quantity of chow. Food intake was measured 1, 2, 4, 8 and 24 hours after injection. 
Body-weight was measured directly before and 24 hours after injection.  
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3.3.6 THE EFFECT OF ICV AUGURIN INJECTION DURING THE EARLY 
LIGHT PHASE ON FOOD INTAKE FOLLOWING A FAST 
As the first study showed a mild reduction in food intake the effect of augurin on food intake 
following a fast was investigated. Rats had their chow removed 24 hours prior to the study. 
Each rat received a single ICV injection of vehicle, 1, 3 or 10 nmol augurin in the early light 
phase (0900-1000 hours, n = 5-10 per group), and was immediately returned to its own cage 
with a preweighed quantity of chow. Food intake was measured 1, 2, 4, 8 and 24 hours after 
injection. Body-weight was measured directly before and 24 hours after injection. 
3.3.7 THE EFFECT OF IPVN AUGURIN INJECTION DURING THE EARLY 
DARK PHASE ON FOOD INTAKE 
This study was performed twice, each time in a different batch of iPVN cannulated rats. During 
study one, ad libitum fed rats received a single injection of vehicle or augurin (0.1, 0.3 or 1 
nmol) in the early dark phase (1900-2000 hours, n = 5-6 per group). Rats were returned to their 
own cages with a preweighed quantity of chow. Food intake was measured 1, 2, 4, 8 and 24 
hours after injection. Body-weight was measured directly before and 24 hours after injection. 
The second study was carried out in order to confirm the findings of the first study, and to 
investigate a higher range of doses. During study two, rats received a single injection of vehicle 
or augurin (0.25, 0.5, 1 or 2 nmol, n = 8-15 per group). Rats were returned to their own cages 
with a preweighed quantity of chow. Food intake was measured at 1, 2, 4, 8 and 24 hours after 
injection. Body-weight was measured directly before and 24 hours after injection. 
3.3.8 THE EFFECT OF IPVN AUGURIN INJECTION DURING THE EARLY 
LIGHT PHASE ON FOOD INTAKE 
This study was performed twice, each time in a different batch of iPVN cannulated rats. Both 
studies were performed as described in 3.3.7, except that rats were injected during the early light 
phase (0900-1000 hours) rather than the early dark phase. 
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3.3.9 THE EFFECT OF IPVN INJECTION OF AUGURIN AND α-hCRH 
DURING THE EARLY DARK PHASE ON FOOD INTAKE  
Ad libitum fed rats received a single iPVN injection of vehicle, 1 nmol augurin, α-hCRH (0.3µg 
or 1µg), or 1 nmol augurin combined with α-hCRH (0.3µg or 1µg), in the early light phase 
(1900-2000 hours, n = 8-13 per group). These doses of α-hCRH have previously been shown to 
potentiate the orexigenic effect of iPVN injection on NPY (Heinrichs et al., 1993). Animals 
were returned to their own cages with a preweighed quantity of chow. Food intake was 
measured 1, 2, 4, 8 and 24 hours after injection. Body-weight was measured directly before and 
24 hours after injection. 
3.3.10 STATISTICS 
All food intake data are presented as mean ± SEM. All data were analysed using One Way 
ANOVA followed by post hoc Dunnett’s test, with the exception of the antagonist study, which 
was analysed using One Way ANOVA followed by post hoc Tukey’s Multiple Comparison 
Test, to allow for comparison of all groups (Prism Graph Pad 5).  
 96  
3.4 RESULTS 
3.4.1 THE EFFECT OF ICV AUGURIN INJECTION ON FOOD INTAKE 
Augurin had no significant effects on food intake (FI) between any time points following ICV 
injection at the start of the dark phase. It appeared to have a mild anorexigenic effect 1 hour post 
injection (Figure 3.2A) (FI/g; vehicle 2.6 ± 0.5; augurin 0.3 nmol 1.8 ± 0.3, p=0.37; 1 nmol 1.7 
± 0.3, p=0.25; 3 nmol 2.3 ± 0.4, p=0.87).  
The effect of higher doses of augurin on food intake was then investigated in fasted rats to 
clarify the robustness and potency of any anorexigenic effect. Again, only a mild, 
non-significant inhibition of food intake over the first hour was seen (Figure 3.2B) (FI/g; 
vehicle 6.7 ± 0.6; augurin 1 nmol 6.2 ± 0.8, p=0.93; 3 nmol 5.5 ± 0.6, p=0.54; 10 nmol 6.0 ± 
0.8, p=0.91). There were no significant differences in food intake between any time points. 
There were no significant differences in body weight change between groups over the 24 hour 




Figure 3.2: The effect of ICV augurin on food intake A) The effect of vehicle or augurin (0.3, 1 
or 3 nmol) injected at the start of the dark phase ICV into male ad libitum fed Wistar rats on 
food intake over the first hour. B) The effect of ICV injection of vehicle or augurin (1, 3 or 10 
nmol) at the start of the light phase into 24 h fasted male Wistar rats on food intake over the first 
hour.  
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3.4.2 THE EFFECT OF IPVN AUGURIN INJECTION DURING THE EARLY 
DARK PHASE ON FOOD INTAKE 
3.4.2.1 Dark phase study one 
Microinjection of 1 nmol augurin into the PVN significantly increased food intake over the first 
hour post injection (FI/g; vehicle 2.7 ± 0.8; augurin 1 nmol 6.5 ± 0.7, p<0.01) (Figure 3.3A). 
Between the first and second hour following injection of 0.3 or 1 nmol augurin food intake was 
significantly decreased (FI/g; vehicle 3.7 ± 0.5; augurin 0.3 nmol 1.2 ± 0.5, p<0.01; 1 nmol 1.0 
± 0.5 g, p<0.01) (Figure 3.3B). There were no significant differences in cumulative food intake 
at any time points (Figure 3.4). There were no significant differences in body weight change 
between groups over the 24 hour duration of the study. 
3.4.2.2 Dark phase study two 
Injection of 1 or 2 nmol augurin into the PVN significantly increased food intake 1 hour 
following injection (FI/g; vehicle 2.4 ± 0.3; augurin 1 nmol 4.6 ± 0.6, p<0.001; 2 nmol 4.0 ± 
0.3, p<0.01) (Figure 3.5A). Food intake was also significantly increased between the first and 
second hour following injection of 2 nmol augurin (FI/g; vehicle 2.4 ± 0.4; augurin 2 nmol 3.8 ± 
0.3, p<0.05) (Figure 3.5B).  
Injection of 1 or 2 nmol augurin significantly increased cumulative food intake over the first 
two hours post injection (FI/g; vehicle 4.8 ± 0.3; augurin 1 nmol 6.8 ± 1.0, p<0.05; 2 nmol 7.3 ± 
0.4, p<0.01) (Figure 3.6A). The increase in cumulative food intake following injection of 2 
nmol augurin remained significant over 4, 8 and 24 hours post injection (0-4 h cumulative FI/g; 
vehicle 8.1 ± 0.6; augurin 2 nmol 11.4 ± 0.6, p<0.01; 0-8 h cumulative FI/g; vehicle 13.9 ± 0.9; 
augurin 2 nmol 19.5 ± 0.8, p<0.01; 0-24 h cumulative FI/g; vehicle 26.1 ± 0.6; augurin 2 nmol 
29.5 ± 0.9, p<0.05) (Figure 3.6A, B and C). There were no significant differences in food intake 
between any other time points. There were no significant differences in body weight change 
between groups over the 24 hour duration of the study. 
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Figure 3.3: Dark phase study one. The effect of microinjection of vehicle or augurin (0.1, 0.3 or 
1 nmol) at the start of the dark phase into the paraventricular nucleus of male ad libitum fed 
Wistar rats on (A) 0-1h food intake, (B) 1-2h, (C) 2-4h, (D) 4-8h, (E) 8-24h. *p<0.05, **p<0.01, 
vs. vehicle.  
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Figure 3.4: Dark phase study one. The effect of microinjection of vehicle or augurin (0.1, 0.3 or 
1 nmol) at the start of the dark phase into the paraventricular nucleus of male ad libitum fed 
Wistar rats on (A) 0-2h cumulative food intake, (B) 0-4h, (C) 0-8h, (D) 0-24h. 
Cumulative 0-2h
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Figure 3.5: Dark phase study two. The effect of microinjection of vehicle or augurin (0.25, 0.5, 
1 or 2 nmol) at the start of the dark phase into the paraventricular nucleus of male ad libitum fed 
Wistar rats on (A) 0-1h food intake, (B) 1-2h, (C) 2-4h, (D) 4-8h, (E) 8-24h. *p<0.05, **p<0.01, 
***p<0.001 vs. vehicle. 
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Figure 3.6: Dark phase study two. The effect of microinjection of vehicle or augurin (0.25, 0.5, 
1 or 2 nmol) at the start of the dark phase into the paraventricular nucleus of male ad libitum fed 
Wistar rats on (A) 0-2h cumulative food intake, (B) 0-4h, (C) 0-8h, (D) 0-24h, *p<0.05, 
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3.4.3 THE EFFECT OF IPVN AUGURIN INJECTION DURING THE EARLY 
LIGHT PHASE ON FOOD INTAKE 
3.4.3.1 Light phase study one 
Microinjection of 1 nmol augurin into the PVN at the start of the light phase significantly 
increased food intake over the first hour post injection (FI/g; vehicle 1.2 ± 0.4; augurin 1 nmol 
2.9 ± 0.5, p<0.05) (Figure 3.7A). Injection of 0.3 or 1 nmol augurin caused a significant 
increased cumulative food intake over the first 2 h (FI/g; vehicle 1.5 ± 0.4; augurin 0.3 nmol 2.7 
± 0.3, p<0.05; 1 nmol 3.4 ± 0.3, p<0.01) (Figure 3.8A). There were no significant differences in 
24 hour cumulative food intake (Figure 3.8D). There were no significant differences in body 
weight change between groups over the 24 hour duration of the study. 
3.4.3.2 Light phase study two 
Injection of 0.5, 1 or 2 nmol augurin into the PVN significantly increased food intake 1 h post 
injection (Figure 3.9A) (FI/g; vehicle 0.7 ± 0.1; augurin 0.5 nmol 1.8 ± 0.4, p<0.05; 1 nmol 2.1 
± 0.4, p<0.05; 2 nmol 2.1 ± 0.3, p<0.01). There were no significant differences in food intake 
between any other time points. Cumulative food intake remained significantly elevated up to 2 
hours post injection of 0.5 or 1 nmol augurin, and up to 4 hours post injection of 2 nmol augurin 
(Figure 3.10A and B) (0-2 h cumulative FI/g; vehicle 0.9 ± 0.2; augurin 0.5 nmol 2.1 ± 0.4, 
p<0.05; 1 nmol 2.3 ± 0.4, p<0.05; 2 nmol 2.3 ± 0.3, p<0.01; 0-4 h cumulative FI/g; vehicle 1.4 ± 
0.2; augurin 2 nmol 2.9 ± 0.5, p<0.01). There were no significant differences in 24 h cumulative 
food intake (Figure 3.10D). There were no significant differences in body weight change 
between groups over the 24 hour duration of the study. 
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Figure 3.7: Light phase study one. The effect of microinjection of vehicle or augurin (0.1, 0.3 or 
1 nmol) at the start of the light phase into the paraventricular nucleus of male ad libitum fed 
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Figure 3.8: Light phase study one. The effect of microinjection of vehicle or augurin (0.1, 0.3 or 
1 nmol) at the start of the light phase into the paraventricular nucleus of male ad libitum fed 
Wistar rats on (A) 0-2h cumulative food intake, (B) 0-4h, (C) 0-8h, (D) 0-24h, *p<0.05, 
**p<0.01, vs. vehicle. 
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Figure 3.9: Light phase study two. The effect of microinjection of vehicle or augurin (0.25, 0.5, 
1 or  2 nmol) at the start of the light phase into the paraventricular nucleus of male ad libitum 
fed Wistar rats on (A) 0-1h food intake, (B) 1-2h, (C) 2-4h, (D) 4-8h, (E) 8-24h. *p<0.05, 
**p<0.01, vs. vehicle. 
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Figure 3.10: Light phase study two. The effect of microinjection of vehicle or augurin (0.25, 
0.5, 1 or  2 nmol) at the start of the light phase into the paraventricular nucleus of male ad 
libitum fed Wistar rats on (A) 0-2h cumulative food intake, (B) 0-4h, (C) 0-8h, (D) 0-24h, 
*p<0.05, **p<0.01, vs. vehicle. 
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3.4.4 THE EFFECT OF IPVN INJECTION OF AUGURIN AND α-hCRH 
DURING THE EARLY DARK PHASE ON FOOD INTAKE  
Microinjection of 1 nmol augurin, with or without α-hCRH, into the PVN at the start of the light 
phase significantly increased food intake over the first hour post injection compared to vehicle 
or α-hCRH injected controls (FI/g; vehicle 2.5 ± 0.3; augurin 1 nmol 4.1 ± 0.5; augurin 1 nmol 
and α-hCRH 1µg 4.8 ± 0.4; augurin 1 nmol and α-hCRH 0.3µg 4.3 ± 0.4; α-hCRH 1µg 3.0 ± 
0.3; α-hCRH 0.3µg 2.7 ± 0.3) (Figure 3.11A). There were no significant differences in food 
intake at any time point when augurin was co-injected with 0.3µg or 1µg α-hCRH, compared 
with injection of augurin alone (Figure 3.11). There we no significant differences in food intake 
between vehicle and either dose of α-hCRH at any time point, and there were no significant 
differences in body weight change between any groups over the 24 hour duration of the study. 
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Figure 3.11: The effect of microinjection of vehicle, augurin (1 nmol), α-hCRH (0.3 or 1µg), or 
augurin and α-hCRH at the start of the dark phase into the paraventricular nucleus of male ad 
libitum fed Wistar rats on (A) 0-1h food intake, (B) 1-2h, (C) 0-2h, (D) 0-4h. Columns without 
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3.5 DISCUSSION 
Augurin is a recently identified secreted peptide of unknown function. The studies discussed in 
chapter 2 suggest that ICV or iPVN injection of augurin stimulates the HPA axis in rats, and 
that this effect is likely mediated by the release of CRH from neurons in the PVN. As CRH is 
potently anorexigenic when injected ICV or iPVN I hypothesised that hypothalamic injection of 
augurin would reduce food intake by stimulating the central release of CRH. ICV injection of 
augurin either at the start of the dark phase or in 24 hour fasted rats caused a mild, 
non-significant decrease in food intake over the first hour post injection compared with vehicle 
injected controls. In contrast with the ICV studies, iPVN injection of lower doses of augurin 
caused a robust orexigenic effect when injected at the start of either the dark or light phase.  
Initially the effect of iPVN augurin on dark phase food intake was investigated because I 
hypothesised that augurin would be anorexigenic. During dark phase study one food intake 
increased two fold over the first hour following injection of 1 nmol augurin, compared with 
vehicle injected controls. Between the first and second hours post injection, doses of 1 and 0.3 
nmol augurin caused a significant decrease in food intake. The pattern of alternating orexigenic 
and anorexigenic effects following administration of appetite regulatory peptides is not 
uncommon, and it is possible that the delayed decrease in food intake following iPVN augurin 
occurred to compensate for the preceding increase (Parkinson et al., 2008). Alternatively it 
could have been an erroneous finding resulting from the inherent variability of the experiment. 
In order to confirm the results from this study and assess whether higher doses of augurin 
further increased food intake, the study was repeated.  
During dark phase study two doses of 1 or 2 nmol augurin increased food intake two fold over 
the first hour compared with vehicle injected controls. Food intake following iPVN injection of 
2 nmol was also significantly increased between the first and second hours post injection. In 
contrast to night time study one augurin did not cause a delayed anorexigenic effect at any dose. 
Interestingly, cumulative food intake after injection of 2 nmol augurin was significantly 
increased at 2, 4, 8, and 24 hours post injection. The data from light phase feeding study two 
shows that 24 hours post injection of 2 nmol augurin, food intake remains higher that in the 
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vehicle group but this effect is not statistically significant. Of the known orexigenic peptides 
very few have been shown to significantly increase cumulative food intake 24 hours after 
central administration (Rossi et al., 1998, Tang-Christensen et al., 2004, Semjonous et al., 
2009), therefore further feeding studies need to be carried out to clarify the duration of 
augurin’s orexigenic effect.  
The effect of iPVN augurin injected during the early light phase was also investigated. During 
Light phase study one injection of 1 nmol augurin increased food intake twofold over the first 
hour, compared with vehicle-injected controls. No significant differences in food intake were 
seen between any other time points. During light phase study two injection of 0.5, 1 or 2 nmol 
augurin significantly increased food intake over the first hour by two, three, and three fold 
respectively. Again, no significant differences in food intake were seen between any other time 
points 
The dark phase feeding study is considered a more physiologically relevant experimental setting 
in which to investigate food intake, compared with the light phase feeding study. Light phase 
food intake can be increased by non-specific or stressful stimuli such as the ‘tail pinch’ 
(Rowland and Antelman, 1976). That augurin should stimulate food intake when injected at the 
start of the dark phase suggests a relatively potent effect, as rats will eat predominantly during 
this period anyway.  
The reasons for the different effect on food intake depending on the site of injection are 
currently unknown. It is possible that augurin, like other neuropeptides, has different actions in 
different hypothalamic nuclei (Williams et al., 2001). Following ICV injection augurin is likely 
to diffuse into many of the hypothalamic nuclei around the 3rd ventricle, and possibly into the 
brainstem (Bittencourt and Sawchenko, 2000). The net effect of simultaneous activation of 
augurin responsive signalling pathways at multiple sites following ICV injection could mask the 
orexigenic effect seen following iPVN injection. Similar observations have been described for 
other neuropeptides such as CART. 
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CART is a neuropeptide implicated in the regulation of the HPA axis and energy homeostasis 
(Murphy, 2005). ICV injection of recombinant CART (55-102) was shown to inhibit feeding in 
both satiated and 24 hour fasted rats in a dose dependent manner, and suppress food intake 
when co-administered with NPY (Kristensen et al., 1998, Vrang et al., 1999). The role of 
CART peptides in appetite has become less clear, since the discovery that ICV injection of 
CART (55-102) causes behaviour reminiscent of elevated anxiety in a number of tests (Kask et 
al., 2000, Aja et al., 2001). It is therefore possible that the anorexigenic effects of ICV CART 
may be secondary to behavioural changes. It was subsequently shown that microinjection of 
CART (55-102) into the individual hypothalamic nuclei, including the ARC and PVN, 
significantly increases food intake compared to controls (Abbott et al., 2001, Hou et al., 2010). 
In addition, chronic up regulation of CART mRNA in the ARC or PVN of male Wistar rats 
significantly increases cumulative food intake and body mass (Kong et al., 2003, Smith et al., 
2008). In light of this, it is possible that, like CART, non-specific effects following injection of 
augurin ICV could mask the orexigenic effect seen after iPVN microinjection. Investigation of 
the behavioural effects caused by ICV injection may suggest reasons that ICV augurin is not 
orexigenic.  
In addition to increasing food intake, my studies in chapter 2 suggest iPVN injection of augurin 
stimulates the HPA axis via the release of CRH. It is possible that augurin has two or more 
separate functions within the PVN, and that microinjection of augurin indiscriminately activates 
augurin responsive neurons resulting in activation of the HPA axis and increased food intake via 
separate or overlapping pathways. Under physiological conditions, neuropeptide release can be 
highly regulated at the synaptic level, allowing neuropeptidergic neurons to independently 
regulate anatomically adjacent targets (Mihaly et al., 2002, Landry et al., 2003, Horvath, 2006). 
In contrast, the iPVN microinjection technique I used in this chapter and chapter 2 is likely to 
cause an unphysiologically rapid and widespread increase in extracellular augurin (Levin, 
2010). 
The HPA axis and energy metabolism are closely linked, and many peptides that regulate food 
intake play a role in the control of the HPA axis (Ludwig et al., 1998, Spinedi and Gaillard, 
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1998, Krysiak et al., 1999, Pecoraro et al., 2004, Thompson et al., 2004a). A role for augurin in 
the regulation of both the HPA axis and energy homeostasis is therefore reasonable. The 
relationship between HPA axis activity and food intake is complex, and it appears that CRH and 
glucocorticoids have opposing effects on food intake. Obesity in humans and rodents is 
associated with chronically increased circulating glucocorticoid levels (Leibel et al., 1989, 
Guillaume-Gentil, 1990). Suppression of endogenous glucocorticoids by adrenalectomy has an 
anorexic effect in rats which can be corrected by corticosterone replacement (Cohn et al., 1955). 
Furthermore, adrenalectomy normalises body weight in lepob/ob mice (Solomon and Mayer, 
1973). The limited data available from human studies supports the orexigenic effect of 
glucocorticoids seen in rodents (Walker and Seckl, 2003). While chronically increased 
glucocorticoid levels promote caloric intake, glucocorticoid and mineralocorticoid receptor 
agonists have no acute effect on food intake in rats with an intact HPA axis (Tempel et al., 
1992). The increase in circulating glucocorticoids caused by iPVN augurin is therefore unlikely 
to cause the orexigenic effect seen. 
In addition to stimulating the release of ACTH from the adenohypophysis, CRH is potently 
anorexigenic (Morley and Levine, 1982, Krahn et al., 1988). That iPVN augurin should 
stimulate the HPA axis and acutely increase food intake therefore seems counterintuitive given 
that PVN CRH neuron project within the PVN to other parvocellular neurons, however a similar 
relationship has been observed with NPY (Liposits et al., 1985, Silverman et al., 1989). The 
PVN is the main site of accumulation of nerve terminals of NPY-containing neurons, the 
perikaryia of which are located primarily in the ARC and the brainstem (Cowley et al., 1999, 
Fuzesi et al., 2007). Electron microscopy has revealed synapses between NPY containing 
neurons and the dendrites and cell bodies of CRH synthesising PVN neurons, suggesting a 
physiological role for NPY in the regulation of both the HPA axis and energy homeostasis 
(Liposits et al., 1988). ICV or iPVN injection of NPY potently increases food intake and 
reduces energy expenditure (Stanley et al., 1985, Stanley et al., 1986, Zarjevski, 1993). ICV or 
iPVN injection of NPY also stimulates the HPA axis (Haas and George, 1989, Albers et al., 
1990, Brooks et al., 1994). Interestingly, iPVN co-injection of NPY with CRH or α-hCRH 
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attenuate and potentiate its orexigenic effect respectively, suggesting CRH and NPY interact 
within the PVN to regulate both food intake and the HPA axis (Heinrichs et al., 1993, Menzaghi 
et al., 1993).  
I therefore investigated whether a similar effect is seen when augurin is co-administered with 
α-hCRH. Co-injection of α-hCRH at a dose shown to potentiate the orexigenic effect of NPY 
did not alter the orexigenic effect of augurin, suggesting in contrast to NPY, augurin does not 
stimulate the local release of CRH within the PVN (Heinrichs et al., 1993). This hypothesis is 
consistent with the findings from my behavioural study in chapter 2. ICV or iPVN Injection of 
CRH causes a reliable behavioural response, characterised by an increase in grooming and a 
decrease in time spent sleeping (Krahn et al., 1988). ICV injection of NPY has also been shown 
to increase time spent grooming (Clark et al., 1984). My results from chapter 2 demonstrate that 
augurin, however, had no effects on grooming or sleeping behaviour when injected iPVN (Table 
2.2). Measurement of neuropeptide release using in vivo microdialysis is a well-established 
technique, and could be used to investigate the effects of augurin on the release of CRH within 
the PVN (Cook, 2001). 
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4 THE DISTRIBUTION OF AUGURIN 
IN THE CNS 
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4.1 INTRODUCTION 
The studies discussed in chapters 2 and 3 suggest injection of augurin into the paraventricular 
nucleus (PVN) of the hypothalamus stimulates the hypothalamo-pituitary-adrenal (HPA) axis 
and increases food intake in male Wistar rats. These data, however, demonstrate a 
pharmacological effect of augurin. As described in chapter 1, relatively little known about 
distribution of augurin in the central nervous system (CNS). In order to investigate the potential 
physiological functions of augurin I aimed to characterise the distribution of preproaugurin-like 
immunoreactivity (LI) and messenger ribonucleic acid (mRNA) in the rat CNS. An overview of 
the relevant techniques, their strengths, and limitations is provided below. 
4.1.1 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) is a powerful technique that can be used to localise specific 
antigens within a tissue or cell (Coons et al., 1942). The principles underlying IHC are simple; 
an antibody is raised against the epitope of interest, applied to the appropriately fixed and 
pre-treated tissue, and the site of reaction revealed by a suitable detection system (Montero, 
2003). Nevertheless, there are many variables that can affect the sensitivity and specificity of 
staining such as the type and quality of antibody, method of tissue fixation and processing, and 
detection system (Saper, 2005, Elias et al., 2008).  
4.1.1.1 Antibodies 
IHC relies on the ability of the immune system to produce antibodies directed against foreign 
antigenic substances. Antibodies are raised by injecting appropriate hosts (commonly rabbits) 
with purified or synthetic antigen, usually dissolved in an adjuvant solution (Ward et al., 1959, 
Montero, 2003). Large antigens are often sufficiently immunogenic that they can be used neat to 
immunise an animal, however, small antigens such as neuropeptides are weakly immunogenic 
and must therefore be chemically coupled to a larger carrier protein such as bovine serum 
albumin (Sutcliffe et al., 1983, Polak et al., 2003). The resultant antiserum contains a 
heterogeneous mix of polyclonal antibodies against several regions of the immunogen produced 
by activated B-lymphocytes (Polak et al., 2003). 
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Polyclonal antisera have certain drawbacks, such as possible cross-reactivity with related 
antigens, or the presence of native immunoreactive antibodies (Larsson, 1988). In addition, a 
limited quantity of serum can be obtained from the host, and it may be difficult to reproduce 
antibodies for some antigens (Polak et al., 2003). These drawbacks fuelled the development of 
monoclonal antibodies (Kohler and Milstein, 1975). The production of monoclonal antibodies is 
possible because individual B-lymphocytes produce only one type of antibody. Following 
immunisation, activated B-lymphocytes from the host spleen isolated and fused with 
non-secreting myeloma cells in vitro, to form an immortalised hybridoma cell line which 
produces a single antibody specific for a single epitope (Kohler and Milstein, 1975). Although 
highly specific, the specificity of monoclonal antibodies can occasionally result in falsely 
negative staining. Where polyclonal antibodies will generally bind to multiple epitopes on the 
same molecule, a monoclonal will bind to only one, resulting in weaker staining (Ramos-Vara, 
2005). In addition, if the epitope is altered by fixation the antibody may not bind at all (Ramos-
Vara, 2005).  
4.1.1.2 Preparation of tissues for IHC 
Tissues must be fixed and sectioned before they are suitable for IHC. Ideally prepared tissues 
should render antigens insoluble in situ, without hindering the availability of antigenic sites to 
antibodies (Slaoui and Fiette, 2011). Processing should also preserve tissue architecture and 
cellular morphology, allowing the identification of immunoreactivity in context (Yan et al., 
2010). Formaldehyde fixation followed by embedding in paraffin has been the preparation 
method of choice for decades because this treatment maintains tissue morphology and 
immunoreactivity particularly well (Bancroft and Gamble, 2008, Shi et al., 2008).  
4.1.1.2.1 Fixation 
The process of fixation aims to preserve antigens in their endogenous loci within a tissue, while 
protecting the tissue during the subsequent staining process. Perfusion fixation with buffered 
formaldehyde is the gold standard for fixing the CNS prior to IHC (Lamberts and Goldsmith, 
1986, Fix and Garman, 2000). Cross-linking fixatives such as formaldehyde fix tissues by 
chemically linking reactive moieties on adjacent proteins (Fox et al., 1985). Although the 
 117  
chemical crosslinking during formaldehyde fixation can adversely affect protein antigenicity, 
immunoreactivity can be restored by heating sections in acidic or alkaline buffer prior to IHC 
(Shi et al., 1993, D'amico et al., 2009).  
4.1.1.2.2 Paraffin embedding 
Once fixation is complete, tissues can be embedded in a support material such as paraffin wax. 
The aim of paraffin embedding is to replace water within the tissue with a support medium that 
provides sufficient strength to allow sectioning of the tissue without damage (Bancroft and 
Gamble, 2008). The tissue is first immersed in increasing concentrations of ethanol until all the 
water has been removed from the tissue. The ethanol is then replaced with xylene, which is in 
turn replaced with molten paraffin wax. The tissue is then embedded in wax on a tissue cassette 
for sectioning. The result is a tissue block which can be stored indefinitely, and from which thin 
sections can be obtained without compromising morphology (Schrell and Sofroniew, 1982). 
After mounting on to slides, sections can be rapidly de-waxed, rehydrated, and are then ready 
for use.  
4.1.1.3 Detection of the antibody-antigen reaction 
Labelling of the antibody-antigen binding sites is required for it to been seen with the light 
microscope (Montero, 2003). The most commonly used labels are enzymes such as horseradish 
peroxidase (HRP), and while fluorescent labels are gaining popularity, their use requires special 
equipment in order to detect fluorescent light (Polak et al., 2003). The primary antibody can 
directly conjugated to the label, but this method lacks the sensitivity required for the detection 
of most antigens so the three step avidin-biotin complex (ABC) method is more commonly used 
(Coons et al., 1942, Bayer et al., 1976). Avidin is a large glycoprotein that has four high affinity 
binding sites for a low molecular weight vitamin called biotin (Guesdon et al., 1979). Each 
biotin molecule has a single binding site for avidin, and can be attached through other sites to an 
antibody (Guesdon et al., 1979). Following application of the unlabelled primary antibody or 
antiserum, a biotin-conjugated secondary antibody is applied (Hsu et al., 1981). The third layer 
consists of large complexes of HRP-conjugated biotin with avidin, which binds to the 
biotin-conjugated secondary antibody (Lloyd et al., 1985).  
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4.1.1.4 Specificity controls for IHC 
Because of the numerous technical pitfalls that can produce spurious results, a crucial part of 
IHC is selecting the appropriate controls (Petrusz et al., 1976, Swaab et al., 1977). When 
evaluating a new antiserum, demonstrating an absence of immunoreactivity in an identically 
processed section from the relevant knockout (KO) mouse is gold standard test of specificity 
(Saper and Sawchenko, 2003). Nevertheless, KO mice do not exist for the vast majority of 
proteins, and therefore the adsorption specificity control is most commonly employed (Larsson, 
1988, Saper, 2005). An absence of immunoreactivity following incubation of the antiserum with 
an excess of synthetic antigen suggests the immunoreactive component of the antiserum is 
indeed raised against that antigen (Larsson, 1988). One caveat is that certain antisera have been 
shown to avidly bind basic amino acids (Scopsi et al., 1986). This can result in non-specific 
staining within sections, and, in cases where the immunogen contains many basic amino acids, 
can also cause false-negative results from the adsorption control (Scopsi et al., 1986).  
4.1.2 IN SITU HYBRIDISATION HISTOCHEMISTRY 
In situ hybridisation histochemistry (ISH) is a technique that allows localisation of a messenger 
ribonucleic acid (mRNA) or deoxyribonucleic acid (DNA) sequence within a tissue, whilst 
maintaining morphological integrity (Pardue and Gall, 1969). ISH takes advantage of the 
specific annealing of complementary nucleic acids through hydrogen bonds formed between 
bases attached to a sugar-phosphate backbone (Watson and Crick, 1953). This base pairing 
underlies the formation of a double stranded complex. Any nucleic acid sequence can therefore 
be specifically detected by use of a labelled nucleotide probe that is the ‘antisense’ reverse 
complementary sequence (Wilcox, 1993). The two main considerations for ISH are specificity 
and sensitivity, which are determined in large part by tissue preparation, probe type, and 
detection method (Wilkinson and Nieto, 1993).  
4.1.2.1 Tissue preparation 
The preparation of tissues for ISH is critical for preserving mRNA in situ (Yan et al., 2010). In 
unstabilised tissue, ubiquitously expressed RNAse enzymes quickly degrade mRNAs, and it is 
therefore imperative to block their activity as quickly as possible (Yang et al., 1999). 
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Transcardial perfusion with buffered formaldehyde is the preferred method for preparation of 
tissues for ISH as formaldehyde rapidly inhibits RNAse enzymes, and effectively preserves 
tissue morphology during the hybridisation procedure (Koopman, 2001, Palop et al., 2011).  
4.1.2.2 Riboprobe preparation 
With the continued development of RNA polymerase methodologies, the use of complimentary 
RNA (cRNA) riboprobes is preferred over cDNA or oligonucleotide probes for several reasons 
(Karr et al., 1995). First, cRNA probes can easily be synthesised easily and rapidly by in vitro 
transcription of a DNA template generated by polymerase chain reaction (PCR) (Young et al., 
1993, Karr et al., 1995). Second, cRNA-mRNA hybridisation complexes are more stable than 
comparable cDNA-mRNA complexes, permitting the use of stringent hybridisation conditions 
specifically conducive to the formation of riboprobe-mRNA complexes (Meltzer et al., 1998). 
Finally, non-specific hybridisation can be drastically reduced by digestion of single stranded 
probe using RNAse (Wilkinson and Nieto, 1993). 
4.1.2.3 Hybridisation  
The main goal of hybridisation is for the probe to anneal to complementary mRNA strands 
under the optimal condition (Kadkol et al., 1999). Factors that affect how well a riboprobe will 
bind to the target mRNA include the pH and ionic concentration of the hybridisation buffer, and 
the temperature and duration of hybridisation (Moens, 2008). Changing these parameters will 
influence the probe’s affinity for its target sequence. High ionic concentration and low 
temperatures and pH enhance hybridisation, but the specificity of hybridisation is also reduced 
(Schaeren-Wiemers and Gerfin-Moser, 1993). Following hybridisation, the slides are washed 
under high stringency conditions to remove unbound probes or probes loosely bound to 
improperly matched sequences (Kelsey et al., 1986, Wilkinson and Nieto, 1993). 
4.1.2.4 Detection 
There are two approaches for localisation of hybridised probes, non-radioactive and radioactive 
(Komminoth et al., 1992). Although historically associated with lower sensitivity, technical 
advances mean that non-radioactive haptens such as digoxigenin (DIG) have largely superseded 
the use of radioisotopes for ISH (Komminoth et al., 1992, De Block and Debrouwer, 1993). 
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DIG labelled probes are detected using an antibody raised against DIG and conjugated to a 
chromogenic enzyme (Wilkinson, 1995). Advantages of DIG labelling include subcellular 
resolution of hybridisation, and the short time required to yield a signal; minutes to hours in the 
case of DIG probes, rather than days to weeks for autoradiographic detection of radioactive 
isotopes (Knoll et al., 2007, Pinaud et al., 2008). 
4.1.2.5 Specificity controls for ISH 
It is essential to establish that a probe has hybridised selectively to the target mRNA sequence, 
and that the resultant pattern of hybridisation is therefore specific (Larsson, 1989). As with IHC, 
the absence of hybridisation in a section from the relevant KO mouse is the gold standard 
specificity control (Larsson and Hougaard, 1993). Nevertheless, as this is often unfeasible 
hybridisation of matched sections with a labelled sense probe is commonplace (Wilkinson and 
Nieto, 1993). An absence of staining in sections hybridised with sense probe indicates that the 
pattern of anti-sense hybridisation is sequence dependant, and therefore likely to be specific to 
the target mRNA (Larsson and Hougaard, 1990). 
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4.2 HYPOTHESIS AND AIMS 
Augurin is a recently identified secreted peptide of unknown function. Preproaugurin mRNA 
has been detected in the brain, but relatively little known about its distribution within the CNS. 
Studies in chapters 2 and 3 suggest injection of augurin into the PVN of male Wistar rats 
stimulates the hypothalamo-pituitary-adrenal (HPA) axis and increases food intake. These data, 
however, demonstrate a pharmacological effect of augurin. In order to investigate the potential 
physiological role of augurin, I aimed to characterise the distribution of preproaugurin -LI and 
mRNA in the rat CNS. 
4.2.1 AIM 
1. Characterise the distribution of preproaugurin-LI in the CNS of male Wistar rats. 
2. Characterise the distribution of preproaugurin mRNA in the CNS of male Wistar rats. 
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4.3 METHODS 
4.3.1 PEPTIDES 
A synthetic fragment of human augurin corresponding to amino acids 71 to 148 of 
preproaugurin was synthesised and purified by Bachem UK Ltd. as described in 2.3.1. Synthetic 
fragments of human augurin corresponding to amino acids 71 to 107, 108 to 132, or 133 to 148 
of preproaugurin were purchased from Phoenix Pharmaceuticals, (Belmont, CA, USA). 
4.3.2 WATER 
Water used to make solutions was ultra pure (18.2mΩ) quality obtained through an ELGA 
system (ELGA Labwater, Marlow, UK). RNAse-free water or TE (Sigma-Aldrich, Poole, UK) 
was used for all experiments involving RNA, with the exception of pre- and post-hybridisation 
ISH washes for which ultra pure water was used.  
4.3.3 ANIMALS 
Male Wistar rats (specific pathogen free; Charles River), weighing 250-300 g were maintained 
in individual cages under controlled temperature (21-23 C) and light (12 h light, 12 h dark 
cycle; lights on at 0700 h) conditions with ad libitum access to food (RM1 diet, SDS Ltd.) and 
water. Animal procedures were approved under the British Home Office Animals Scientific 
Procedures Act 1986 (Project Licence 70/6402). 
4.3.4 TISSUE PREPARATION 
Sections for both IHC and ISH were prepared from tissues fixed by transcardial perfusion and 
embedded into paraffin wax. Tissues preparation was identical for both ISH and IHC. 
4.3.4.1 Perfusion fixation 
4.3.4.1.1 Materials 
Flush solution (appendix) 
Fixative solution (appendix) 
Pentobarbitone (Merial) 
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4.3.4.1.2 Method 
Fixation by transcardial perfusion was carried out using an established protocol (Fix and 
Garman, 2000). Each rat was injected ip with a lethal dose of pentobarbitone (Merial Animal 
Health Ltd, UK). The pedal reflex test was used to ensure that a surgical plane of anaesthesia 
had been reached. The rat was placed in a dorsal recumbent position and a transverse incision 
was made just caudal to the xiphoid process. The diaphragm was incised, followed by the left 
and right lateral ribcage. The xiphoid process was clamped and held rostrally to expose the chest 
cavity. An 18-gauge needle, connected to a two-way valve was then inserted into the left 
ventricle and clamped into position. A small nick was made in the right atrium and the animal 
was perfused with from a 1m height under gravitational pressure. Transcardial perfusion was 
done in two stages. Firstly, exsanguination was accomplished using 40-50mls flush solution, 
and then the brain was fixed using fixative solution (1ml/g body weight fixative was perfused 
over 10-15 minutes). Perfused brains were left in situ for two hours, sectioned coronally into 
5mm thick blocks and then post-fixed is the same fixative for 16 hours at 4oC.  
4.3.4.2 Paraffin-embedding 
Following fixation, tissue blocks were placed in plastic cassettes and transferred to 70% ethanol 
for paraffin embedding. Tissues were paraffin-infiltrated in a V.I.P. Tissue Tek Processor 
(Miles/Sakura, Torrance, CA) and then embedded in Paraplast X-Tra Tissue Embedding 
Medium (Fisher Scientific, Pittsburgh, PA) at a Tissue-Tek embedding station (Miles/Sakura, 
Torrance, CA). Four µm sections were sectioned using a rotary microtome (Leitz, Wetzlar, 
Germany), floated onto ultra pure water, and mounted on poly-L-lysine-coated slides.  
4.3.5 ANTISERA 
Details for each antiserum used in this chapter are shown in Table 4.1. 
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Table 4.1: Antisera used in this chapter.  
Abbreviations: AP, alkaline phosphatase; DIG, digoxigenin. 
Name Immunogen Type Host species Source 
Anti-(71-107) Amino acids 71-107 of human preproaugurin protein Polyclonal Rabbit Phoenix Pharmaceuticals, Belmont, CA, USA 
Anti-(108-132) Amino acids 108-132 of human preproaugurin protein Polyclonal Rabbit Phoenix Pharmaceuticals, Belmont, CA, USA 
Anti-(133-148) Amino acids 133-148 of human preproaugurin protein Polyclonal Rabbit Phoenix Pharmaceuticals, Belmont, CA, USA 
Anti-(71-148) Amino acids 71-148 of human preproaugurin protein Polyclonal Rabbit Peninsula Laboratories, Belmont, CA, USA 
Anti-DIG-AP Digoxigenin Polyclonal Sheep Roche Diagnostics, Mannheim, Germany 
Biotinylated anti-rabbit Rabbit immunoglobulin G (heavy and light chain) Polyclonal Goat Vector Laboratories, Peterborough, UK 
Table 4.2: Primer sequences used to amplify preproaugurin cDNA by PCR. The expected size of the product is in base pairs. Accession number refers to that 
published in the Nucleotide Sequence Database (Sayers et al., 2011).  
Abbreviations: T3, T3 RNA polymerase; T7, T7 RNA polymerase; bp, base pairs. 
Name Promoter sequence Complimentary sequence  bp Accession Number 
T3 Forward ATTAACCCTCACTAAAGGGA GACCTGTTCCATCAAAGACG 
350 NM_032411 
T7 Reverse TAATACGACTCACTATAGGG TCATAGTTGACACTGGCTCC 
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4.3.6 IHC 
All IHC protocols were adapted from (Polak et al., 2003). 




0.01M PBS (appendix) 
0.01M citrate buffer pH6 (appendix) 
Normal goat serum (NGS) (Invitrogen) 
Antibody diluent (appendix) 
Biotinylated goat anti-rabbit (Jackson Labs) 
Avidin Biotin Complex (ABC) (Vector Labs) 
3’3’-diaminobenzidine tetrahydrochloride hydrate (DAB) (Sigma-Aldrich) 
Copper sulphate solution (appendix) 
DPX mountant (Thermo Fisher Scientific) 
Wax pen (Vector Labs) 
Haematoxylin (Vector Labs) 
4.3.6.1.2 Method 
Paraffin sections were dewaxed in two changes of xylene (5 minutes each) and rehydrated 
through graduated ethanol washes (2 x 100%, 1 x 70%, 1 x 50%) for 3 minutes each before 
rinsing in ultrapure water. Antigen retrieval was carried out on the sections by boiling for 20 
minutes in a microwave oven in pre-boiled 0.01M citrate buffer pH6, after which, sections were 
allowed to cool for a further 15 minutes before rinsing in 0.01M PBS. Endogenous peroxidase 
activity was blocked by incubation in 0.01M PBS containing 1.6% v/v hydrogen peroxide for 
10 minutes. Following a 5 minute wash in water, sections were incubated for 30 minutes at 
room temperature with 10% v/v NGS in antibody diluent. The primary antiserum was diluted to 
the appropriate concentration in antibody diluent and incubated on the sections overnight at 
room temperature. Negative control sections were routinely processed by omitting the primary 
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antiserum to detect any non-specific staining caused by unwanted binding of the secondary 
antibody, ABC, or any endogenous enzyme activity. Sections were then washed in 0.01M PBS, 
incubated in biotinylated goat anti-rabbit for 30 minute at room temperature, before being 
washed in PBS and incubated with avidin-biotin complex horseradish peroxidase at room 
temperature for a further 30 minutes. After a final wash in 0.01M PBS, the antigen-antibody 
complex was visualised by incubation in 0.01M PBS containing 0.05% w/v DAB and 0.03% v/v 
hydrogen peroxide. After 10 minutes sections were rinsed in PBS and then water. DAB staining 
was enhanced by incubation in copper sulphate for 4 minutes. Sections were then rinsed in 
water before being dehydrated though ascending ethanol concentrations (50-100%) for 3 
minutes each, incubated in xylene for 2 x 5 minutes, and then mounted using DPX. In some 
instances sections were lightly counterstained using Haematoxylin before dehydration and 
mounting.  
4.3.6.2 Titre test 
A titre test was used initially to evaluate each primary antiserum. IHC was performed as 
described in section 4.3.6.1, and each primary antiserum was serially diluted in antibody diluent 
to a final concentration of 1:30, 1:100, 1:300, 1:900, or 1:2700. 
4.3.6.3 Adsorption control 
4.3.6.3.1 Materials 
Synthetic peptide used to raise antiserum (Table 4.1) 
Poly-L-lysine MW 3000-6000 (Sigma) 
Antibody diluent (appendix) 
4.3.6.3.2 Method 
Appropriately diluted antiserum was incubated at 4°C overnight with 10 nmol/ml of the 
corresponding synthetic peptide used to raise the antiserum (Polak et al., 2003). To control for 
antibody binding to bind basic amino acids, synthetic peptide was replaced with the equivalent 
concentration of poly-L-lysine (Polak et al., 2003). The following day IHC staining was 
performed as described in section 4.3.6.1. 
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4.3.7 ISH 
4.3.7.1 RNA extraction 
4.3.7.1.1 Materials 





Total RNA was extracted using Tri-reagent according to the manufacturer’s protocol. Frozen 
hypothalami were homogenised using an Ultra Turrax T25 homogeniser (IKA Labortechnik, 
Staufen, Germany) in Tri-reagent (10x v/w Tri-reagent solution per hypothalamus). Following 2 
minutes incubation at room temperature the mixture was transferred to silanised Corex tubes 
and incubated for a further 5 minutes at room temperature. To separate the mixture into aqueous 
and organic phases, 0.1x v/v of 1-bromo-chloro-propane was added and mixed vigorously. The 
mixture was incubated for 5 minutes at room temperature before being centrifuged at 12000g 
for 15 minutes at 4°C (centrifuge 5417 C/R, Eppendorf, Hamburg, Germany). The upper, 
aqueous phase containing the RNA was then transferred to a new Corex tube, precipitated by 
addition of 0.5x v/v propan-2-ol for 10 minutes at room temperature and then centrifuged at 
12000g for 10 minutes at 4°C. The supernatant was removed and the pellet washed twice with 
70% ethanol before being centrifuged at 12000g for 10 minutes at 4°C. The supernatant was 
then removed and the pellet allowed to air dry before being re-suspended in 400µl BPC water. 
RNA concentration and purity was determined spectrophotometrically, and the integrity was 
then confirmed by denaturing agarose gel electrophoresis. 
4.3.7.2 Verification of RNA integrity 
4.3.7.2.1 Materials 
Agarose, type II-A medium EEO (Sigma-Aldrich) 
Formaldehyde (VWR) 
20 x MOPS pH7 (appendix) 
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Ethidium bromide (VWR) 
DENAT (appendix) 
Gel loading buffer (appendix) 
TE pH7.5 (appendix) 
2M Sodium Acetate (NaAc) pH5.2 (appendix) 
Ethanol (VWR)  
4.3.7.2.2 Method 
A 1% agarose denaturing gel was prepared in 1 x MOPS buffer with 7.5% formaldehyde (v/v). 
5 µg of RNA was added to 12µl DENAT then the samples were denatured at 65°C for 5 minutes 
and 3µl gel loading buffer was added. The samples were then loaded onto the gel and run in 1 x 
MOPS buffer with 7.5% formaldehyde v/v at 140 volts for approximately 40 minutes until the 
gel front had run 10cm. The gel was then stained in TE with 0.01% v/v ethidium bromide on a 
shaking platform for 30 minutes. The gel was then de-stained overnight in 1 x TE to allow 
visualisation under ultraviolet light of the 18s and 28s ribosomal bands and to ensure that the 
RNA had not degraded. 
4.3.7.3 Reverse transcription reaction  
4.3.7.3.1 Materials 
RNA samples  
10mM dNTPs (Amersham Biosciences, Little Chalfont, UK) 
5 x reverse transcriptase buffer (Promega, Madison WI) 
Avian myoblastoma virus reverse transcriptase (RT) 10 U/µl (Promega) 
Oligo dT (12-18) 200 ng/µl (Amersham Biosciences) 
4.3.7.3.2 Method 
The reaction was set up in a final volume of 20µl containing the following: 1 µg RNA, 1 x 
reverse transcriptase buffer, 1mM dNTPs and 10 mg/ml oligo dT. The solution was heated to 
65°C for 5 minutes and allowed to cool to room temperature for 30 minutes. 10 U RT was 
added and the reaction incubated at 42°C for 60 minutes. The reaction was used directly as the 
PCR template. 
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4.3.7.4 Riboprobe template design 
A riboprobe template was generated by polymerase chain reaction (PCR) (Sitzmann and 
Lemotte, 1993). Primer-BLAST was used to generate 20 pairs of primers to which T3 or T7 
polymerase sequences were added to the 5’ ends (Sayers et al., 2011). Each pair of primers was 
checked for specificity, self-complementarity, and the propensity to form primer dimers until a 
suitable pair was identified (Rozen and Skaletsky, 2000). The primers selected to amplify the 
DNA template are detailed in Table 4.2.  
4.3.7.5 Preparation of DNA template by PCR 
4.3.7.5.1 Materials  
10 x Taq buffer (Sigma-Aldrich) 
20 µM oligonucleotide primers (Eurogentec) 
Taq DNA polymerase (5U/µl) (Sigma-Aldrich) 
10mM dNTPs (Amersham Biosciences) 
4.3.7.5.2 Method 
A 2µl aliquot of the reverse transcription reaction generated in 4.3.7.3 was added to a tube 
containing 1 x Taq buffer, 0.2mM dNTPs, 200 nM forward and reverse primers. The reaction 
was heated to 95°C for 5 minutes and then 5 U Taq DNA polymerase added. The reaction was 
cycled 25 times through the following temperatures: 95°C for 30s, 55°C for 30s and 72°C for 
30s. After completion of the reaction, correct size of the PCR was confirmed by agarose gel 
electrophoresis. 
4.3.7.6 Agarose gel electrophoresis of DNA template 
4.3.7.6.1 Materials 
Agarose, type II-A medium EEO (Sigma-Aldrich) 
50x Tris-acetate-EDTA buffer (TAE) (appendix) 
Ethidium bromide (10mg/ml) (VWR) 
DNA marker (1Kb ladder, Invitrogen) 
Gel loading buffer (appendix) 
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4.3.7.6.2 Method 
A 1% w/v agarose gel was prepared by dissolving the agarose in 1 x TAE using a microwave 
oven (Panasonic, NNE205W). The gel was cooled to 45°C and ethidium bromide added to a 
final concentration of 0.5 µg/ml. Once set, the gel was placed into an electrophoresis tank 
containing 0.5x TAE, run for 150 volts for approximately 40 minutes and visualised under 
ultraviolet light. 
4.3.7.7 Phenol-chloroform extraction of DNA template 
4.3.7.7.1 Materials  
Phenol chloroform (VWR) 
Ethanol (VWR) 
2M sodium acetate (NaAc) pH5.2 (appendix) 
4.3.7.7.2 Method 
Once size had been verified the remaining PCR reaction was phenol chloroform extracted by 
addition of an equal volume of phenol chloroform. Solutions were thoroughly mixed before 
centrifugation at 12000g for 3 minutes. The supernatant was carefully removed and precipitated 
with the addition of 0.1x v/v of NaAc and 2.5x v/v of ethanol for one hour at -20°C. Following 
precipitation, suspensions were centrifuged at 12300g for 7 minutes, the supernatant was 
removed and the pellet washed twice with 70% ethanol before being centrifuged at 12000g for 
10 minutes at 4°C. Pellets were re-suspended in 100µl TE and the concentration and purity of 
the DNA template was determined spectrophotometrically.  
4.3.7.8 Riboprobe preparation 
4.3.7.8.1 Materials 
DNA riboprobe template 
100mM dithiothreitol (DTT) (Promega) 
30U/µl RNAse inhibitor (Invitrogen) 
T3 or T7 RNA polymerase (Promega)  
10x DIG RNA labelling mix (Roche) 
5x polymerase buffer (Promega) 
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DNAse I (Invitrogen) 
10x DNAse buffer (appendix) 




The DIG-labelled riboprobe was produced by in vitro transcription of the DNA template. Two 
hundred nanograms of DNA template was added to a reaction containing 5mM DTT, 1x 
polymerase buffer, 30 U RNAse inhibitor and 1x DIG labelling mix in a total volume of 19µl. 
Finally, 20 U RNA polymerase was added (T3 to the anti-sense reaction and T7 to the sense 
reaction) and this was incubated at 37°C for 2 hours. After incubation, 3µl DNAse buffer and 
7.5 U DNAseI were added and the reaction incubated for a further 15 minutes at 37°C. The 
riboprobe was precipitated by addition of 0.1x v/v 8M LiCl and 2.5x v/v ethanol. The 
precipitate were centrifuged at 12300g for 7 minutes, the supernatant was removed and the 
pellet washed twice with 70% ethanol before being centrifuged at 12000g for 10 minutes at 4°C.  
The pellet was then resuspended in 100µl TE. The concentration and purity of the DIG-labelled 
probe was determined spectrophotometrically, and the integrity was then confirmed by 
denaturing agarose gel electrophoresis as described in 4.3.7.2. 
4.3.7.9 Hybridisation and detection 
4.3.7.9.1 Materials  
0.01M PBS (Gibco) 
0.01M citrate buffer (appendix) 
Ethanol (VWR) 
Hybridisation buffer (appendix) 
20x SSC (appendix) 
1x RNAse buffer (Promega) 
RNAse A (Promega) (appendix) 
Maleic buffer (Roche) 
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Blocking solution (appendix) 
Anti-DIG-AP, Fab fragments (Roche) 
DIG wash (Roche) 
Detection buffer (appendix)  
4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate, 4-toluidine salt kit 
(BCIP/NBT alkaline phosphatase substrate kit) (Vector Laboratories) 
Xylene (VWR) 
DPX mountant (Thermo Fisher Scientific) 
Wax pen (Vector Laboratories) 
10% w/v Poly-vinyl alcohol solution 
Formamide (VWR) 
4.3.7.9.2 Methods 
Paraffin sections were dewaxed in two changes of xylene (5 minutes each) and rehydrated 
through graduated ethanol washes (2 x 100%, 1 x 70%, 1 x 50%) for 3 minutes each before 
rinsing in ultrapure water. Antigen retrieval was carried out on the sections by boiling for 20 
minutes in a microwave oven in pre-boiled 0.01M citrate buffer pH6, after which, sections were 
allowed to cool for a further 15 minutes before rinsing in ultra pure water (Sperry et al., 1996). 
Slides were then dehydrated through 50%, 70%, and 100% ethanol for 3 minutes each, and 
individual sections were circumscribed using a hydrophobic wax pen and allowed to air dry. 
Pre-hybridisation of sections was carried out using hybridisation buffer not containing any 
DIG-labelled probe. Slides were incubated in this solution for 1 hour at 57°C in a humidified 
chamber. Fifteen minutes before hybridisation, probes were added to hybridisation buffer at a 
final concentration of 1ng/ml and denatured at 75°C for 15 minutes, before cooling on ice for 5 
minutes. Hybridisation buffer containing the denatured probe was applied to the sections which 
were then hybridised overnight at 57°C. Negative control sections were routinely hybridised 
with the same concentration of sense rather than antisense riboprobe to identify non-specific 
staining. 
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Slides were then washed once in 5x SSC at 60°C for 5 minutes, before RNAse treatment by 
incubation in 1x RNAse buffer containing 50µg/ml RNAse A for 30 minutes at 37°C (Sitzmann 
and Lemotte, 1993). Slides were again washed in 5x SSC at 60°C for 10 minutes, before a series 
of increasing stringency washes at 60°C in 50% formamide/2 x SSC for 30 minutes, 2 x SSC for 
30 minutes, and twice in 0.2x SSC for 30 minutes each. Slides were then incubated in maleic 
buffer at room temperature for 5 minutes before undergoing blocking in blocking solution for 
30 minutes at room temperature. Sections were then subjected to two hours incubation in a 
humidified chamber with blocking solution containing anti-DIG-AP, Fab fragments at a 1:2000 
concentration (Weiszmann et al., 2009).  
Slides were then washed in DIG wash twice for 15 minutes at room temperature. Sections were 
briefly rinsed in detection buffer for 5 minutes before incubation in detection buffer, an equal 
volume of 10% poly-vinyl alcohol, and 2 drops of reagents 1, 2 and 3 (BCIP-NBT kit) per 5 ml 
detection buffer (De Block and Debrouwer, 1993). Slides were incubated in this solution in the 
dark and development was monitored microscopically over the following 1-2 hours. Following 
sufficient development, slides were washed in water three times for 5 minutes each, before 
dehydration through 50%, 70% and 100% ethanol each for 15 seconds. Finally slides were 
immersed in xylene for 30 seconds and mounted using DPX.  
4.3.8 PHOTOMICROGRAPHY 
Representative images rat brain sections were photographed using a GXCAM-3 camera (GX 
Optical, Suffolk, UK) attached to a Nikon Eclipse 50i microscope (Nikon, Melville, NY). 1000x 
images were photographed using a Leica DFC320 camera attached to a Lecia DM LB2 
microscope (Leica Microsystems Inc., Bannockburn, IL). Only linear adjustments to the 
contrast, brightness, or colour of photomicrographs were made using Adobe Photoshop 
Elements 7 (Adobe, San Jose, CA).  
 
 134  
4.4 RESULTS 
4.4.1 EVALUATION OF AUGURIN ANTISERA  
4.4.1.1 Antibody titre test 
The choroid plexus (CP) was used as the positive control for antibody titration as high levels of 
mRNA have been reported there previously (Mirabeau et al., 2007). Anti-(71-148) showed high 
levels of uniformly distributed non-specific staining. The estimated optimal dilution for the 
three remaining antisera tested was 1:300 (Table 4.3).  
Table 4.3: Antisera titration using serial dilutions. Relative intensities were estimated by visual 
comparison of stained sections: -, absent; +, weak; ++, moderate; +++, strong; ++++, very 
strong.  
Abbreviations: CP, choroid plexus. 
 Anti-(71-107) Anti-(108-132) Anti-(133-148) Anti-(71-148) 
Dilution CP Background CP Background CP Background CP Background 
1:30 +++ ++++ +++ ++++ ++++ ++++ +++ ++++ 
1:100 +++ +++ +++ +++ ++++ ++ ++ ++++ 
1:300 +++ ++ ++ + +++ - ++ +++ 
1:900 + + + + ++ - + +++ 
1:2700 - - - + + - - +++ 
 
4.4.1.2 Adsorption specificity control 
Overnight incubation of anti-(133-148) at the estimated optimal dilution with 10 nmol/ml of the 
corresponding synthetic peptide used to raise the antiserum resulted in the absence of staining 
(Figure 4.1). Substitution of synthetic peptide for an equal mass of poly-L-lysine had no effect 
on the pattern of staining (Figure 4.1). Some staining remained following incubation of 
anti-(108-132) or anti-(71-107) at the estimated optimal dilution with 10 nmol/ml of the 
corresponding synthetic peptide used to raise the antiserum (Figure 4.1). The specificity of 
augurin (71-148) was not tested because of its high background staining. Anti-(133-148) was 
used for mapping the distribution of preproaugurin-LI because the adsorption control was 
successful, and it demonstrated high signal to noise ratio.  
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Figure 4.1: Representative light-field photomicrographs of rat CP showing adsorption 
specificity controls. Anti-(133-148) showed strong immunoreactivity in the CP  (Brown; A), 
which was absent following pre-adsorption of the primary antibody with 10nmol/ml synthetic 
preproaugurin-(133-148) (B). Pre-adsorption of the primary antibody with 10nmol/ml 
poly-L-lysine had no effect (C). Anti-(108-132) and anti-(71-107) also showed 
immunoreactivity in the CP (D and F respectively), however some staining remained following 
pre-adsorption of the primary antibody with 10nmol/ml of the corresponding synthetic peptide 
(E and F respectively). All sections were counterstained with Haematoxylin (blue nuclei). 
 
Figure 4.2: Representative light-field photomicrographs of male Wistar rat CP showing 
preproaugurin antisense (A [200x]) and sense (B [200x]) riboprobe hybridisation. Prominent 
antisense riboprobe hybridisation (blue) is observed, while sense riboprobe hybridisation is 
negligible (B).  
 
A B C 
D E F G 
A B 
 136  
4.4.2 EVALUATION OF AUGURIN RIBOPROBE 
4.4.2.1 Riboprobe production 
Rat hypothalamus tissue expressed preproaugurin mRNA as shown by RT-PCR (Figure 4.3). 
Sequencing of the purified PCR reaction confirmed it matched the PCR product predicted be 
Primer-BLAST. The size of both the sense and antisense riboprobe generated by in vitro 
transcription matched that of the DNA template.  
4.4.2.2 Hybridisation specificity 
Pronounced hybridisation of the antisense probe was observed in the choroid plexus (Figure 
4.2). No hybridisation was detected when the antisense probe was omitted or replaced with the 
same concentration of sense probe (Figure 4.2). The observed pattern of staining is in line with 
the published distribution of preproaugurin, suggesting the antisense riboprobe hybridised 
preproaugurin mRNA (Mirabeau et al., 2007, Gonzalez et al., 2011). 
Figure 4.3: Preproaugurin mRNA expression in rat hypothalamus as determined by RT-PCR. 
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4.4.3 DISTRIBUTION OF AUGURIN IN THE CNS 
4.4.3.1 General expression pattern 
The distributions of preproaugurin-LI and mRNA in the CNS are summarised in Table 4.4. The 
distribution of preproaugurin-LI matched that of augurin-mRNA throughout the CNS and 
discordance was not observed at any location. In line with previously published data, 
preproaugurin-LI and mRNA were found in the choroid plexus (Figure 4.1) (Mirabeau et al., 
2007, Gonzalez et al., 2011). Preproaugurin-LI and mRNA were also observed in other CNS 
regions including the telencephalon, diencephalon, rhombencephalon, and cerebellum.  
Table 4.4: Distribution and intensity of preproaugurin-LI and mRNA in the rat CNS. Relative 
intensities were estimated by visual comparison: -, absent; +, weak; ++, moderate; +++, strong; 
++++, very strong. 
CNS region IHC ISH 
1. Telencephalon  
1.1. Olfactory bulb ++++ ++++ 
1.2. Cerebral cortex - - 
1.3. Hippocampal formation ++ ++ 
1.4. Amygdala - - 
1.5. Basal ganglia - - 
2. Diencephalon  
2.1. Thalamus - - 
2.2. Hypothalamus ++ ++ 
3. Mesencephalon  
3.1. Sensory  - - 
3.2. Motor  - - 
3.3. Behavioural  - - 
4. Rhombencephalon  
4.1. Pons - - 
4.2. Medulla ++ ++ 
5. Cerebellum  
5.1. Cerebellar cortex +++ +++ 
5.2. Cerebellar nuclei - - 
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4.4.3.2 Telencephalon 
Within the rat telencephalon preproaugurin-LI and mRNA were observed in the olfactory bulb 
(OB), subventricular zone (SVZ), and hippocampal formation (HPF). Within the OB, high 
levels of preproaugurin-LI and mRNA were observed in the mitral layer of the OB (Figure 4.4). 
More caudally, preproaugurin-LI and mRNA were prominent in the rostral migratory stream 
(RMS) and the SVZ (Figure 4.4). Within the HPF, preproaugurin-LI and mRNA were observed 
in neuron-like cells throughout the CA1-3 regions of the HPF, and the subgranular zone (SGZ) 
of the hippocampal dentate gyrus (Figure 4.4).  
4.4.3.3 Diencephalon 
Within the rat diencephalon preproaugurin-LI and mRNA were only observed in the 
hypothalamus. Within the hypothalamus, high levels of preproaugurin were observed in the 
ependymal cell layer lining the 3rd cerebral ventricle (3V) (Figure 4.5). Preproaugurin-LI and 
mRNA were also found in several areas of the hypothalamic parenchyma. Immunoreactive cells 
with neuronal appearance and punctate immunoreactivity were most prominent in the SON and 
PVN (Figure 4.5). Some immunoreactive neurons in the supraoptic nucleus (SON) displayed 
morphological features of magnocellular cells (Figure 4.5), with staining of the somata, sparing 
of the nuclei, and labelling of processes with dendritic appearance.  
4.4.3.4 Mesencephalon 
No preproaugurin-LI or mRNA was observed in any part of the mesencephalon. 
4.4.3.5 Rhombencephalon 
Scattered cells within nucleus of the tractus solitarius (NTS) of the dorsal vagal complex (DVC) 
showed strong preproaugurin-LI and mRNA expression (Figure 4.6). 
4.4.3.6 Cerebellum 
Within the cerebellum, the cell soma of Purkinje cells showed strong preproaugurin-LI and 
mRNA expression, and preproaugurin-LI was also observed in Purkinje cell dendritic processes 
(Figure 4.6). Both preproaugurin-LI and mRNA were absent from granular and molecular cell 
layers (Figure 4.6). 
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Figure 4.4: Representative light-field photomicrographs of preproaugurin-LI and mRNA in the 
telencephalon of male Wistar rats. Preproaugurin-LI was seen in the MCL of the OB (A [40x] 
and B [200x]), SVZ of the LV (D [100x]), migratory chains within the RMS (F [200x]), and in 
the HPF (H [40x]). Preproaugurin mRNA was also present in the MCL (C [40x]), SVZ (E 
[200x]), and HPF (G [10x] and I [40x]) A, B, D, and F, were counterstained with Haematoxylin. 
Abbreviations: CP, choroid plexus; DG, dentate gyrus; GL, granule layer; GLL, glomerular 
layer; LV, lateral ventricle; MCL, mitral cell layer; OPL, outer plexiform layer; SGZ, 
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Figure 4.5: Representative light-field photomicrographs of preproaugurin-LI and mRNA in the 
hypothalamus of male Wistar rats. Preproaugurin-LI was observed in the ependymal cell layer 
adjacent to the 3V (A [200x]), the PVN (B [40x]), the SON (D [100x] and E [200x]), and ARC 
(I [100x]). Preproaugurin immunoreactive cell within the SON with the morphological 
appearance of a magnocellular neuron (F [1000x]), immunoreactivity is restricted the cell 
cytoplasm where it is diffuse and punctate. Preproaugurin mRNA was also present in the PVN 
(C [200x]), SON (G [200x]), and ARC (H [100x]). A, B, D, and E, were counterstained with 
Haematoxylin. 
Abbreviations: 3V, 3rd cerebral ventricle; ARC, arcuate nucleus; PVN, paraventricular nucleus; 
SON, supraoptic nucleus; ot, optic tract.  
A B C 
D E F 
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Figure 4.6: Representative light-field photomicrographs of preproaugurin-LI and mRNA in the 
cerebellum and brainstem of male Wistar rats. Within the cerebellum, preproaugurin-LI was 
restricted to Purkinje cell soma and their dendrites (A [40x] and B [200x]). Within the 
brainstem, preproaugurin-LI was observed in the NTS (D [100x]), in what appeared to be 
neurons (E [200x]). Preproaugurin mRNA was also present in Purkinje cells within the 
cerebellum (C [100x]), and the brainstem NTS (F [200x]). 
Abbreviations: 4V, 4th cerebral ventricle; GL, granule cell layer; ML, molecular layer; NTS, 
nucleus of the tractus solitarius; PU, Purkinje cell layer; WM, white matter. 
A B 
C 
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4.5 DISCUSSION 
The studies discussed in chapters 2 and 3 suggest injection of augurin into the hypothalamic 
PVN stimulates the HPA axis and increases food intake in male Wistar rats. To investigate 
whether augurin could have a physiological role in the regulation of the HPA axis or food 
intake, I aimed to characterise its endogenous distribution in the rat CNS using IHC and ISH. 
My results suggest discrete populations of cells positive for preproaugurin-LI and mRNA are 
present in several regions of the CNS including the hypothalamus and brainstem. 
The primary consideration when evaluating a new antiserum or riboprobe is the specificity of 
staining (Kadkol et al., 1999, Saper and Sawchenko, 2003). Taken together, the studies in this 
chapter indicate that the observed pattern of both preproaugurin-LI and preproaugurin anti-sense 
riboprobe hybridisation represent the distribution of endogenous preproaugurin in the CNS. 
With regards to the IHC, the absence of staining following incubation of the antiserum with an 
excess of synthetic antigen, but not poly-L-lysine, suggests the immunoreactive component of 
the antiserum recognises that antigen specifically (Scopsi et al., 1986, Larsson, 1988). With 
regards to the ISH, no staining was observed following hybridisation with the same 
concentration of sense riboprobe as antisense, indicating that the pattern of anti-sense riboprobe 
hybridisation is sequence dependant, and therefore likely to be specific to the target mRNA 
(Larsson and Hougaard, 1990). Most importantly, the patterns of immunoreactivity and 
hybridisation in my studies showed strict concordance, strongly supporting the specificity of my 
results (Saper and Sawchenko, 2003). Furthermore, my results are in agreement with several 
studies published during preparation of this thesis (Roberton et al., 2009, Kujuro et al., 2010, 
Gonzalez et al., 2011). 
Prior to beginning work for this thesis, the only study investigating the distribution of augurin 
within the CNS was carried out by Mirabeau et al. who reported high levels of preproaugurin 
mRNA in the CP (Mirabeau et al., 2007). In addition to the CP, I observed the highest levels of 
preproaugurin-LI and mRNA in the SVZ, RMS, and SGZ; regions of the CNS primarily 
associated with neural stem cells (NSCs) (Merkle et al., 2007, Conti and Cattaneo, 2010). 
Although neurogenesis primarily occurs during embryonic development, it continues into adult 
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life in rodents and humans largely confined to the SVZ and SGZ (Lledo et al., 2006). In the 
SVZ for example, slowly dividing astrocyte-like NSCs give rise to neural precursor cells 
(NPCs) that migrate toward the OB in chains, forming the RMS (Mirzadeh et al., 2008, Zhao et 
al., 2008). After reaching the OB the NPCs differentiate into functional local interneurons 
(Imayoshi et al., 2008, Lledo et al., 2008). Although adult neurogenesis is now a well-
established occurrence, much is still unknown about the signalling mechanisms that regulate 
adult neurogenesis and cell fate (Suh et al., 2009). Given the high levels of preproaugurin in 
regions of the CNS associated with NSCs, it is possible augurin regulates NSC/NPC 
proliferation, migration, or both. 
A role for augurin as in neurogenesis would be consistent with the distribution of preproaugurin, 
and its reported anti-proliferative effects. The gene encoding preproaugurin, Chromosome 2 
open reading frame 40 (C2orf40), was originally suggested to be a tumour suppressor gene in 
human oesophageal squamous cell carcinoma (OSCC), and decreased expression has since been 
associated with multiple forms of cancer (Su et al., 1998, Mori et al., 2007, Gotze et al., 2009, 
Li et al., 2009, Vanaja et al., 2009). Preproaugurin mRNA expression correlates negatively with 
OSCC disease stage, and may be an independent prognostic factor for poor survival (Mori et al., 
2007, Li et al., 2009). In vitro studies indicate that preproaugurin regulates numerous aspects of 
tumour progression and metastasis. Transfection with preproaugurin cDNA reduces the rate of 
proliferation, invasion, and migration of several cancer cell lines (Li et al., 2009, Li et al., 
2010b). Based on the evidence indicating C2orf40 serves as a tumour suppressor gene, and the 
studies of Kujuro et al. suggesting preproaugurin is a secreted inducer of cell NPC senescence, I 
hypothesise that augurin is an endogenous inhibitor of adult neurogenesis in the SVZ and SGZ 
(Gotze et al., 2009, Li et al., 2009, Kujuro et al., 2010). If augurin is a physiological inhibitor of 
neurogenesis, antagonists of its receptor could be candidates for neurorestorative therapeutics 
(Geraerts et al., 2007, Taupin, 2009, Lindvall and Kokaia, 2010). 
Two studies published during the preparation of this thesis have reported preproaugurin-LI in 
cells with neuronal morphology in the rodent CNS (Roberton et al., 2009, Kujuro et al., 2010). 
In accord with their observations, my studies indicate that preproaugurin-LI is present in 
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neurons within the rat CNS. Furthermore, the results discussed in this chapter are the first to 
report preproaugurin mRNA in neurons. Preproaugurin-LI cells in the OB, hypothalamus, and 
cerebellum exhibited quintessential neuronal morphology (Paxinos, 2004, Su et al., 2004, 
Young et al., 2008). Within neurons, preproaugurin-LI was diffuse, punctate, and present 
throughout the cytoplasm and in what appeared to be dendritic and axonal processes. This 
pattern of staining is consistent with storage in cytoplasmic secretory granules, and is 
characteristic of a neuropeptide (Polak and Bloom, 1987). 
The data presented in this chapter are in agreement with a recent study by Roberton et al. 
describing the distribution of preproaugurin-LI in the hypothalamus (Roberton et al., 2009). 
They observed preproaugurin-LI in magnocellular neurons within the PVN and SON, 
synaptic-capillary interfaces in the median eminence, and in Herring bodies in the posterior 
pituitary (Roberton et al., 2009). Furthermore, preproaugurin-LI co-localised with arginine 
vasopressin (AVP)- and oxytocin (OXT)-LI to secretory granules (Roberton et al., 2009). The 
majority of magnocellular neurons in the PVN and SON project to the posterior pituitary where 
they release neuropeptides such as AVP and OXT into the circulation (Bourque, 2008). Augurin 
may therefore also be released in the circulation, and exert a regulatory effect on target organs. 
My studies in chapters 2 and 3 suggest iPVN injection of augurin is biologically active, 
stimulating the HPA axis and increasing food intake in male Wistar rats. Multiple neuropeptides 
including neuropeptide Y, cocaine-and amphetamine-regulated transcript protein, glucagon-like 
peptide-1, melanocortin-concentrating hormone, and prolactin releasing peptide, are all released 
into the PVN and peri-PVN area where they modulate neuroendocrine function (Rinaman, 
1999, Stanley et al., 2001, Lin et al., 2002, Mihaly et al., 2002, Pissios et al., 2006). The data 
presented in this chapter suggest preproaugurin positive neurons are present within the PVN 
itself, and, in areas that project directly to the PVN such as the ARC and NTS (as discussed in 
chapter 3). Furthermore, my data are in agreement with several studies published during 
preparation of this thesis (Roberton et al., 2009, Kujuro et al., 2010, Gonzalez et al., 2011). The 
distribution of preproaugurin neurons in the CNS is therefore consistent with a role in the 
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regulation of food intake and the HPA axis via the PVN (Larsen and Mikkelsen, 1995, Ulrich-
Lai and Herman, 2009). 
Considerable work remains to delineate the neuroanatomy of the CNS augurin system, and to 
establish whether endogenous augurin has a physiological role within the hypothalamic PVN. 
Neuropeptides usually do not exist alone as neurotransmitters but colocalise with classical 
neurotransmitters, with other neuropeptides, or both (Hokfelt et al., 2000). Identification of 
coexisting transmitters in augurin-producing neurons would help to develop new hypotheses 
about anatomical connections of augurin neurons and possible regulatory roles of the augurin 
system. Induction of the immediate-early gene cfos is a well-established marker of neuronal 
activation (Sagar et al., 1988, Hoffman and Lyo, 2002). Retrograde neuronal tracing combined 
with IHC for Fos-LI would indicate which augurin neurons, if any, projected directly to the 
PVN, and whether those neurons were activated in response to altered energy balance or 
stressors (Li and Sawchenko, 1998, Vinuela and Larsen, 2001). 
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5 FINAL DISCUSSION 
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5.1 FINAL DISCUSSION 
Work presented in this thesis has attempted to investigate whether the putative neuroendocrine 
peptide augurin has a role in the regulation of neuroendocrine function. Considerable efforts 
have been made to identify and characterise novel neuroendocrine peptides (NEPs) because of 
their capacity to modulate physiological functions and the opportunities for development of drug 
therapies resulting from their characterisation (Clark et al., 2003, Hokfelt et al., 2003). NEPs 
function as both hormones and neurotransmitters, and as a result frequently play important roles 
in the orchestration of both somatic and behavioural responses to relevant environmental stimuli 
(Hokfelt, 1991). Augurin is a recently identified putative NEP of unknown function (Mirabeau 
et al., 2007). Because of its prominent expression in the central nervous system (CNS), 
pituitary, and endocrine organs, I hypothesised augurin may have a physiological role in the 
neuroendocrine system (Steck et al., 2002, Mirabeau et al., 2007).  
As the hypothalamus and pituitary are sites at which many NEPs have some biological activity, 
and are pivotal components of the neuroendocrine system, I began by investigating the effects 
of augurin on the hypothalamo-pituitary axes in male Wistar rats. Studies in chapter 2 suggest 
that intracerebroventricular (ICV) or intraparaventricular nucleus (iPVN) injection of augurin 
selectively activates the hypothalamo-pituitary-adrenal (HPA) axis in rats, and that this effect is 
likely mediated by the release of corticotrophin releasing hormone (CRH) from neurons in the 
PVN. The HPA axis is the final common pathway in the stress response. It is the humoral 
component of an integrated neural and endocrine system that maintains homeostasis in response 
to stressors (Ulrich-Lai and Herman, 2009). Activation of the HPA axis culminates in the 
secretion of glucocorticoids (Herman et al., 2003). Hypophysiotrophic CRH and arginine 
vasopressin (AVP) parvocellular neurosecretory neurons (PCNs) within the PVN control 
glucocorticoid secretion, and are the focal point for neurocircuitry projecting from 
hypothalamic, brainstem and forebrain nuclei conveying information regarding stressors 
(Ulrich-Lai and Herman, 2009). Glucocorticoids act at multiple levels, temporarily redirecting 
resources to restorative processes and promoting allostasis.  
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Nevertheless, inappropriate or sustained glucocorticoid secretion is highly detrimental to an 
organism. Dysregulation of the HPA axis and of plasma glucocorticoid levels has been 
implicated in the pathogenesis of hypertension, obesity, type II diabetes, and depression 
(Buckingham, 2006). Various pharmacotherapies have been developed based on components of 
the HPA axis. Glucocorticoid receptor agonists are widely used as anti-inflammatory and 
immunosuppressive agents (Rhen and Cidlowski, 2005). More recently, CRH receptor (CRHR) 
antagonists have shown promise in the treatment of anxiety, depression, sleep disorders, 
addictive behaviour, and preterm labour (Habib et al., 2000, Zoumakis et al., 2006). Based on 
my results it is conceivable that the augurin system may be a viable pharmacological target for 
manipulation of the HPA axis. 
Neuropeptides commonly have several biological functions within the hypothalamus (Williams 
et al., 2001). The proopiomelanocortin derived peptide α-melanocyte-stimulating hormone (α-
MSH), for example, has been implicated in the regulation of energy homeostasis, HPA axis 
activity, reproduction and fertility, blood pressure, and arousal (Wardlaw and Ferin, 1990, Van 
Der Ploeg et al., 2002, Leibel, 2006, Belgardt et al., 2008, Greenfield et al., 2009). Results from 
chapter 2 suggest that augurin stimulates the release of CRH from neurons in the PVN. The 
PVN has an important role in the regulation of food intake as well as HPA axis activity, and in 
addition to stimulating the secretion of glucocorticoids, hypothalamic CRH is a potent 
physiological inhibitor of food intake (Grill and Kaplan, 2002, Morton et al., 2006). Studies 
have shown that CRH is a downstream mediator of α-MSH’s effects on both food intake and the 
HPA axis (Gardner et al., 1998, Uehara et al., 1998, Lu et al., 2003). I therefore hypothesised 
that hypothalamic injection of augurin would reduce food intake by stimulating the central 
release of CRH. 
Unexpectedly, my results from chapter 3 indicate that augurin had a robust orexigenic effect 
when injected into the PVN at the start of either the dark or light phase. My results from chapter 
2 suggest that augurin stimulates the release of CRH in vivo following hypothalamic injection, 
and from ex vivo hypothalamic explants. That iPVN augurin should stimulate the HPA axis and 
increase food intake therefore seems counterintuitive, however, many peptides that regulate 
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food intake play a role in the control of the HPA axis, and role for augurin in the regulation of 
both is therefore possible (Ludwig et al., 1998, Spinedi and Gaillard, 1998, Krysiak et al., 1999, 
Pecoraro et al., 2004, Thompson et al., 2004a). 
The data presented in chapters 2 and 3 demonstrate pharmacological effects of augurin 
following injection into the PVN. To explore whether augurin might have a physiological role 
in the regulation of the HPA axis or food intake, I investigated its endogenous distribution in the 
rat CNS using immunohistochemistry (IHC) and in situ hybridisation histochemistry (ISH).  
The studies in chapter 4 suggest preproaugurin positive neurons are present within the PVN 
itself, and, in areas that project directly to the PVN such as the arcuate nucleus and dorsal vagal 
complex (as discussed in chapter 3). The distribution of preproaugurin neurons in the CNS is 
therefore consistent with a role in the regulation of food intake, the HPA axis, or both, via the 
PVN (Larsen and Mikkelsen, 1995, Ulrich-Lai and Herman, 2009). 
The data presented in chapter 4 are in agreement with several studies published during 
preparation of this thesis describing preproaugurin neurons within the PVN itself, and, in areas 
that project directly to the PVN (Roberton et al., 2009, Kujuro et al., 2010, Gonzalez et al., 
2011). These data indicate that preproaugurin derived peptides are present endogenously in the 
PVN. Results discussed in chapter 3 suggest augurin has an orexigenic effect in the PVN, and it 
is therefore possible augurin may have a physiological role promoting food intake. If augurin is 
a physiological orexigen, antagonists at its receptor could be a potential treatment for obesity.  
The prevalence of obesity is reaching epidemic proportions (Abelson and Kennedy, 2004). 
Obese people, defined as having a body-mass index of 30.0 or higher, have increased all cause 
mortality, and higher death rates from heart disease, stroke, and cancer (Whitlock et al., 2009, 
Welborn and Dhaliwal, 2011, Zheng et al., 2011). Treatment options for obesity are limited. 
Studies of lifestyle advice and dietary intervention show that while moderate, clinically 
significant weight loss is achievable and results in concomitant improvements in comorbidities, 
it is invariably transient and recidivism is almost universal (Yanovski and Yanovski, 2002, 
Padwal and Majumdar, 2006). Although pharmacotheraputic options have shown promise, they 
are currently inadequate to address many obesity-associated comorbidities (Padwal and 
 150  
Majumdar, 2007, Field et al., 2009). Further understanding of augurin’s role in the 
neuroendocrine circuits that regulate energy homeostasis would indicate whether it could 
provide a bases for novel therapies for the treatment of obesity. 
Neuropeptides are a critically important and diverse set of regulatory molecules whose 
functions are to convey specific information among cells and organs. Their diversity makes 
defining a neuropeptide challenging, and in general they are best characterised by their shared 
characteristics. Hallmarks of neuropeptides are 1) preprohormone gene expression and 
posttranslational processing by neurons, 2) regulated release, and 3) the ability to modulate or 
mediate neural functioning by acting on specific receptors (Burbach, 2010). Although no 
receptor for augurin has been identified, augurin appears to fulfil the first and possibly second 
criteria.  
Firstly, the studies presented in this thesis, and those recently published by Roberton et al. and 
Kujuro et al., suggest preproaugurin is endogenously expressed in several neuronal populations 
within the CNS, and that posttranslational cleavage produces several candidate neuropeptides 
(Roberton et al., 2009, Kujuro et al., 2010). Secondly, experimental evidence suggests that 
secretion of augurin by neurons is likely to be regulated rather than constitutive. Neurons 
expressing classical neuropeptides use the regulated secretory pathway, allowing storage of 
neuropeptides in large dense-cored vesicles (LDCVs) and controlled release upon a stimulus 
(Brownstein et al., 1980). Several studies have demonstrated that the preproaugurin-LI co-
localises with peptides known to be stored in LDCVs, such as insulin, AVP, and OXT, strongly 
suggesting stimulus dependant release (Watson et al., 1982, Leng et al., 1999, Mirabeau et al., 
2007, Roberton et al., 2009).  
 151  
5.2 FINAL CONCLUSION 
Taken together, the results discussed in this thesis, and those of several recently published 
studies, support the hypothesis that augurin is a novel neuropeptide with a role in the 
neuroendocrine system (Mirabeau et al., 2007, Roberton et al., 2009, Kujuro et al., 2010, 
Gonzalez et al., 2011). Further work is required to determine if pharmacological manipulation 
of the augurin system holds therapeutic potential for the treatment of diseases. Identifying the 
endogenous forms of augurin, their receptor(s), and structural analogues acting as antagonists or 
agonists would provide valuable tools for investigating the physiological role of augurin, and its 
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APPENDIX I: RADIOIMMUNOASSAY 
RIA is a technique for measuring low levels of biological substances in small volume tissue and 
plasma samples. The principle of RIA is competition between unlabelled antigen (in the sample) 
and radiolabelled antigen to bind to a fixed concentration of antibody. The most commonly used 
radiolabel is 125I, and antibodies are often obtained from rabbit immunisation with 
antigen/peptide plus adjuvant (though polyclonal antibodies from other species and monoclonal 
antibodies can be used). The concentrations of radiolabelled antigen and antibody remain 
constant. Increasing the concentration of unlabelled antigen will therefore decrease the binding 
sites available for binding to the radiolabelled antigen. Thus the amount of radiolabelled antigen 
bound to the antibody is inversely proportional to the amount of unlabelled antigen in the 
sample being examined. A series of reference standards or a ‘standard curve’ is constructed of 
known concentrations of the peptide.  
Each RIA has optimum conditions in terms of buffer, volume, antibody titre, incubation time, 
and separation method. Phosphate and sodium barbitone buffers are used for a wide range of 
RIAs. Assays are often incubated at 4oC for 3-5 days. Once equilibrium has been achieved, the 
amount of antibody bound to antigen, and the amount of free antibody and antigen are constant. 
Separation of the unbound radiolabelled antigen from the radiolabelled antigen-antibody 
complex and counting the proportion of radiolabel present in the two fractions enables direct 
measurement of the amount of unlabelled antigen that has bound to the antibody. By reference 
to the standard curve, the concentration of unknown samples can be calculated.  
The simplest method of separation of free radiolabelled antigen from the antibody complex is 
adsorption, for example with charcoal. Dextran is added to a charcoal suspension to block the 
larger holes in the porous charcoal. The suspension is then added to the RIA tubes, where it 
traps the free radiolabelled antigen. The tubes are then centrifuged and the supernatant (bound 
antibody complex) and carbon pellet (free radiolabelled antigen) separated by aspiration, and 
counted in a gamma counter.  
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Appropriate quality control is must for obtaining robust and reproducible data. The precision of 
an assay is commonly estimated by calculating the intra and interassay coefficients of variation 
(!!). The !! is a measure of the dispersion of a probability distribution. It is defined as the ratio 
of the standard deviation (!) to the mean (!), and reported as a percentage by multiplying by 
100 (Equation 1). The !! is appropriate when describing the distribution of positive valued 
variables that approximate a normal distribution. Inter-assay variation is calculated by assaying 
aliquots of the same sample in each assay performed and comparing the concentrations obtained 
in each, while intra-assay variation is calculated by assaying aliquots of the same sample in 
separate assays.  
 
 
!!! = !! !×100 
Equation 1 The coefficient of variation 
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APPENDIX II: AMINO ACID THREE AND ONE LETTER 
CODES 
Amino Acid  Codes 
 Three letter  Single letter 
Glycine  Gly G 
Proline Pro P 
Alanine Ala A 
Valine Val V 
Leucine Leu L 
Isoleucine Ile I 
Methionine Met M 
Cysteine Cys C 
Phenylalanine Phe F 
Tyrosine Tyr Y 
Tryptophan Trp W 
Histidine His H 
Lysine Lys K 
Arginine Arg R 
Glutamine Gln Q 
Asparagine Asn N 
Glutamic Acid Glu E 
Aspartic Acid Asp D 
Serine Ser S 
Theronine Thr T 
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APPENDIX III: SUPPLIERS 
Associated Dental Products Ltd, Kemdent Works, Purton, Swindon, UK 
Bachem St. Helens, UK 
Bayer UK, Bury St. Edmonds, UK 
BioXtal, Mundelsohm, France 
Bright Instruments, Huntingdon, UK 
Campden Instruments, Loughborough, UK  
Charles River, Bicester, UK. 
Clark Electromedial Instruments, Pangbourne, Reading, UK 
Fisher Scientific, Leicestershire, UK 
Gibco BRL (Life Technologies Ltd.), Paisley, Renfrewshire, UK. 
GraphPad, La Jolla, CA, USA 
Harvard Apparatus, Massachusetts, USA 
Helena Biosciences, Sunderland, UK 
Invitrogen, Paisley, UK 
Life Sciences Technology, Eggenstein, Germany 
Millipore S.A., France 
New England Bioloabs, Hitchin, Herts, UK 
Parke-Davis, Pontypool, Gwent, UK. 
Peptide Institute, Kyoto, Japan. 
Perkin Elmer, Massachusetts, USA 
Pharmacia Biotechnology Ltd., St. Albans, Hertsfordshire, UK. 
Phoenix Pharmaceuticals Belmont, CA, USA  
Plastics One Inc, Roanoke, VA, USA. 
Promega, Southampton, UK 
Research Diets Inc, New Brunswick, NJ, USA 
Schering-Plough Corporation, Welwyn Garden City, Herts, UK 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK. 
Systat Ltd., Evanston, Illinois, USA. 
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APPENDIX IV: SOLUTIONS 
Fixative 
15g of NaCl, 28.2g Na2HPO4.2H20 and 5.44g KH2PO4 were dissolved in 800mls H20. 100mls of 
40% formaldehyde were added and the solution made up to 1L. Adjust to pH 7.4 with NaOH.  
Flush 
15g of NaCl, 28.2g Na2HPO4.2H20 and 5.44g KH2PO4 were dissolved in 900mls H20 and the 
solution made up to 1L. Adjust to pH 7.4 with NaOH. 
Artificial cerebrospinal fluid (aCSF) 
Make aCSF immediately before use. To make 500 ml aCSF mix 100ml 0.1M NaHCO
3
, 100ml 
0.63M NaCl, 5ml 0.09M Na2HPO4.2H2O, 5ml 0.59M KCl, 5ml 0.09M MgSO4
.
7H2O, 450 mg 
glucose, 88 mg ascorbic acid, 5ml aprotinin (Trasylol, Bayer Corp) and 270ml ultra pure water. 
Saturate with 95% O2
 
and 5% CO2. Add 10ml 0.07M CaCl2.2H2O after gassing.  
56mM KCl (stimulatory) aCSF 
Make aCSF immediately before use. To make 100ml 56mM KCl aCSF, mix 20ml 0.1M 
NaHCO3, 11.6ml 0.63M NaCl, 1ml 0.09M Na2HPO4.2H2O, 10ml 0.59M KCl, 1ml 0.09M 
MgSO4
.
7H2O, 90 mg glucose, 17.6mg ascorbic acid, 1ml aprotinin (Bayer Corp) and 53.4ml 
ultra pure water. Saturate with 95% O2
 
and 5% CO2. Add 2ml 0.07M CaCl2.2H2O after gassing.  
aCSF stock solutions 
0.09M disodium hydrogen orthophosphate dehydrate: Dissolve 1.56g Na2HPO4.2H2O in 100ml 
ultra pure water   
0.07M calcium chloride dehydrate: Dissolve 1.04g CaCl2.2H2O in 100ml ultra pure water   
0.09M magnesium sulphate heptahydrate: Dissolve 2.2g MgSO4
.
7H2O in 100ml ultra pure water   
0.59M potassium chloride: Dissolve 4.42g KCl in 100ml ultra pure water   
0.1M sodium bicarbonate: Dissolve 4.62g NaHCO3 in 500ml ultra pure water   
0.63M sodium chloride: Dissolve 18.43g NaCl in 500ml ultra pure water  
0.01M citrate buffer 
Dissolve 19.2g citric acid in 900ml ultra pure water. pH to 6 and make up to 1L with ultra pure 
water.  
1% Copper sulphate solution 
Dissolve 1g of copper sulphate in 100ml ultra pure water. 
Deionised formamide 
Add 1g of amberlite MB6113 (indicator) mixed resin per 10ml formamide. Incubate for 1 hour 
in the 37°C shaker until indicator turns yellow. Pass through a sterile filter before use. 
Denhart’s solution 
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Dissolve 10g of each of ficoll, polyvinyl-pyrrolidone and BSA in 500ml ultra pure water . Store 
in aliquots at -20°C. 
Detection buffer 
Mix 0.8ml 5M NaCl, 1.6ml MgCl2, 8ml 0.5M Tris-HCl pH9.8 and add 20mg levamisol. Make 
up to 20ml with ultra pure water and add 20ml of 10% polyvinyl acetate. For development, omit 
the MgCl2 and add 2 drops of reagent 1, 2, and 3 per 5 ml detection buffer. 
Dextran coated charcoal 
Add 2.4g charcoal and 0.24g dextran to 100ml phosphate buffer with gelatine and mix for 20 
mins at 20°C 
DNA loading buffer 
Mix 3.125ml 80% glycerol, 50µl 0.5M CH14H2O8Na2.2H2O (EDTA) and 6.075ml ultra pure 
water , add 10mg orange G. 
dNTP mix for PCR and reverse transcription 
Mix 20µl each of 100mM dGTP, dCTP,dATP and dTTP in 120µl filtered ultra pure water . 
0.5M ethylenediaminetetra-acetic acid (EDTA) 
Dissolve 186.1g CH14H2O8Na2.2H2O (EDTA) in 800ml ultra pure water and adjust pH to 8.0. 
Make up to 1L with ultra pure water. 
Hybridisation buffer  
Add 5ml deionised formamide, 2.5ml 20x SSC, 200µl 100 x Denhardts Solution, 100µl 1M Tris 
pH7.5, 250µl 10% SDS, 20µl 0.5M EDTA pH8, 1.25ml 10mg/ml tRNA, 680µl BPC water, 1g 
dextran sulphate together and mix well.   
Kemteck buffer (0.05M) (RIA buffer)  
Dissolve 22.4g NaH2PO4.2H2O, 9.96g Na2HPO4.2H2O, 14.8g C10H14H2O8Na2.2H2O, 1g 
C9H9HgNaO2S, 26.6ml of 30% BSA in 5L of ultra pure water that has been boiled and allowed 
to cool. Adjust to pH 7.4 with sodium hydroxide. Store at 4°C. 
1M magnesium chloride 
Dissolve 203.3g MgCl2 in 1L ultra pure water.  
Maleic buffer 
Dissolve 116g maleic acid and 88g NaCl into 800ml ultra pure water. pH to 7.5 with NaOH and 
make up to 1L with ultra pure water  
20x MOPS 
Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g sodium acetate, 7.4g 
C10H14H2O8Na2.2H2O and 2.5ml formaldehyde to 800ml ultra pure water.  Adjust to pH 7.0 with 
10M sodium hydroxide and make up to 1L. 
Phosphate buffer (0.06M) (RIA buffer) 
Dissolve 48 g of Na2HPO4.2H2O, 4.13 g KHPO4, 18.61 g C10H14H2O8Na2.2H2O, 2.5 g NaN3
 
in 5 
L of ultra pure water that has been boiled and allowed to cool. Measure the pH to confirm it is 
7.4±0.1. Store at 4°C.  
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Phosphate buffer (0.06M) with gelatin 
The buffer is produced as above with 12.5 g of gelatine dissolved in the boiling ultra pure water 
then cooled before the addition of the other ingredients.  
10x Phosphate buffered saline (PBS)  
Add 80g of NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 to 800ml ultra pure water. Adjust 
volume to 1L with ultra pure water , adjust pH to 7.4 and sterilise by autoclaving. 
1x PBS 
Add 100ml 10x PBS to 900ml ultra pure water. Sterilise by autoclaving. 
10% Polyethylene glycol (RIA) 
Dissolve 100g of polyethylene glycol into 1L ultra pure water. 
10mg/ml RNAse A 
Add 100mg RNAse A, 50µl 2M Tris and 30µl 5M NaCl to 9.92ml ultra pure water, and boil for 
15 minutes. Allow to cool and aliquot. 
20 x Standard sodium citrate (SSC) 
Add 1753g NaCl and 882g Na3C6H5O7.2H2O to 8L ultra pure water, adjust to pH 7.0 and make 
up to 10L. 
5M sodium chloride 
Dissolve 292.2g NaCl in 1L ultra pure water.  
10M sodium hydroxide 
Dissolve 400g of NaOH in 500ml ultra pure water . Once dissolved, make up to 1L with ultra 
pure water.  
30% sucrose solution  
Dissolve 300g of sucrose in 1L 1xPBS. 
50 x Tris-acetate-EDTA (TAE) buffer  
Dissolve 242g Trizma base in 843ml ultra pure water and mix in 57ml glacial acetic acid and 
100ml 0.5M C10H14H2O8Na2.2H2O. 
TAE running buffer 
To 1L ultra pure water, add 75µl ethidium bromide and 10ml 50 x TAE. 
100 x TE 
Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml ultra pure water and 
adjust to pH 7.5 with HCl. Make up to 1L. 
1M Tris-HCl pH7.5 
Dissolve 121.1g Trizma base in 800ml ultra pure water and adjust to pH 7.5 with HCl. Make up 
to 1L. 
2M Tris-HCl pH 8.0 
Dissolve 121.1g Trizma base in 450ml ultra pure water and adjust to pH 8.0 with HCl. Make up 
to 500ml. 
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APPENDIX V: PUBLICATIONS RELATING TO THIS THESIS 
Tadross, J. A., Patterson, M., Suzuki, K., Beale, K. E., Boughton, C. K., Smith, K. L., Moore, 
S., Ghatei, M. A. & Bloom, S. R. 2010. Augurin stimulates the hypothalamo-pituitary-adrenal 


























hypothalamo-pituitary-adrenal axis via the release
of corticotrophin-releasing factor in ratsbph_655 1663..1671
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Background and purpose: The functional characterization of secreted peptides can provide the basis for the development of
novel therapeutic agents. Augurin is a recently identified secreted peptide of unknown function expressed in multiple
endocrine tissues, and in regions of the brain including the hypothalamus. We therefore investigated the effect of hypothalamic
injection of augurin on the hypothalamo-pituitary-adrenal (HPA) axis in male Wistar rats.
Experimental approach: Augurin was given as a single injection into the third cerebral ventricle (i.c.v.) or into the paraven-
tricular nucleus (iPVN) of the hypothalamus. Circulating hormone levels were then measured by radioimmunoassay. The effect
of augurin on the release of hypothalamic neuropeptides was investigated ex vivo using hypothalamic explants. The acute
effects of iPVN augurin on behaviour were also assessed.
Key results: i.c.v. injection of augurin significantly increased plasma ACTH and corticosterone, compared with vehicle-injected
controls, but had no effect on other hypothalamo-pituitary axes hormones. Microinjection of lower doses of augurin into the
PVN caused a similar increase in plasma ACTH and corticosterone, without significant alteration in behavioural patterns.
Incubation of hypothalamic explants with increasing doses of augurin significantly elevated corticotrophin-releasing factor
(CRF) and arginine vasopressin release. In vivo, peripheral injection of a CRF1/2 receptor antagonist prevented the rise in ACTH
and corticosterone caused by i.c.v. augurin injection.
Conclusions and implications: These data suggest that augurin stimulates the release of ACTH via the release of hypothalamic
CRF. Pharmacological manipulation of the augurin system may therefore be a novel target for regulation of the HPA axis.
British Journal of Pharmacology (2010) 159, 1663–1671; doi:10.1111/j.1476-5381.2010.00655.x; published online 8
March 2010
Keywords: augurin; hypothalamo-pituitary-adrenal axis; paraventricular nucleus; CRF
Abbreviations: aCSF, artificial cerebrospinal fluid; AVP, arginine vasopressin; CRF, corticotrophin-releasing factor; ECRG4,
oesophageal cancer-related gene 4; HPA, hypothalamo-pituitary-adrenal; i.c.v., intracerebroventricular; PVN,
paraventricular nucleus
Introduction
Novel secreted peptides represent an important field of
research because delineation of their function affords new
insights into the pathophysiological processes causing
disease, and provides opportunities for the development of
pharmacological therapies. Secreted peptide systems are par-
ticularly amenable to pharmacological modulation as their
receptors are generally found on the cell surface and acces-
sible to circulating factors. Synthetic secreted peptides or
structural analogues can therefore be used directly as thera-
peutic agents for various diseases.
Augurin is a recently identified secreted peptide of
unknown function encoded by the gene c2orf40 (Mirabeau
et al., 2007), a potential tumour suppressor gene in human
oesophageal epithelium (Su et al., 1998). Down-regulation of
c2orf40 expression due to hypermethylation can occur in
human oesophageal squamous cell carcinoma and may be
an independent prognostic factor for poor survival (Yue
et al., 2003). The product of c2orf40 is the highly conserved
148-amino-acid oesophageal cancer-related gene 4 protein
(ECRG4 protein). ECRG4 protein has characteristic features
of a preprohormone; it contains a canonical signal peptide
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sequence and at least one basic residue, prohormone cleavage,
site. Augurin is produced by post-translational processing of
ECRG4 protein (Mirabeau et al., 2007).
The primary sequence of endogenous augurin has not been
determined. ECRG4 protein contains one canonical dibasic
prohormone cleavage site corresponding to residues Lys69
and Arg70. Cleavage at this site has been demonstrated in vitro
following transfection of a pancreatic cell line with the
c2orf40 gene in which the Flag antigen sequence was inserted
between Arg70 and Gln71 (Mirabeau et al., 2007). Western
blotting of supernatant from Flag augurin-transfected cells
revealed two immunoreactive bands consistent with secretion
of an Arg70 cleaved 10 kDa peptide (augurin 71–148) and a
smaller 8 kDa peptide. It is suggested the 8 kDa peptide results
from a second, unknown, C-terminal non-canonical cleavage
site (Mirabeau et al., 2007).
c2orf40 expression has been quantified in various tissues.
Microarray data suggest that, in humans, the highest expres-
sion is found in the thyroid, pituitary, testis and adrenal.
In mice, the highest expression is found in the adrenals,
ovaries, digits, retina and trachea [GNF Symatlas: http://
symatlas.gnf.org/SymAtlas/ (last accessed 12 April 2009)] (Su
et al., 2004). In the human brain c2orf40 expression is highest
in the olfactory bulb, cerebellum, hypothalamus and
amygdala, an expression pattern mirrored in mice (Su et al.,
2004). In situ hybridization in mouse embryos has detected
c2orf40 mRNA in the intermediate lobe of the pituitary, glom-
erular layer of the adrenal cortex, choroid plexus and atrio-
ventricular node of the heart (Mirabeau et al., 2007).
The distribution of ECRG4-like immunoreactivity in hypo-
thalamus has been reported in an abstract submitted for a
recent scientific meeting (Roberton et al., 2009). In addition
to the choroid plexus, ECRG4-like immunoreactivity was
detected in the paraventricular nucleus (PVN) and supraoptic
nucleus of the hypothalamus, where it colocalized with vaso-
pressin (AVP) and oxytocin. Immunoreactivity was localized
to synaptic–capillary interfaces in the median eminence, and
Herring bodies in the posterior pituitary. This pattern of
immunoreactivity is characteristic of a secreted peptide and
suggests that ECRG4 or a product thereof may be a novel
hypothalamic neuropeptide.
As c2orf40 is expressed in the brain and endocrine organs,
we hypothesized that its product may be involved in the
neuroendocrine system. Substantial expression in the hypo-
thalamus could be consistent with a physiological role in the
hypothalamo-pituitary axis. We therefore investigated the
effects of hypothalamic injection of augurin 71–148, a prob-
able endogenous form, on the hypothalamo-pituitary axis.
The present study found that injection of augurin into the
third cerebral ventricle (i.c.v.) or into the PVN (iPVN) elevated
plasma adrenocorticotrophin (ACTH) and corticosterone
compared with vehicle-injected controls, and that incubation
with augurin increased the release of corticotrophin-releasing
factor (CRF) and AVP from hypothalamic explants. The rise in
plasma ACTH and corticosterone following i.c.v. injection of
augurin was blocked by pretreatment with a CRF receptor
antagonist. Dysregulation of the hypothalamo-pituitary-
adrenal (HPA) axis and of plasma glucocorticoid levels have
been implicated in the pathogenesis of hypertension, obesity,
type II diabetes and depression (Buckingham, 2006). These
studies suggest that the augurin system may be an attractive
pharmacological target for manipulation of the HPA axis.
Methods
Animals
All animal care and experimental procedures complied with
the British Home Office Animals (Scientific Procedures) Act
1986 (Project Licence 70/6402). Male Wistar rats (specific
pathogen free; Charles River, Margate, UK) weighing 250–
300 g were maintained in individual cages under controlled
temperature (21–23°C) and light conditions (12 h light, 12 h
dark cycle; lights on at 0700 h), with ad libitum access to food
(RM1 diet, SDS Ltd., Witham, UK) and water.
Peptides
A synthetic fragment of human augurin corresponding to
amino acids 71–148 of ECRG4 protein was synthesized by
Bachem UK Ltd. (Merseyside, UK). The synthesis was per-
formed using a Symphony automated peptide synthesizer
(Protein Technology, Inc., Woburn, MA, USA). The product
was initially purified by flash chromatography with a reversed
phase resin (Daisogel), followed by reversed phase high pres-
sure liquid chromatography (HPLC). Analyses of the purified
peptide by matrix-assisted laser desorption/ionization mass
spectroscopy, HPLC and amino acid analysis showed above
91% purity (average molecular weight 9689).
Rat neuromedin U (NMU) 23 and astressin were purchased
from Bachem UK Ltd.
For all studies lyophilized augurin was first dissolved in a
small amount of 0.05 M HCl, and then diluted in saline for in
vivo studies or in artificial cerebrospinal fluid [(aCSF; see below
for composition) for hypothalamic or pituitary explant
studies] containing sufficient NaOH to neutralize the HCl. For
all studies the vehicle control was prepared using identical
amounts of HCl and NaOH.
Intracerebroventricular cannulation and injections
Intracerebroventricular cannulation was carried out using an
established protocol (Rossi et al., 1997). A 22-gauge stainless
steel guide cannula (Plastics One, Roanoke, VA, USA) project-
ing into the third cerebral ventricle was stereotactically
implanted into each rat using coordinates calculated from the
rat brain atlas of Paxinos and Watson (0.8 mm caudal to
bregma in the midline and implanted 6.5 mm below the
outer surface of the skull) (Paxinos and Watson, 2007), as
previously described (Rossi et al., 1997). Prior to commence-
ment of surgery, each rat received a single s.c. injection of
buprenorphine (45 mg·kg-1; Schering-Plough, Welwyn Garden
City, UK) for analgesia. Following surgery, rats were allowed a
7 day recovery period during which time they were checked
daily. Prior to the studies, each rat received two sham injec-
tions (one of angiotensin II and one of saline) to acclimatize
them to the procedure. Only animals with correct cannula
placement, as confirmed by a sustained drinking response to
i.c.v. angiotensin II (50 ng per rat), were included in the
studies.
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For i.c.v. injections, peptides were dissolved as described
above and administered in 5 mL volume via a stainless steel
injector projecting 1 mm beyond the tip of the cannula. Rats
were returned to their own cages following the injection
procedure.
Intraparaventricular cannulation and injection
Unilateral intrahypothalamic cannulation directed at the
PVN (iPVN) was carried out using an established protocol
(Abbott et al., 2003). Rats were maintained as for i.c.v. cannu-
lation. A 26-gauge stainless steel guide cannula (Plastics One)
was stereotactically implanted using established coordinates
obtained from the Paxinos and Watson rat brain atlas
(1.8 mm caudal to the bregma, 0.3 mm lateral, 7.5 mm below
the outer surface of the skull) (Paxinos and Watson, 2007).
For iPVN injections, peptides were dissolved as described
above and administered in 1 mL volume via a stainless steel
injector projecting 1 mm beyond the tip of the cannula.
Correct cannula placement was confirmed histologically at
the end of the study period by injection of India ink as
previously described (Abbott et al., 2003). Data from rats were
excluded if the injection site extended more than 0.4 mm
outside the intended injection site, or if any ink was detected
in the cerebral ventricular system. In total 71% of cannulae
were correctly positioned. Figure S1 shows a representative
section of the PVN containing India ink.
Study 1: The effect of i.c.v. augurin on plasma hormone levels
Each rat received a single i.c.v. injection of vehicle or 5 nmol
augurin (n = 9–10 per group) in the early light phase (0900–
1200 h). Rats were killed by decapitation 60 min after injec-
tion. Trunk blood was collected in plastic lithium heparin
tubes containing 4200 kallidinogenase inactivator units of
aprotinin (Bayer Corp., Haywards Heath, UK) for luteinizing
hormone (LH), follicle stimulating hormone (FSH), growth
hormone (GH), thyroid stimulating hormone (TSH), prolac-
tin, testosterone, free tri-iodothyronine (T3), free thyroxine
(T4) and corticosterone assays, and in plastic EDTA contain-
ing tubes for ACTH assays. Serum was immediately separated
by centrifugation, frozen on dry ice and stored at -20°C
(lithium heparin tubes) or -80°C (EDTA tubes).
Study 2: The effect of i.c.v. augurin on plasma corticosterone and
ACTH
Each rat received a single i.c.v. injection of vehicle, 0.6, 1.7 or
5 nmol augurin in the early light phase (0900–1200 h). Rats
were killed by decapitation 20 or 60 min post injection (n =
8–10 per group per time point). Trunk blood was collected
and stored as above.
Study 3A: The effect of iPVN augurin on plasma corticosterone
and ACTH
Each rat received a single iPVN injection of vehicle, 0.1, 0.3 or
1 nmol augurin in the early light phase (0900–1200 h). Rats
were killed by decapitation 20 or 60 min post injection (n =
5–8 per group per time point). Trunk blood was collected and
stored as above.
Study 3B: The effect of iPVN augurin on behaviour
Each rat received a single iPVN injection of vehicle, 1 nmol
augurin or 0.3 nmol NMU 23 (n = 6–8 per group) in the early
light phase (0900–1200 h). Behavioural patterns were moni-
tored for 120 min following injection by observers unaware of
the experimental treatments. Behaviour was classified into
eight different categories: feeding, drinking, grooming, bur-
rowing, rearing, locomotion, head down and sleeping,
adapted from Fray et al. (1980). These methods have previ-
ously been used to demonstrate abnormal behaviour follow-
ing iPVN injection of peptides (Wren et al., 2002). During the
analysis, each rat was observed for 15 s every 5 min. Each 15 s
period was further subdivided into three and the predomi-
nant behaviour of the rat during each 5 s episode was noted.
NMU was used as a positive control as it is known to increase
grooming behaviour and decrease sleeping (Wren et al.,
2002).
Study 4: The effect of augurin on the release of CRF and AVP
from ex vivo hypothalamic explants.
A static incubation system was used as described previously
(Bewick et al., 2005). Briefly, a 1.9 mm slice was taken from
the basal hypothalamus and incubated in individual tubes
containing 1 mL aCSF (20 mM NaHCO3, 126 mM NaCl,
0.09 mM Na2HPO4, 6 mM KCl, 1.4 mM CaCl2, 0.09 mM
MgSO4, 5 mM glucose, 0.18 mg·mL-1 ascorbic acid and
100 mg·mL-1 aprotinin) saturated with 95% O2 and 5% CO2 at
37°C. After an initial 2 h equilibration period, hypothalamic
slices were incubated for 45 min in 600 mL aCSF (basal
period), before being treated with 1, 10 or 100 nM augurin in
600 mL aCSF for 45 min (n = 13–15 hypothalami per group).
Finally, tissue viability was assessed by 45 min incubation in
isotonic aCSF containing 56 mM KCl. Explants that failed to
show peptide release above the basal level in response to aCSF
containing 56 mM KCl were excluded from the data analysis.
At the end of each period, aCSF was collected and
stored at -20°C until measurement of CRF and AVP by
radioimmunoassay (RIA).
Study 5: The effect of peripheral CRF receptor antagonism on
augurin-stimulated ACTH and corticosterone secretion
Intracerebroventricular cannulated rats were injected i.p. with
100 mg·kg-1 astressin or vehicle 15 min before receiving an
i.c.v. injection of 5 nmol augurin or vehicle. Astressin (cyc30-
33[D-Phe12,Nle21,38,Glu30,Lys33]CRF-(12-41)) is a CRF1/2 receptor
antagonist (Gulyas et al., 1995), not known to cross the
blood–brain barrier. This dose of astressin has previously been
used to block the increase in plasma ACTH and corticosterone
caused by i.c.v. injection of GLP-1 (Kinzig et al., 2003). Rats
were decapitated 30 min after the i.c.v. injection (n = 7–9 per
group). Trunk blood was collected and stored as above.
Study 6A: The effect of peripherally administered augurin on
plasma hormone levels
Rats were handled daily and received twice weekly i.p. injec-
tions to acclimatize them to the injection procedure. On the
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day of the study, rats were injected i.p. with 100 nmol·kg-1
augurin or vehicle during the early light phase (0900–1200 h).
Study 6B: The effect of augurin on ACTH release from
pituitary segments
Static pituitary explants were performed as previously
described (Smith et al., 2006). Briefly, the pituitaries of ad
libitum fed rats were harvested immediately following decapi-
tation. The posterior pituitary was removed and discarded,
and the remaining anterior pituitary was bisected along the
mid-saggital line and then divided into four pieces of approxi-
mately equal size. After an acclimatization period, the seg-
ments were then incubated in one of aCSF alone, or aCSF
containing 10 nM augurin, 100 nM augurin, 1000 nM
augurin or 100 nM CRF for 4 h (n = 17–19 per group). At the
end of this period the incubation medium was collected and
stored at -20°C until assayed for ACTH.
Radioimmunoassays
RIAs for CRF immunoreactivity and AVP immunoreactivity
were performed using established methods (Dhillo et al.,
2003). The intra- and interassay coefficients of variation were
<10% for the CRF RIA, and 11% and 20%, respectively, for the
AVP RIA. Plasma corticosterone was measured using an RIA kit
from MP Biomedicals, Inc. (Orangeburg, NY, USA), for which
the intra- and interassay coefficients of variation were less
than 10% and 7% respectively. For studies 1, 2 and 3A, plasma
ACTH was measured by immunoradiometric assay purchased
from Euro-Diagnostica B.V. (Arnhem, the Netherlands). The
intra- and interassay coefficients of variation were both less
than 4%. For study 5, plasma ACTH was measured by immu-
noradiometric assay purchased from BioSource Europe S.A.
(Nivelles, Belgium) because the previously used kit was no
longer available. The intra- and interassay coefficients of
variation were 6.4% and 6.2% respectively. Plasma TSH, LH,
FSH, prolactin, GH and ACTH release from pituitary segments
were measured, using methods and reagents provided by the
National Hormone and Pituitary programme. Total plasma
testosterone, free T3 and free T4 were measured using com-
mercial Coat-a-Count assay kits (Euro/DPC Limited, Caernar-
fon, UK).
Statistics
Data from hypothalamic explant, pituitary explant and ter-
minal studies are presented as mean! SEM. Data from behav-
ioural analyses are presented as median frequency and
interquartile range for each behaviour. For plasma ACTH and
corticosterone studies, values were log-transformed to
homogenize variances among groups, and to improve the
normality of residuals (Bland and Altman, 1996). Trans-
formed values were then analysed by Student’s t-test, or one-
or two-way ANOVA followed by post hoc Holm-Sidak test (Sig-
maStat 3.5, San Jose, CA, USA). Data from hypothalamic
explant release were analysed using paired Student’s t-test
between the basal period and the test period. Data from pitu-
itary explant release were analysed using one-way ANOVA fol-
lowed by post hoc Holm-Sidak test (SigmaStat 3.5, San Jose,
CA, USA). Data from the behavioural study were analysed
using Kruskal-Wallis one-way ANOVA on ranks (Systat 11, San
Jose, CA, USA).
Nomenclature
The nomenclature of receptors and peptides described in this
manuscript conform to BJP’s Guide to Receptors and Chan-
nels (Alexander et al., 2009).
Results
Study 1: The effect of i.c.v. augurin on plasma hormone levels
Augurin significantly increased plasma ACTH 60 min after
injection (Table 1). Plasma corticosterone was raised but failed
to reach statistical significance. There were no significant
changes in plasma LH, FSH, GH, TSH, prolactin, testosterone,
free T3 or free T4 (Table 1).
Study 2: The effect of i.c.v. augurin on plasma corticosterone
and ACTH
Plasma ACTH and corticosterone levels were significantly
elevated following i.c.v. injection of augurin compared with
vehicle-injected controls (Figure 1). In the case of ACTH, two-
way ANOVA revealed that there was a significant main effect of
dose (F(3,60) = 11.789; P < 0.001), a significant main effect of
time (F(1,60) = 7.956; P < 0.01) and a significant interaction
(F(3,60) = 3.181; P < 0.05). Post hoc analysis demonstrated that
i.c.v. injection of 5 nmol augurin significantly increased
plasma ACTH 20 min post injection (P < 0.001). All doses of
augurin significantly increased plasma ACTH 60 min post
injection (P < 0.01 for all doses).
In the case of corticosterone, two-way ANOVA revealed that
there was a significant main effect of dose (F(3,68) = 8.510; P <
0.001), a significant main effect of time (F(1,68) = 3.799; P <
0.05) and no significant interaction (F(3,68) = 0.954; P = 0.420).
Table 1 Effect of a single i.c.v. injection of augurin (5 nmol) or
vehicle in ad libitum fed rats on plasma hormone concentrations at
60 min post injection
Vehicle Augurin (5 nmol)
Mean SEM Mean SEM
ACTH (pg·mL-1) 21.3 3.2 66.7*** 16.3
Corticosterone (ng·mL-1) 152.8 25.9 300.0 65.1
LH (ng·mL-1) 0.60 0.09 0.54 0.12
FSH (ng·mL-1) 8.97 0.65 7.18 0.88
Testosterone (ng·mL-1) 4.25 0.87 4.96 1.39
TSH (ng·mL-1) 2.38 0.14 2.21 0.37
Free T4 (ng·L-1) 20.5 1.1 22.7 1.2
Free T3 (pg·L-1) 12.8 1.1 12.1 1.3
PRL (ng·mL-1) 5.28 0.79 5.15 0.81
GH (ng·mL-1) 20.27 4.38 22.39 11.54
Results are mean ! SEM.
***P < 0.001 versus vehicle, n = 9–10 per group.
FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing
hormone; PRL, prolactin; T3, tri-iodothyronine; T4, thyroxine; TSH, thyroid
stimulating hormone.
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Post hoc analysis demonstrated that i.c.v. injection of 5 nmol
augurin significantly increased plasma corticosterone 20 min
post injection (P < 0.001).
Study 3A: The effect of iPVN augurin on plasma corticosterone
and ACTH
Plasma ACTH and corticosterone levels were significantly
elevated following iPVN microinjection of augurin compared
with vehicle-injected controls (Figure 2). In the case of ACTH,
two-way ANOVA revealed that there was a significant main
effect of dose (F(3,45) = 9.891; P < 0.001), a significant main
effect of time (F(1,45) = 5.363; P < 0.05) and no significant
interaction (F(3,45) = 0.600; P = 0.618). Post hoc analysis dem-
onstrated that iPVN microinjection of 1 nmol augurin signifi-
cantly increased plasma ACTH 20 and 60 min post injection
(P < 0.001 and P < 0.01 respectively).
In the case of corticosterone, two-way ANOVA revealed that
there was a significant main effect of dose (F(3,45) = 6.247; P <
0.001), no significant main effect of time (F(1,45) = 2.275; P =
0.138) and no significant interaction (F(3,45) = 1.129; P = 0.347).
Post hoc analysis demonstrated that iPVN microinjection of
1 nmol augurin significantly increased plasma corticosterone
20 min post injection (P < 0.01).
Study 3B: The effect of iPVN augurin on behaviour
There were no significant behavioural differences between
iPVN augurin- or vehicle-injected rats. Injection of 0.3 nmol
NMU significantly increased time spent grooming and
decreased time spent sleeping or feeding (Table 2).
Study 4: The effect of augurin on the release of CRF and AVP
from ex vivo hypothalamic explants.
Incubation of hypothalamic explants with augurin signifi-
cantly increased the release of CRF and AVP (Figure 3).
Study 5: The effect of peripheral CRF receptor antagonism on
augurin-induced ACTH and corticosterone secretion
Pretreatment with astressin completely blocked the increase
in plasma ACTH and corticosterone 30 min post i.c.v. injec-
tion of 5 nmol augurin (Figure 4).
Study 6A: The effect of peripherally administered augurin on
plasma hormone levels
There were no significant differences in plasma corticoster-
one, LH, FSH, GH, TSH, prolactin, free T3 or free T4, 30
minutes following i.p. injection of 100 nmol·kg-1 augurin
(Table S1).
Study 6B: The effect of augurin on ACTH release from
pituitary segments
No significant change in ACTH release was seen following
incubation of pituitary segments with 10, 100, or 1000 nM
augurin, compared with aCSF alone. Incubation with 100 nM
CRF resulted in a significant increase in ACTH release (ACTH
ng/explant; vehicle 192.9 ! 23.1; CRF 100 nM 296.7 ! 36.2,
P < 0.01) (Figure S2).
Discussion
Augurin is a recently identified secreted peptide of unknown
function. It is expressed in the CNS and endocrine organs (Su
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Figure 1 Effect of a single i.c.v. injection of augurin (0.6, 1.7 or 5 nmol) or vehicle in ad libitum fed male Wistar rats on plasma ACTH and
corticosterone (CORT) at 20 (A and C) and 60 (B and D) min post injection. **P < 0.01, ***P < 0.001 versus vehicle, n = 8–10 per group per
time point. Results are mean ! SEM.
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et al., 2004; Mirabeau et al., 2007). We therefore examined the
effects of augurin on the hypothalamo-pituitary axes. Both
i.c.v. and iPVN injection of augurin elevated plasma ACTH
and corticosterone compared with vehicle-injected controls,
and augurin increased the release of CRF and AVP from hypo-
thalamic explants. The rise in plasma ACTH and corticoster-
one following i.c.v. injection of augurin was blocked by
pretreatment with a CRF receptor antagonist.
Intracerebroventricular injection of 5 nmol augurin signifi-
cantly increased plasma ACTH and corticosterone 20 min after
injection, compared with vehicle-injected controls. Injection
of 0.6 or 1.7 nmol augurin appeared to cause a delayed rise in
plasma ACTH, evident only at 60 min. The reason for this
delay is unclear; it is possible that it represents the time taken
for the peptide to diffuse to its site(s) of action. Alternatively,
small differences in plasma ACTH at 20 min may have been
masked by the stress of the experimental procedure.
Corticotrophin-releasing factor and AVP are the main regu-
lators of ACTH levels; they act synergistically on the pituitary
to stimulate ACTH secretion (Whitnall, 1993). Augurin
increased the release of CRF and AVP from explanted hypo-
thalami, and pretreatment with a CRF1/2 receptor antagonist
blocked the rise in plasma ACTH and corticosterone caused by
i.c.v. injection of augurin. This suggests augurin stimulates
the secretion of ACTH via the release of hypothalamic CRF
and AVP, although the relative contribution of AVP cannot be
determined from the antagonist study as CRF is necessary for
AVP stimulated ACTH release (Whitnall, 1993).
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Figure 2 Effect of a single iPVN (paraventricular nucleus) injection of augurin (0.1, 0.3 or 1 nmol) or vehicle in ad libitum fed male Wistar rats
on plasma ACTH and corticosterone (CORT) at 20 (A and C) and 60 (B and D) min post injection. *P < 0.05, **P < 0.01, ***P < 0.001 versus
vehicle, n = 5–8 per group per time point. Results are mean ! SEM.
Table 2 Effect of a single iPVN injection of augurin (1 nmol), NMU (0.3 nmol) or vehicle in ad libitum fed male rats on behaviour
Feeding Rearing Drinking Locomotion Grooming Burrowing Head down Sleeping
0–60 min
Vehicle 2 [0:4] 8 [6:15] 0 [0:0] 5 [3:7] 6 [4:8] 0 [0:1] 1 [0:1] 11 [7:14]
Augurin 1 nmol 7 [4:9] 10 [8:13] 0 [0:0] 8 [6:9] 5 [4:8] 0 [0:0] 1 [0:3] 2 [0:9]
NMU 0.3 nmol 0 [0:0] 7 [6:9] 0 [0:0] 5 [3:6] 21 [18:24]** 1 [0:4] 1 [0:3] 0 [0:0]**
61–120 min
Vehicle 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:2] 35 [31:36]
Augurin 1 nmol 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:0] 2 [0:4] 32 [30:36]
NMU 0.3 nmol 0 [0:0] 0 [0:0] 0 [0:0] 0 [0:1] 10 [2:18]* 0 [0:0] 1 [0:4] 23 [17:24]*
0–120 min
Vehicle 3 [1:4] 8 [6:16] 0 [0:0] 5 [3:8] 6 [4:8] 0 [0:1] 3 [0:5] 47 [38:48]
Augurin 1 nmol 7 [4:9] 10 [8:14] 0 [0:0] 8 [6:9] 6 [4:9] 0 [0:0] 3 [3:6] 32 [30:45]
NMU 0.3 nmol 0 [0:0]* 7 [6:9] 0 [0:0] 5 [3:6] 30 [20:40]*** 1 [0:4] 2 [1:8] 23 [17:24]*
Data presented are median frequency and interquartile range.
*P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle, n = 6–8 per group.
NMU, neuromedin U; PVN, paraventricular nucleus.
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Corticotrophin-releasing factor neurons in the PVN are the
major conduit for endocrine, autonomic and behavioural
responses to stress (Herman, 1997). The PVN contains a sub-
population of hypophysiotropic neurons that constitute the
primary source of CRF and AVP (Whitnall, 1993). We there-
fore examined the effects of injecting augurin directly into the
PVN. Intranuclear injection of lower doses minimizes any
non-specific side effects of peptide administration that may
occur following i.c.v. injection (Dhillo et al., 2003).
Microinjection of 1 nmol augurin iPVN significantly
increased plasma ACTH and corticosterone, a much lower
dose than required for a similar effect when given i.c.v. This
could indicate that the receptors for augurin are found within
or close to the PVN. It is, however, possible that lower con-
centrations of augurin could diffuse into adjacent nuclei, and
we cannot discount administration of augurin to other hypo-
thalamic areas having a similar effect. We did not observe any
significant effects on ACTH or corticosterone following iPVN
injection of 0.1 or 0.3 nmol augurin. However, we cannot rule
out slightly elevated ACTH levels in the vehicle group
masking minor effects at the 20 min time point. There were
no significant differences in behaviour in the 2 h following
iPVN microinjection of 1 nmol augurin, compared with
vehicle-injected controls. In particular, no adverse behaviour
was observed in the augurin group, indicating that non-
specific activation of the HPA axis as a result of a noxious
effect is unlikely.
Intracerebroventricular injection of 5 nmol augurin had no
effect on plasma LH, FSH, testosterone, TSH, free T3, free T4,
prolactin or GH at 60 min post injection, suggesting the neu-
roendocrine effects of augurin are specific to the HPA axis.
Peripheral administration of augurin at doses of
100 nmol·kg-1 had no effect on plasma corticosterone at
30 min (Table S1). This dose is relatively high; i.p. injection of
4.2 nmol·kg-1 of CRF causes a significant rise in ACTH
(Watanabe et al., 1991). In addition, we have shown that
incubation of pituitary segments with augurin at concentra-
tions of up to 1000 nM has no effect on ACTH release. It
therefore appears unlikely that peripheral augurin acts
directly on the pituitary to release ACTH unless it is released
into the circulation at very high concentrations. To date, the
presence of augurin in the circulation has not been
investigated.
The primary sequence or sequences of endogenous augurin
are unknown. While these data show residues 71–148 have a
biological effect, it is also possible shorter fragments of












































Figure 3 Effect of augurin (1, 10 or 100 nM) on corticotrophin-
releasing factor (CRF) (A) and arginine vasopressin (AVP) (B) release
from hypothalamic explants. Data presented as percent of basal
release. *P < 0.05 versus basal release, n = 13–15 hypothalami per





































































Figure 4 Effect of a single i.c.v. injection of augurin (5 nmol) or
vehicle in ad libitum fed male Wistar rats pretreated with
100 nmol·kg-1 astressin on plasma ACTH (A) and corticosterone
(CORT; B) 30 min post i.c.v. injection. *P < 0.05, **P < 0.01 versus
vehicle, n = 7–9 per group. Results are mean ! SEM.
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augurin may be biologically active. The N-terminal segment
of augurin adjacent to the dibasic cleavage site has substan-
tially higher interspecies conservation than the rest of the
peptide (Mirabeau et al., 2007). We hypothesize that the
increase in conservation implies the N-terminal segment is
important for biological activity. Identifying the endogenous
forms of augurin and determining the minimum biologically
active sequence would provide a basis for developing struc-
tural analogues acting as agonists or antagonists of the
augurin system
Data from our studies demonstrate injection of augurin
into the hypothalamus stimulates the HPA axis, culminating
in the release of glucocorticoids. Various pharmacotherapies
have been developed based on components of the HPA axis.
Glucocorticoid receptor agonists are widely used as anti-
inflammatory and immunosuppressive agents (Rhen and
Cidlowski, 2005). More recently, antagonists of the CRF recep-
tors have shown promise in the treatment of anxiety and
depression, sleep disorders, addictive behaviour and preterm
labour (Habib et al., 2000; Zoumakis et al., 2006). While the
data presented suggest a novel role for augurin, these are
preliminary studies. Currently, little is known about the
physiology of the augurin system. Further characterization of
the neuroanatomy, identification of receptors and the devel-
opment of functional analogues would aid us in establishing
whether the augurin system is a viable target for manipulating
the HPA axis.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Photomicrograph of the spread of 1 mL India ink
injected into the paraventricular nucleus. The section was not
stained so that the ink could be clearly seen. 3V, third ven-
tricle; ot, optic tract.
Figure S2 Effect of augurin (10, 100 or 1000 nM) or
corticotrophin-releasing factor (CRF) (100 nM) on ACTH
release from pituitary segments. **P < 0.01, n = 17–19 per
group. Results are mean ! SEM.
Table S1 Effect of a single i.p. injection of augurin
(100 nmol·kg-1) or vehicle in ad libitum fed rats on plasma
corticosterone, LH, FSH, GH, TSH, prolactin, free T3 and free
T4 at 30 min post injection
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Supplemental Figure list 
Figure S1: Photomicrograph of the spread of 1µl India ink injected into the PVN. The section was not 
stained so that the ink could be clearly seen. 3V, 3rd ventricle; ot, optic tract. 
Figure S2: Effect of augurin (10, 100, or 1000nM) or CRH (100nM) on ACTH release from pituitary 



























Supplementary Table 1 
 
 Vehicle Augurin  (100 nmol/kg) 
 Mean SEM Mean SEM 
CORT (ng/ml) 34.5 12.6 22.3 4.45 
LH (ng/ml) 0.84 0.11 0.59 0.05 
FSH (ng/ml) 9.40 0.67 7.74 0.58 
TSH (ng/ml) 2.21 0.19 2.25 0.15 
Free T4 (ng/L) 22.5 1.1 21.1 1.0 
Free T3 (pg/L) 10.8 1.5 12.3 1.0 
PRL (ng/ml) 3.87 0.66 2.29 0.38 
GH (ng/ml) 105.9 33.1 64.7 23.5 
     
Effect of a single ip injection of augurin (100 nmol/kg) or vehicle in ad libitum fed rats on plasma 
corticosterone, LH, FSH, GH, TSH, prolactin, free T3, and free T4 at 30 minutes post injection. 
Results are mean ± SEM, n = 7-9 per group.  
 
 
 
